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Introduction 
The Introduction section includes chapters taken and adapted from Peterlik et al. (2016a): 
 
Peterlik, D., Flor, P.J., Uschold-Schmidt, N., 2016a. The Emerging Role of Metabotropic 
Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders. Curr. 
Neuropharmacol., 14(5), 514–39 
 
(Curr. Neuropharmacol. permits the author to include published journal articles in full or 
in part in the author’s dissertation) 
 
Peterlik D. is responsible for design, content and writing of the first draft of the 
manuscript. 
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1. Stress and its physiological systems 
Hans Selye, the founder of the modern stress concept, stated “everybody knows what stress 
is and nobody knows what it is” (Selye, 1973). In spite of its frequent use, the word 
“stress” is at best an ambiguous term. In fact, it has been used to describe both what creates 
the stress and the response of the body to it. In order to circumvent this ambiguity, two 
different terms have been introduced: “stressor” and “stress response”. A stressor is 
defined as anything that disrupts physiological balance independent of whether it is an 
actual or anticipated disruption of homeostasis or an anticipated threat to well-being 
(Bartolomucci, 2007; Chrousos, 2009). On the other hand, the stress response is an 
adaptive behavioral and physiological reaction aiming to re-establish homeostasis even in 
the most demanding of circumstances (Chrousos, 2009; Dhabhar, 2002; McEwen, 2004), 
thereby involving an efficient and highly conserved set of interconnected physiological 
systems (Ulrich-Lai and Herman, 2009). In mammalian species, the two major stress 
system mediating behavioral and physiological responses are the autonomic nervous 
system (ANS), especially its sympathetic branch (SNS), and the hypothalamic-pituitary-
adrenocortical (HPA) axis. The activation of the SNS provides the most immediate 
response to stressor exposure within seconds via exclusively neuronal pathways. These 
pathways originate in the thoracolumbal regions of the spinal cord and in turn project to 
end organs and to chromaffin cells in the adrenal medulla (Figure 1a). In the latter case, 
they trigger the release of adrenaline/noradrenaline into the blood (Mason, 1968; Ulrich-
Lai and Herman, 2009). In contrast to the fast acting SNS, activation of the HPA axis, 
which is driven by hormones, takes longer to develop. Stimulation of the HPA axis is 
triggered by the secretion of corticotropin releasing hormone (CRH) and arginine 
vasopressin (AVP) from the parvocellular region of the paraventricular nucleus (PVN) of 
the hypothalamus into the portal circulation of the pituitary. By binding to respective 
receptors expressed in the anterior pituitary, CRH promotes there the synthesis and 
secretion of adrenocorticotropic hormone (ACTH) into the peripheral blood, which, in 
turn, stimulates adrenal cortical cells to produce and secrete glucocorticoids (GC) into the 
blood stream (Figure 1b). Termination of the stress response is achieved by negative 
feedback inhibition via GC acting at glucocorticoid receptors (GR) and mineralocorticoid 
receptors (MR) at different brain levels, e.g. the hippocampus and hypothalamus (Harris et 
al., 2013; Keller-Wood, 2015; Lupien et al., 2009). 
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Figure 1. Schematic illustration of the sympathetic nervous system (SNS) and the hypothalamic-
pituitary-adrenocortical (HPA) axis. The SNS (left-hand side; schematic overview adapted from 
http://wc1.smartdraw.com/cmsstorage/exampleimages/bf159507-dfa1-47d1-910e-f6903c30c35c.png) and the 
HPA axis (right-hand side; adapted from Lupien et al. (2009)) represent the primary mammalian systems 
responsible for maintaining or reinstating homeostasis during stress. (a) Stressor exposure results in 
activation of preganglionic sympathetic neurons in the intermediolateral cell column of the thoracolumbal 
region of the spinal cord. These preganglionic neurons project to pre- or paravertebral ganglia that in turn 
project to end organs and to chromaffin cells of the adrenal medulla. This sympathetic activation represents 
the classic “fight or flight” response that generally increases circulating levels of adrenaline (primarily from 
the adrenal medulla) and noradrenaline (primarily from sympathetic nerves), which in turn increases heart 
rate and force of contraction, peripheral vasoconstriction, and energy mobilization. In addition, the 
parasympathetic tone can also be modulated during stress. In the parasympathetic system (not shown), 
activation of craniosacral preganglionic nuclei activates postganglionic nuclei located in or near the end 
organs that they innervate; parasympathetic actions are generally opposite to those of the sympathetic system. 
(b) For the HPA axis, stressor exposure activates hypophysiotrophic neurons in the paraventricular nucleus 
(PVN) of the hypothalamus that secrete releasing hormones, such as corticotropin-releasing hormone (CRH) 
and arginine vasopressin (AVP), into the portal circulation of the median eminence. These releasing 
hormones act in the anterior pituitary to promote the secretion of adrenocorticotropic hormone (ACTH), 
which in turn acts on the inner adrenal cortex (zona fasciculata) to initiate the synthesis and release of 
glucocorticoids (GC). Following activation of the system, and once the perceived stressor has subsided, 
feedback loops are triggered at various levels of the system in order to shut down the HPA axis and to return 
to a homeostatic point. Adapted from Ulrich-Lai and Herman (2009). 
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1.1 Acute, repeated and chronic stress 
Although the term “stress” commonly bears a negative meaning, an acute stress response is 
one of the most important mechanisms of an organism to adapt appropriately to challenges 
and threats in the environment. An acute stress response results in immediate behavioral 
and physiological changes including enhanced attention and arousal, increased energy 
mobilization and increased cardiovascular and respiratory rates, whereas digestive and 
reproductive functions are inhibited (Charmandari et al., 2005). The fundamental process 
through which the organism actively adjusts to stressful challenges is referred to as 
“allostasis” and represents an essential component of maintaining homeostasis (McEwen, 
1998). When not overstrained, these changes are adaptive and beneficial as they increase 
an individual’s chance of survival. In case of excessive and prolonged activation during 
repeated or chronic stressor exposure, these adaptive systems may become overstimulated, 
a condition termed “allostatic load” (McEwen and Stellar, 1993; McEwen and Wingfield, 
2003; McEwen, 1998). Accordingly, inappropriate, severe or prolonged stress is associated 
with changes in the brain that impair its ability to regulate appropriately physiological and 
behavioral responses (Arnsten, 2009; McEwen, 2007). Thus, important criteria to 
distinguish stress are its duration and intensity. While acute stress is defined to last for 
minutes to hours, chronic stress persists for days to month (Dhabhar, 2000). On the other 
hand, stress intensity can be measured by the magnitude of heart rate and blood pressure 
and by stress hormone levels (GC, catecholamines) in blood. Acute stressor exposure 
results in an increase of blood GC levels after 15-30 min and a decline to basal levels 60-
120 min later (de Kloet et al., 2005; Keeney et al., 2006). In contrast, chronic stressor 
exposure may result in persistently elevated levels of plasma corticosterone (CORT). For 
instance, sustained increased basal plasma CORT levels were reported following chronic 
subordination for 14 days (Albeck et al., 1997) or repeated restraint stress for 7 days with 
1.5 h/day (Zelena et al., 1999) compared to unstressed controls. Such prolonged elevations 
of plasma CORT levels are considered the most toxic because they are most likely to result 
in long-term or permanent changes in emotional, physiological and behavioral responses 
that influence susceptibility to disease (Chrousos, 2009; de Kloet et al., 2005; Karatsoreos 
et al., 2010). Interestingly, although HPA axis hyperactivity (hypercorticism) has been 
generally linked to prolonged stressor exposure, there is accumulating evidence for even 
opposite alterations (Heim et al., 2000). There are chronic or repeated stress models 
leading even to reduced or unaffected plasma GC levels. For instance, chronic isolation 
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stress resulted in reduced basal plasma CORT (Djordjevic et al., 2012), whereas repeated 
exposure to noise did not affect basal plasma CORT levels (Armario et al., 1986). 
Concurrently, chronic or repeated exposure to the same (homotypic) stressor is often 
associated with an adaptation of the stress response (Bartolomucci, 2007; Wood et al., 
2010), a mechanism that enables the organism to habituate to innocuous, not life 
threatening challenges. However, despite adaptation to these familiar stressors, it is 
important for the individual to respond adequately to novel, possibly dangerous threats. So 
far, possible mechanisms underlying habituation to familiar and sensitization to subsequent 
novel stressors include functional changes at the level of the adrenal gland (Uschold-
Schmidt et al., 2012) or altered negative feedback regulation of the HPA axis (Aguilera, 
1994).  
Of note, the consequences of chronic or repeated stressor exposure can vary based on 
individual differences. For example, while some individuals perceive a challenging 
situation as stressful, others that are resilient can actively cope with the same situation. 
Evidence supports the hypothesis that genetic predisposition (DeRijk and de Kloet, 2005; 
Gillespie et al., 2009) as well as adverse (early) life experiences (Eiland and McEwen, 
2012; Gola et al., 2012; Veenema et al., 2008) strongly increase the individual’s 
vulnerability to stress-related pathological conditions.   
Until now, numerous studies have focused on physiological and behavioral consequences 
of an acute stress response that are generally well understood. Instead, although chronic 
stress-induced physiological and behavioral alterations are likely to play a major role in the 
etiology of various diseases, the detailed underlying mechanisms are less well understood 
due to, at least in part, the lack of appropriate animal models (Langgartner et al., 2015). 
 
1.2 Psychosocial stress 
Hans Selye’s theory of the “general adaptation syndrome” involved the description of an 
organism’s reaction to stressors of exclusively physical nature including intoxication or 
cold (Selye, 1998). Even nowadays many physical stressors are frequently used in 
laboratory such as restraint or forced swim stress. However, the major limitation these 
stress paradigms have is that they do not mimic the animal’s natural situation, i.e. when 
exposed to psychological and social stressors (Bartolomucci et al., 2005). More 
importantly, physical stressors do not reflect the typical situations humans have to face in 
today’s highly demanding society. Nowadays it is widely acknowledged that, for instance, 
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work-related stress represents a common feature of modern life at high costs of an 
individual’s health and performance. Most of the challenges and threats humans face today 
are of psychological nature, such as changing world of work, demand for flexible contracts 
accompanied with increased job insecurity as well as poor work-life balance. Concurrently, 
psychological stress occurs when an individual perceives that these environmental 
demands strain or exceed the own adaptive capacity to deal with (Cohen et al., 2007). Of 
note, most of these challenges include social interactions between individuals like 
competition for resources or social rank and workplace bullying. Accordingly, social stress 
represents one of the most potent but also naturalistic type of challenges (Koolhaas et al., 
1997; Tamashiro et al., 2005). Psychosocial stress, the combination of psychological and 
social aspects of stress, is accepted as a major risk factor for the development of a wide 
variety of somatic and affective disorders in humans (Bennett et al., 1998; Heim and 
Nemeroff, 2001; Lupien et al., 2009; Sgoifo and Meerlo, 2002). In view of this, animal 
models utilizing a chronic psychosocial stress component represent the most promising 
approach on a preclinical basis to unravel the mechanism underlying chronic stress-
promoted pathologies as they more accurately reflect the human situation. The chronic 
subordinate colony housing (CSC) model has emerged as one such appropriate model, as it 
combines chronic, psychological and social aspects of stress, and promotes the 
development of both somatic and affective pathologies (Langgartner et al., 2015; Peterlik 
et al., 2016a; Reber et al., 2007; detailed description see below). 
 
1.3 Established rodent models for the evaluation of stress 
Understanding the biological basis of the stress response is essential for a better 
comprehension of the etiology of stress-related disorders. Animal models have turned out 
to be instrumental in this respect and, like in humans, animals use coping strategies when 
exposed to stress. They can express both active coping mechanisms manifested by 
aggressive behaviors as well as exploratory activity or passive coping manifested by 
freezing, immobility and submission (Franklin et al., 2012). All these behaviors can be 
reliably measured in different animal models. In the following, a number of animal models 
are discussed in which the animal’s stress response is reflected either upon exposure to 
acute or to a chronic stressor. Paradigms that employ acute stressor exposure include 
stress-induced hyperthermia (SIH), the forced swim test (FST), the tail suspension test 
(TST), elevated plus maze (EPM) and learned helplessness (LH), to name a few. On the 
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other hand, chronic mild stress/chronic unpredictable stress (CMS/CUS), chronic social 
defeat stress (CSDS) and chronic subordinate colony housing (CSC) represent chronic 
stress models, all of which employ relatively long-term exposure to inescapable or 
uncontrollable stress events. 
 
1.3.1 Assessment of acute stress in rodents 
The SIH Test 
In general, SIH is known to be a physiological phenomenon when a mammalian organism 
is confronted with an either physical or psychological stressor (Adriaan Bouwknecht et al., 
2007; Olivier et al., 2003; Vinkers et al., 2013; Zethof et al., 1994). Notably, the SIH test 
in rodents is also referred to a physiological animal model for anxiety (Adriaan 
Bouwknecht et al., 2007). Typical for the test is that, modified from the version originally 
described by Borsini et al. (1989), the basal temperature is measured rectally (T1) followed 
by a second rectal measurement 15 minutes later (T2). During these 15 minutes, the 
temperature usually rises due to the physical stress the animal is exposed to (handling, 
rectal measurement). Conveniently, potential anxiolytic-like effects of drugs are measured 
by a decrease in the SIH response (Adriaan Bouwknecht et al., 2007). Those measurements 
of the body temperature are not dependent on the animal’s motoric activity, which makes 
SIH different from other mild stress models/anxiety tests that depend on locomotor 
performance of the animal, for instance the EPM or open field test. 
 
The FST and TST 
The FST and TST are the two most widely used preclinical screening tests that allow rapid 
detection of substances with potential antidepressant-like activity (good predictive 
validity). In general, both tests are based on the same principle, which is the measurement 
of the duration of immobility while rodents are exposed to an acute, short-term (minutes) 
inescapable situation. In the FST, first described by Porsolt et al. (1977a,b), a mouse or a 
rat is placed in a water-filled cylinder, in which the animal is unable to escape from. 
Following an initial period of escape-oriented movements, the animal will eventually 
display an immobile posture, a passive behavior characterized by the absence of 
movements except those necessary to keep the head above the water level. By contrast, in 
the TST, immobility is scored while mice are suspended by their tails and, as water is not 
required, this test is not confounded by challenges of thermoregulation. In both tests, the 
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immobility is typically interpreted as an expression of behavioral despair (Cryan et al., 
2005a, 2005b; Lucki, 2001), which can be reversed by the acute administration of 
compounds with antidepressant potential. So, testing of new substances in these stress 
models allows a simple and rapid screening of potential antidepressant activity by the 
measurement of their acute effect on immobility. However, this poses a problem for the 
model, as antidepressants used in depressed humans in the clinics generally require many 
weeks of administration to elevate mood. Nevertheless, both the FST and TST are 
currently popular models mostly due to their low cost, their ease of use and their reliability 
across laboratories (Borsini and Meli, 1988; Holmes, 2003). 
 
The EPM test 
The EPM represents one of the most widely used anxiety models, in which anxiety-related 
behavior is typically measured by indices of open-arm avoidance and locomotor activity by 
the frequency of closed-arm entries (Lister, 1987; Rodgers et al., 1999). In principle, this 
test exploits the balance between the preference of rodents for avoiding open exposure to 
potential predators vs. exploration for possible rewards. When placed in the center portion 
of the plus-maze and allowed to explore each of the arms freely, animals with higher 
anxiety levels will show reduced open-arm activity and vice versa. This tendency can be, 
for instance, suppressed by anxiolytics and potentiated by anxiogenic agents (Belzung and 
Griebel, 2001). As short-term exposure of animals to heights and bright open spaces 
demonstrates an acutely stressful situation, the EPM can also be used and interpreted as a 
test for mild acute stressor exposure (Salomé et al., 2006). 
 
The LH model 
The LH model can be basically viewed as analogous to the abovementioned tests, with the 
difference that it involves a series of stressors over a few hours or even days (Nestler and 
Hyman, 2010). Following an uncontrollable stressor such as exposure to inescapable 
electric foot shocks, animals eventually will either display increased escape latency or 
completely fail to escape from a subsequent situation in which escape is possible 
(Seligman and Beagley, 1975; Seligman et al., 1975; Willner, 1984). Importantly, escape 
deficits can be reversed by a variety of antidepressants (Henn and Vollmayr, 2005). 
Following one or more sessions of inescapable shock, animals have been shown to develop 
persistent changes that are reminiscent of depression, including weight loss, alterations in 
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sleep pattern, changes in HPA axis activity and loss of spines in hippocampal regions 
(Cryan and Mombereau, 2004; Nestler et al., 2002a, 2002b). The attractiveness of LH is 
that the model is based on the consideration that cognitive functions (e.g. learning) are 
linked to other behavioral outcomes (e.g. neurovegetative modalities), and thus, this model 
helps to provide a reasonably integrated and broad picture of depressive symptomatology 
analogous to the human situation. However, the major drawback of the model is that most 
of the depression-like symptomatology does not persist beyond 2-3 days following 
cessation of the uncontrollable shock. Moreover, another limitation is – in contrast to the 
FST and TST – the difficulty to replicate between laboratories, particularly in mice.  
Until today, these acute stress models clearly represent the first line of behavioral tests 
used to rapidly screen putative antidepressant and anxiolytic compounds and to phenotype 
transgenic animals. Even though direct links to emotional disorders in man are obviously 
weak due to utilizing only acute stressors and testing only acute antidepressant/anxiolytic 
responses, these acute stress models have helped enormously to reveal important molecular 
players within the CNS emotion circuitry (Krishnan and Nestler, 2011, 2010, 2008; 
Krishnan et al., 2008). 
 
1.3.2 Assessment of chronic stress in rodents 
While acute stress paradigms are used broadly for their ease, automation potential, and 
rapid phenotyping abilities, they offer singular readouts that often cannot be 
unambiguously interpreted. For instance, increased immobility in the FST is typically 
interpreted as an expression of despair. However, it can also be understood as a successful 
and adaptive behavioral response that functions to conserve energy (West, 1990). Today’s 
chronic stress models are distinguished by their remarkable ability to simultaneously 
produce a set of behavioral alterations with strong face validity for depression and anxiety 
disorders (behavioral manifestations that should be similar to the symptoms observed in 
affected humans). Based on the clinical evidence that chronic stress significantly increases 
pathogenesis of affective diseases, these stress models are potentially of high value to 
better understand the underlying physiological mechanisms (Krishnan and Nestler, 2008; 
Nestler and Hyman, 2010). Basically, they are composed of repeated and/or permanent 
applications of uncontrollable and unpredictable stressors that are associated with 
quantifiable molecular, behavioral and physiological changes. 
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The CMS model 
In the CMS model, also referred to as chronic unpredictable stress (CUS) paradigm 
(Willner, 1997; Willner et al., 1992), rodents are exposed to a variety of relatively mild, 
mostly physical, stressors such as restraint, isolation housing, disruption of light-dark 
cycles, intermittently for relatively prolonged time periods (e.g. several weeks). Typically, 
a variety of stressors is used within the CMS schedule in order to prevent or delay 
habituation, which can occur rapidly when a single stressor is presented repeatedly 
(Willner, 1997; Willner et al., 1992). In addition to a reduction in sucrose preference 
(Muscat and Willner, 1992), CMS has also been shown to result in a number of other 
changes that are difficult to objectively quantify, such as grooming deficits and changes in 
aggressive and sexual behavior. Interestingly, many of these changes can be reversed by 
chronic antidepressants applied either during the stress procedure or as a post-stress 
treatment (Guidotti et al., 2013; Strekalova et al., 2006). However, as the CMS model only 
employs physical stressors and often lacks cross-laboratory reliability, other approaches to 
develop chronic psychosocial stress-based models, more reminiscent of human depression, 
have emerged in recent years. 
 
The CSDS model 
The stress models described above are based exclusively on physical stressors, and thus, 
are lacking the relevance of mimicking most important situations that human beings 
encounter in everyday life – i.e. social interactions (Brinkborg et al., 2011; DeVries et al., 
2007; Kouzis and Eaton, 1998; Vega et al., 2004). As opposed to CMS, the CSDS model 
clearly includes an important social stress component, and thus displays remarkable 
strength as it relies on innate social behavior. The model is based on the principle that two 
animals interact socially and physically such that one achieves dominant status and the 
other becomes subordinate. Much of the preclinical aggression research has been 
conducted so far in territorial male resident rats or mice confronting an intruder 
conspecific. As a consequence of territoriality, the resident will attack unfamiliar males 
intruding in its home cage. However, there are many versions of CSDS for mice and rats. 
For example, a typical procedure in mice lasts for 21 days where the experimental animal 
is exposed repeatedly to 10 intermittent bouts (5-10 min, once daily) of social defeat. Here, 
the experimental mice are forced to intrude into cage space occupied by a larger mouse of 
a more aggressive strain, leading to subordination of the experimental mice. In addition to 
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the short-time physical stress during direct contact with the dominant male, the 
experimental mice are exposed to additional psychological stress in form of prolonged “not 
physical” contact by housing them for 24 h in the same cage as the residents, but with a 
transparent partition allowing only sensory interaction (Wagner et al., 2014, 2011). Other 
laboratories expose the experimental mice also daily to 10 min of physical interaction with 
a resident, followed by 24 h of sensory contact, but only for 10 consecutive days (Berton et 
al., 2006; Razzoli et al., 2011; Tsankova et al., 2006). For rats there are protocols where 
the experimental animals are placed in a resident’s home cage for 5 min physical 
interaction followed by 10 min of sensory threat for 4 consecutive days (Duclot and 
Kabbaj, 2013; Hollis et al., 2010), or where the intruders are placed in the cage of the 
resident for intermittent physical interaction until submission followed by 30 min of 
sensory threat for 1 to 3 consecutive days (Razzoli et al., 2009, 2007, 2006). Following 
repeated exposure to a dominant encounter, independent of the protocol used, animals 
reliably show decreased sucrose preference, indicative of an anhedonia-like state, and 
show reduced social interaction/sociability as well as alterations in HPA axis and 
autonomic function (Avgustinovich et al., 2005; Hollis and Kabbaj, 2014; Krishnan et al., 
2007). Importantly, many of these changes can be reversed by chronic, but not acute, 
antidepressant drug administration, illustrating pharmacological validity of this stress 
model (Balsevich et al., 2014; Der-Avakian et al., 2014; Venzala et al., 2012). 
 
The CSC model 
The CSC paradigm was established by Reber et al. (2007) and represents a chronic 
psychosocial stress model with similarities to the CSDS model, but with the difference of 
applying psychosocial stress not only intermittently but permanently over a period of 19 
days (24 h per day; Figure 2a). This chronic stress model is a very reliable animal model in 
combining chronic, psychological and social aspects of stress. In doing so, and as 
compared to the other stress models of above, it more comprehensively mimics the type of 
health compromising stressors that humans are exposed to in daily life. Typically, four 
male mice are housed together with a larger male resident in its homecage for 19 
consecutive days. This results in immediate subordination of the four intruder CSC mice, 
and a hierarchy within each colony is formed, in which the resident clearly obtains the 
dominant position. To avoid habituation to the dominant mouse, the four CSC mice are 
transferred into the homecage of a novel larger male resident mouse on days 8 and 15. 
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Single-housed animals that remain undisturbed serve as unstressed controls (SHC; Reber 
and Neumann, 2008). Importantly, studies by the group of Reber S.O. clearly demonstrate 
that CSC exposure leads to the development of affective and somatic changes and also 
results in reduced GC signaling (Langgartner et al., 2015; Figure 2b), and thus provides a 
powerful experimental tool to study the mechanisms underlying several relevant stress-
induced conditions. In detail, is has been shown that exposure to CSC alters several 
parameters indicative of chronic stress, including reduced body weight gain, decreased 
thymus weight and increased pituitary and adrenal weights (Reber et al., 2007; Uschold-
Schmidt et al., 2012). The latter finding is accompanied by a reduced responsiveness of 
adrenal explants to an ACTH challenge in vitro. Importantly, adrenal ACTH sensitivity 
seems to be not only diminished under in vitro conditions, as CSC mice show unaffected 
basal morning plasma CORT despite elevated plasma ACTH levels in comparison with 
SHC mice. Moreover, CSC mice show basal evening hypocorticism, suggested by 
decreased basal evening plasma CORT levels compared to SHC mice (Reber et al., 2007; 
Uschold-Schmidt et al., 2013, 2012). The decline in GC signaling is further amplified by a 
reduced GC sensitivity seen in lipopolysaccharide-stimulated splenocytes (Reber et al., 
2007) and plate-bound anti-CD3-stimulated T helper (Th) 2 cells from peripheral lymph 
nodes (Schmidt et al., 2010) of CSC compared to SHC mice. These are interesting 
findings, as an insufficient GC signaling can be observed in numerous affective and 
somatic disorders in man following chronic psychosocial stressor exposure (Caplan et al., 
1979; Heim et al., 2000; Yehuda, 1997a, 1997b). In addition, CSC-stressed mice develop 
spontaneous colonic inflammation, indicated by an increased secretion of proinflammatory 
cytokines from mesenteric lymph node cells in vitro and an increased histological damage 
score of colonic tissue (Peters et al., 2012; Reber et al., 2007; Veenema et al., 2008). 
Moreover, CSC exposure was also shown to increase the risk for the development of 
inflammation-induced colorectal cancer (CRC), indicated by the development of 
macroscopic suspect lesions, as well as a trend towards an increased incidence of low- 
and/or high-grade colonic dysplasia (Peters et al., 2012). Interestingly, in humans, 
inflammatory bowel disease (IBD) has been shown to be a consequence of chronic life 
stress and colorectal cancer poses one of the most serious complications in these patients 
(Cairns et al., 2010; Eaden, 2004, 2003; Eaden et al., 2000; van Hogezand et al., 2002). 
Furthermore, IBD was also shown to be comorbid in patients suffering from depression 
(Bitton et al., 2003; Duffy et al., 1991; Levenstein et al., 2000). These findings further 
indicate that the CSC paradigm is an appropriate model of chronic psychosocial stress with 
Introduction 
23 
 
high construct validity (i.e. high disease relevance of methods by which the animal model 
is constructed; Nestler and Hyman, 2010). With respect to their behavior, CSC mice show 
reduced open-arm activity on the EPM and reduced center-activity in an open field after 19 
days of CSC, further illustrating that chronic stressor exposure increases anxiety-related 
behavior, a phenomenon that co-occurs with depression in humans (Kennedy, 2008). 
Moreover, CSC mice spend a similar time investigating an empty cage and a cage with an 
unknown conspecific during the social preference/avoidance test (SPAT) on day 20 of 
CSC, suggesting a lack of social preference (Slattery et al., 2012). In addition, CSC mice 
also show an increased ethanol (EtOH) preference and total intake, which was already 
shown following 14 days of CSC exposure (Peters et al., 2013). Interestingly, in humans, 
chronic psychosocial stress represents a strong risk factor for the development of substance 
abuse such as alcoholism, which is often co-morbid with anxiety disorders (Boger et al., 
2014; Cooper et al., 2014; Morley et al., 2014). Taken together, the CSC paradigm 
represents an animal model that utilizes a chronic psychosocial stress component and 
results in decreased GC signaling and concomitant affective and somatic pathologies, in 
particular the stress-induced anxiogenic phenotype and the systemic proinflammatory 
phenotype (Figure 2b). Thus, the CSC model is likely to have more translational value than 
other stress models in animals, e.g. when compared to the CMS or CSDS model, which 
lack either social or truly chronic components. Most interestingly, CSC exposure is 
associated with hypocorticism, a phenomenon that is not apparent after CMS or CSDS, but 
occurs in humans suffering from mood disorders. In contrast, CMS and CSDS are 
associated with greatly elevated plasma CORT levels (hypercorticism). Interestingly, in 
addition to mice, the CSC paradigm was also established in rats (Nyuyki et al., 2012). 
However, to date the effects of CSC exposure in rats are not that well characterized as 
compared to mice. Overall, the CSC paradigm is a promising animal model that makes it 
also possible to gain further insight into how stress-induced pathophysiological changes 
(e.g. HPA axis alterations) eventually lead to affective and somatic disorders in man. 
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Figure 2. Schematic illustration of the experimental design of the chronic subordinate colony housing 
(CSC) paradigm in mice and a summary of the main effects of CSC on behavioral, immunological and 
physiological parameters. (a) In the CSC paradigm, male mice weighing 19-21 g are housed singly for one 
week before they are assigned to the single-housed control (SHC) or the CSC group in a weight-matched 
manner. In order to induce chronic psychosocial stress, CSC mice are housed together with a larger dominant 
male for 19 consecutive days. In detail, four experimental CSC mice are put into the homecage of resident (1) 
on day 1 of CSC, resulting in immediate subordination of the four intruder CSC mice. The latter are then 
housed together with this dominant resident (1) for 7 consecutive days. On day 8, and again on day 15 of 
CSC, the four experimental CSC mice are transferred into the homecages of resident (2) (day 8) and resident 
(3) (day 15), respectively, in order to avoid habituation. On day 19, CSC and SHC mice are usually tested for 
their innate or physiological anxiety and on day 20 immunological and physiological parameter are assessed. 
(b) Compared to SHC mice, CSC mice show affective and somatic changes and develop decreased 
glucocorticoid (GC) signaling. Thus, the CSC paradigm represents a promising animal model to mimic 
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diseases in which decreased GC signaling is a core feature and to unravel the underlying mechanisms of 
stress-related pathology in humans. Abbreviations: EPM, elevated plus-maze; LDB, light-dark box; EPF, 
elevated platform; OF, open field; SPAT, social preference/avoidance test; mes LN cells, mesenterial lymph 
node cells; ACTH, adrenocorticotropic hormone; CORT, corticosterone; LPS, lipopolysaccharide; Th2, T 
helper 2; Adapted from Peterlik et al. (2016a). 
 
Taken together, the rodent models explained above can be performed in mice as well as in 
rats. Which species to use probably depends on the particular research question to be 
answered. However, in case of the CSC model, mice are the first choice to gain more 
knowledge about the role of the brain glutamatergic neurotransmitter system in the 
development of the resulting affective and somatic changes, as the effects of chronic 
psychosocial stressor exposure using this model are much better characterized and robust 
in mice. Other advantages of mouse models are lower costs and less space necessary. 
Moreover, mouse models also offer the possibility to use transgenic animals, e.g. knockout 
mice, in order to analyze the underlying mechanisms. 
 
 
2. The glutamate system is implicated in stress-related physiology and 
disorders 
Major depression, anxiety, and drug abuse disorders represent the most prevalent stress-
related psychiatric conditions and are an enormous health concern worldwide (Aas et al., 
2012; Cryan and Holmes, 2005; Schneiderman et al., 2005). The etiology of these 
pathologies is complex, with chronic psychosocial stressors being the most acknowledged 
risk factors (Caspi et al., 2003; Cryan and Holmes, 2005; Cryan and Slattery, 2007; de 
Kloet et al., 2005; Schneiderman et al., 2005; Virtanen and Kivimäki, 2012; Virtanen et al., 
2013). These factors include continuing adverse conditions, such as social decline along 
with poverty, or life events that possess a high degree of chronic threat (e.g. medical 
disabilities), long lasting negative emotions and experience of personal loss (de Kloet et 
al., 2005; Hammen, 2005; Virtanen and Kivimäki, 2012; Virtanen et al., 2013). The 
majority of these types of factors has been demonstrated to increase both anxiety- and 
depression-related behavior, but also alcohol and drug abuse (Blanchard et al., 2005, 2006; 
Kotov et al., 2010; Schmidt et al., 2007). Indeed, and not surprisingly, there’s a high 
comorbidity between anxiety and depression/mood disorders, with approximately half of 
Introduction 
26 
 
the patients suffering from major depression also meeting criteria for comorbid anxiety 
(Kennedy, 2008). 
As disorders of mood and emotion may show a common excessive or inappropriate brain 
excitability within crucial brain circuits, the L-glutamate system, which represents the 
primary excitatory neurotransmitter system in emotion and cognition circuits, is 
increasingly considered to play an important role in mental disease etiology and 
persistence. Several lines of evidence from human clinical studies link dysfunction in the 
L-glutamate system to the pathogenesis of psychiatric disorders (Cortese and Phan, 2005). 
For instance, changes in glutamate levels have been found in plasma, cerebrospinal fluid 
(CSF), and in the brain of patients suffering from mood and anxiety disorders (Levine et 
al., 2000; Mauri et al., 1998; Mitani et al., 2006). Interestingly, recent postmortem studies 
showed significant increases in glutamate levels in the frontal cortex and dorsolateral 
prefrontal cortex of depressed and bipolar patients, respectively (Hashimoto et al., 2007; 
Lan et al., 2009). Furthermore, various clinical neuroimaging studies have consistently 
demonstrated volumetric changes in brain regions, in which glutamatergic neurons 
predominate, such as the hippocampus, amygdala and several cortical regions (Lorenzetti 
et al., 2009). 
The L-glutamate neurotransmitter system of the emotion and cognition circuitry of 
mammalian brains is composed of a large diversity of genetically regulated factors, 
including a group of vesicular, glial and synaptic glutamate transporters (Sheldon and 
Robinson, 2007) as well as two families of glutamate receptors: ligand-gated ionotropic 
glutamate receptors (iGlu) comprising (2R)-2-(methylamino)butanedioic acid (NMDA)-, 
2-amino-3-(5-methyl-3-oxo-2,3-dihydro-1,2-oxazol-4-yl)propanoic acid (AMPA)- and 
(2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate (kainate, 
KA)-receptors (Nakanishi, 1992; Planells-Cases et al., 2006; Willard and Koochekpour, 
2013; Xiao et al., 2001), and the G protein-coupled metabotropic glutamate receptor 
(mGlu) subtypes -1 to -8 (mGlu1-8; Conn, 2003; Nicoletti et al., 2011; Pinheiro and Mulle, 
2008; Willard and Koochekpour, 2013).  
Throughout the last three decades, several drug discovery efforts were made targeting iGlu 
receptors, with preclinical and clinical data demonstrating NMDA and AMPA receptors to 
be promising targets in controlling cognitive and emotional changes observed in stress-
related disorders (Boyce-Rustay and Holmes, 2006; Graybeal et al., 2012; Kim et al., 1996; 
Magariños and McEwen, 1995). In this regard, a major breakthrough came from clinical 
studies using the NMDA receptor antagonist ketamine by showing clinical efficacy in 
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treatment-resistant depression (TRD) and major depressive disorder (MDD) patients. 
Interestingly, ketamine administered intravenously showed strong decreases in the 
Hamilton Depression Rating Scale (HDRS) analysis, with an improvement observed 2 h 
after infusion that remained significant for over 1 week (Berman et al., 2000; Zarate et al., 
2006). However, this iGlu receptor-based strategy is not devoid of limitations and risks, as 
ketamine administration has also been shown to be associated with cognitive and 
dissociative adverse effects, which thus limits ketamine’s widespread application for the 
treatment of mood disorders (Pilc et al., 2008; Witkin et al., 2007). In contrast, therapeutic 
strategies targeting mGlu receptors represent a more subtle alternative in regulating 
excitatory (and possibly inhibitory) neurotransmission and are therefore considered to have 
a more favorable side-effect profile than ligand-gated ion channel modulation (Cartmell 
and Schoepp, 2000; Niswender and Conn, 2010). Indeed, signaling via mGlu receptors is 
slower and longer lasting than via iGlu receptors, allowing fine-tuning of glutamate 
regulation and its cellular responses, which could eventually avoid the adverse effects 
associated with direct modulation of iGlu receptors. In addition to that, growing evidence 
gives rise to mGlu-based compounds to be effective in regulating iGlu receptor signaling, 
further emphasizing the modulatory potential of mGlu receptors. 
 
2.1 Glutamate signaling via mGlu receptors in the CNS 
The existence of neuromodulatory glutamate receptors, namely the mGlu receptors, 
provides a mechanism by which binding of glutamate, in contrast to the fast synaptic 
responses mediated by iGlu receptors, slowly modulates cell excitability, synaptic 
neurotransmission and plasticity. mGlu receptor-induced modulation occurs via second 
messenger signaling pathways and their interactions with ion channels (C. H. Kim et al., 
2008; Rondard and Pin, 2015; Willard and Koochekpour, 2013; Yin and Niswender, 2014). 
According to sequence homology, second messenger coupling and pharmacological 
properties, the mGlu receptor family is subdivided into three groups. The group I members, 
mGlu1 and mGlu5, are coupled to Gq/11 proteins and primarily elevate 
{[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-
bis(phosphonooxy)cyclohexyl]oxy}phosphonic acid (IP3), diacylglycerol (DAG), and Ca
2+
 
signal transduction. In general, these receptor subtypes function to enhance glutamate-
mediated postsynaptic excitation (Abe et al., 1992; Bordi and Ugolini, 1999; Cartmell and 
Schoepp, 2000; S. J. Kim et al., 2008; D. Youn, 2014; D.-H. Youn, 2014). In contrast, 
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group II (mGlu2 and mGlu3) and group III (mGlu4, -6, -7, and -8) receptors inhibit 
adenylyl cyclase activity and other effector proteins via coupling to Gi/o proteins and 
thereby negatively modulate excitatory neurotransmitter efflux and neuronal excitability 
upon activation (Cartmell and Schoepp, 2000; Kintscher et al., 2012; Lavreysen and 
Dautzenberg, 2008; McMullan et al., 2012; Mercier and Lodge, 2014; Schoepp, 2001; 
Tang et al., 2013). Interestingly, various mGlu receptors are expressed in both neurons and 
glial cells of the CNS, as well as in peripheral tissue like the enteric nervous system or 
adrenal gland cells (Julio-Pieper et al., 2011). In neurons, group I receptors show 
predominantly postsynaptic location and modulate cell excitability, while group II and III 
members are mainly expressed at the presynapse and are involved in regulating 
neurotransmitter release, mostly inhibiting release (Conn and Pin, 1997; Swanson et al., 
2005). As they are members of class C GPCR, all mGlus are characterized by a large 
extracellular N-terminal “Venus flytrap domain” (VFTD), which is known to serve as the 
orthosteric ligand binding site and shows abundant homology between the different mGlu 
receptor subtypes. The binding site for allosteric modulators of the mGlus is located 
topographically distinct within the transmembrane domain (Christopoulos and Kenakin, 
2002; Flor and Acher, 2012; Gregory et al., 2013; Nickols and Conn, 2014; Wood et al., 
2011; Wu et al., 2014). As the allosteric binding site contains a higher level of sequence 
diversity between the receptor subtypes, allosteric ligands typically show greater subtype 
selectivity (Conn et al., 2009a, 2009b). Importantly, the widespread distribution of mGlu 
subtypes suggests that these modulatory receptors have the ability to participate in a broad 
array of physiological functions throughout the CNS and may represent suitable targets for 
therapeutic intervention in a variety of CNS disorders. Thus, the therapeutic potential of 
the mGlu receptors is increasingly receiving attention as possible treatment strategies for 
CNS diseases such as Parkinson’s disease (PD), Fragile X syndrome (FXS), schizophrenia, 
addiction and in particular depression and anxiety-related disorders (Herman et al., 2012; 
Nicoletti et al., 2015; Picconi and Calabresi, 2014; Pomierny-Chamioło et al., 2014; Scharf 
et al., 2014). 
 
2.1.1 Group I mGlu receptors: neurobiochemistry and distribution 
In general, the group I members mGlu1 and mGlu5 couple to Gq/11 proteins and activate 
phospholipase C, a process that results in the formation of IP3 and DAG (Figure 3). This 
classical pathway leads to intracellular Ca2+ mobilization and activation of protein kinase C 
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(PKC). Apart from this, group I receptors can also activate a range of further downstream 
effectors, most notably proteins involved in synaptic plasticity, such as mitogen-activated 
protein kinase/extracellular receptor kinase (MAPK/ERK) and a mammalian target of 
rapamycin (mTOR) (Fieblinger et al., 2014; Pałucha-Poniewiera et al., 2014b; Zhang et al., 
2015). With respect to their distribution, expression of both mGlu1 and mGlu5 primarily 
overlaps within brain regions implicated in mood disorders (Witkin et al., 2007). However, 
there are also distinct differences, with mGlu1’s expression being abundant in cerebellum, 
olfactory bulb, the CA3 region of the hippocampus, in thalamus, dentate gyrus and 
substantia nigra, whereas mGlu5 is highly expressed in telencephalic regions, CA1 and 
CA3 regions of the hippocampus, septum, basal ganglia, striatum, amygdala and nucleus 
accumbens (Ferraguti and Shigemoto, 2006; Pilc et al., 2008). In addition, mGlu5 is also 
expressed in glial cells (Figure 3), particularly in astrocytes, where its expression has been 
highlighted with respect to a number of potential physiological roles, e.g. neuroprotection 
(Bruno et al., 2001a, 2001b, 1999; D’Antoni et al., 2011; Verkhratsky and Kirchhoff, 
2007; Wierońska and Pilc, 2009).  
 
2.1.2 Group II mGlu receptors: neurobiochemistry and distribution 
In contrast to group I, the group II members mGlu2 and mGlu3 are coupled predominantly 
to Gi/o proteins, negatively modulating adenylyl cyclase activity and directly regulating ion 
channels and other downstream signaling components via the release of the Gβγ subunit. In 
addition, group II mGlus also couple to MAPK and phosphatidyl inositol 3- (PI3-) kinase 
pathways which are implicated in synaptic plasticity (D’Onofrio et al., 2001; Lin et al., 
2014; Niswender and Conn, 2010). Both mGlu2 and mGlu3 are localized presynaptically 
in rather preterminal than terminal axonal portions, distant from the active zone of 
neurotransmitter release, where they are potentially activated by synaptic glutamate 
spillover (Tamaru et al., 2001). mGlu2 mRNA is observed to be highly expressed in 
pyramidal neurons in the enthorhinal and parasubicular cortical regions and in granule cells 
of the dentate gyrus (Hayashi et al., 1993; Ohishi et al., 1993a). In contrast, mGlu3 mRNA 
is highly expressed in neurons of the cerebral cortex and the caudate-putamen and in the 
granule cells of the dentate gyrus (Ohishi et al., 1993b; Tanabe et al., 1993). In addition, 
the mGlu3 receptor subtype (Figure 3) is also prominently expressed in glial cells 
throughout the whole brain, and its activation provides robust neuroprotection in vitro and 
in vivo (Battaglia et al., 2014; Ciceroni et al., 2010; Durand et al., 2014, 2013). 
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2.1.3 Group III mGlu receptors: neurobiochemistry and distribution 
Group III represents the largest family of mGlu receptors and comprises the subtypes 
mGlu4, mGlu6, mGlu7 and mGlu8. Like group II, group III members are predominantly 
expressed presynaptically (Shigemoto et al., 1997; Figure 3) where they regulate 
neurotransmitter release (Antflick and Hampson, 2012; de Rover et al., 2008; Grueter and 
Winder, 2005; Panatier et al., 2004; Pinheiro and Mulle, 2008; Woodhall et al., 2007). By 
coupling to Gi/o proteins, their activation inhibits cAMP formation and indirectly affects 
synaptic transmission and neurotransmitter release by modulating membrane Ca2+- and K+-
channels (Lavreysen and Dautzenberg, 2008; Mercier and Lodge, 2014; Pin and Duvoisin, 
1995). As with group II mGlu receptors, the group III subtypes also couple to other 
signaling pathways, including MAPK and PI3-kinase, providing further complexity to the 
mechanisms by which they regulate synaptic transmission (Iacovelli et al., 2014, 2004, 
2002). Except for the mGlu6 receptor subtype, whose expression is restricted to the retina, 
all other group III mGlus are widely expressed throughout the mammalian brain and also 
in peripheral tissue (Julio-Pieper et al., 2011; Pilc et al., 2008). In detail, in the CNS the 
mGlu4 receptor subtype is highly expressed in the cerebellum, the olfactory bulb and 
thalamus as well as in the hippocampus, the cerebral cortex and basal ganglia in pre- and 
post-synaptical position (Corti et al., 2002; Kinoshita et al., 1996; Shigemoto et al., 1997). 
In addition, widespread peripheral mGlu4 expression has been shown also in the pancreas, 
adrenal glands and gastrointestinal tract (Akiba et al., 2009; Brice et al., 2002; Chang et al., 
2005; Sarría et al., 2006). The mGlu7 receptor is highly localized in the presynaptic active 
zone and abundantly expressed in brain regions such as neocortex, hippocampus, 
amygdala, locus coeruleus, thalamus and hypothalamus (Kinoshita et al., 1998; Kosinski et 
al., 1999; Ngomba et al., 2011). In the periphery, mGlu7 expression has been reported in 
the adrenal glands, the colon and stomach, among other areas (Julio-Pieper et al., 2010; 
Nakamura et al., 2010; Scaccianoce et al., 2003). The mGlu8 receptor is found 
predominantly in the CNS in presynaptic terminals in the olfactory bulb, hippocampus, 
cerebellum and cortical areas (Ferraguti and Shigemoto, 2006), but also in peripheral tissue 
such as pancreas and testis (Julio-Pieper et al., 2011). Interestingly, general expression 
levels of mGlu8 receptors seem considerably lower than those of mGlu4 and mGlu7 
(Niswender and Conn, 2010). 
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Figure 3. Schematic representation of mGlu receptors at the synapse. In general, group I mGlu subtypes 
are localized postsynaptically, whereas group II and III receptors are localized mainly in presynaptic 
locations. While the mGlu7 receptor subtype is localized in the active zone, mGlu subtypes 2, 3, 4, and 8 are 
generally found in perisynaptic locations on the presynapse. Group II and III receptors modulate the release 
of glutamate (right, red circles) or 4-aminobutanoic acid, GABA (left, blue circles). At the postsynaptic 
terminal, the ionotropic (2R)-2-(methylamino)butanedioic acid (NMDA)-, 2-amino-3-(5-methyl-3-oxo-2,3-
dihydro-1,2-oxazol-4-yl)propanoic acid (AMPA)- and (2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-en-2-
yl)pyrrolidine-2-carboxylate (kainate, KA)-receptors respond to glutamate with increases in intracellular 
sodium or calcium, promoting cell excitability. Group I mGlus signal via Gq/11 proteins to increase 
diacylglycerol (DAG) and phosphatidylinositol (PI). Importantly, mGlu5 and NMDA receptors are closely 
linked to each other via Shank, Homer and PSD-95 (postsynaptic density-95) proteins. Postsynaptic mGlu2/3 
and GABAB receptors couple to cAMP inhibition. Instead, GABAA chloride channels modulate intracellular 
chloride levels. Expression of mGlu3 and mGlu5 on glial cells has emerged as another key site for regulation 
of synaptic activity, however, the consequences of receptor activation on these cells and the exact signaling 
pathways are presently not well understood. Adapted from Peterlik et al. (2016a). 
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2.2 Dysregulation of brain mGlu receptor gene expression in chronic stress models 
– state of the art 
Recent findings clearly have sparked interest in neurobiological systems that were 
previously little explored in mood disorders, such as the glutamatergic system. In particular 
the clinical findings with ketamine have inspired new lines of preclinical research to 
explore the glutamate system in more detail, including modulatory receptors that could be 
targeted to achieve better side-effect profiles (Maeng and Zarate, 2007), and to investigate 
the underlying neural mechanisms. To my knowledge, only few studies have dealt with 
chronic stress and the involvement of mGlu receptors in the manifestation of stress-
induced changes. But some promising results have already emerged. Wierońska et al. 
(2001) addressed changes of mGlu5 expression in response to CMS exposure and reported 
an increase of mGlu5 protein expression in CA1 and a decrease in CA3 of the rat 
hippocampus. Furthermore, O’Connor and co-workers (2013a) found no changes of 
hippocampal group III mGlu receptor mRNA expression upon either chronic 
immobilization stress or chronic social defeat and concluded that hippocampal group III 
mGlu receptors may not be involved in the manifestation of behavioral and physiological 
changes observed in these models. However, early-life stress induced by maternal 
separation specifically reduced the expression of mGlu4 mRNA in the hippocampus, 
whereas mGlu7 and mGlu8 mRNA remained unaffected (O’ Connor et al., 2013). Taken 
together, they could demonstrate that there were only very few, but selective changes to 
group III mGlu receptors under early-life stress conditions. These findings ask for further 
research efforts to study mGlu receptors as potentially important players in chronic stress-
induced pathology. 
 
2.3 Current knowledge of mGlu receptor genetic and pharmacological modulation 
in acute and chronic stress 
A possible aim of pharmacological intervention targeting glutamate neurotransmission in 
stress-related disorders could be that excessive glutamate exposure in specific brain areas 
should be blocked, whereas normal glutamatergic neurotransmission should be kept 
unaffected. New ways of fine-tuning the glutamatergic system are now emerging via the 
pharmacological modulation of mGlu receptor subtypes (Bergink et al., 2004; Pilc et al., 
2008; Swanson et al., 2005; Witkin et al., 2007). The wide functional diversity and distinct 
distribution patterns of mGlu receptor subtypes provide an opportunity for selectively 
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targeting individual mGlu receptor subtypes in order to attempt the development of novel 
treatment strategies for emotional disorders. A large body of preclinical studies suggests 
that ligands for specific mGlu subtypes have potential in multiple mood disorders, 
including anxiety disorders and depression. More recently, data from clinical studies with 
mGlu subtype-selective ligands are beginning to emerge and are providing remarkable 
clinical efficacy of some of these compounds, which I discuss below. In doing so, I will 
elucidate the role of group I and III receptors in stress physiology and especially bring into 
focus the recent efforts on modulation of mGlu5 and mGlu7. 
 
2.3.1 Role of group I mGlu receptors in stress physiology – focus on mGlu5 
functional blockade 
Group I mGlu receptors are broadly distributed within the peripheral and central nervous 
system and are expressed at post- and perisynaptic sites in several areas implicated in 
anxiety and emotional processing, and there is evidence for the involvement of particularly 
the mGlu5 subtype in the pathophysiology of different emotional and somatic disorders. 
For example, human post-mortem studies reported specific reductions of total mGlu5 
mRNA and protein levels in the lateral cerebellum (S H Fatemi et al., 2013; S Hossein 
Fatemi et al., 2013)  and prefrontal cortex (Deschwanden et al., 2011) in MDD patients 
(Newell and Matosin, 2014). Furthermore, a study by Wierońska et al. (2001) showed an 
increase of mGlu5 expression in CA1 and a decrease in CA3 of rat hippocampus in 
response to CMS, supporting the involvement of mGlu5 in the pathophysiology of mood 
disorders in response to chronic stress. The mGlu5 receptor subtype functionally interacts 
with NMDA receptors by indirect physical and positive feedback linkage via a variety of 
intracellular mechanisms including Homer, Shank and PSD-95 proteins (Collett and 
Collingridge, 2004; Homayoun et al., 2004; Pignatelli et al., 2014; Stoop et al., 2003; Tu et 
al., 1999; Turle-Lorenzo et al., 2005; Wagner et al., 2014; Figure 3). This close functional 
association and positive reciprocal regulation between mGlu5 and NMDA makes the 
mGlu5 receptor subtype an attractive target for the indirect modulation of NMDA receptor 
function, which is known to be dysregulated in a variety of neuropsychiatric pathologies 
including mood disorders (Geddes et al., 2011; Hashimoto, 2013; Tokita et al., 2012; 
Weickert et al., 2013). Importantly, as pharmacological activation of mGlu5 is shown to 
cause neurotoxicity and neurodegeneration (Battaglia et al., 2004; Bruno et al., 2001a; 
Nicoletti et al., 1999), the activating mode of action will not be considered in the context of 
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mGlu5’s potential therapeutic application. In contrast, pharmacological blockade of mGlu5 
function has recently emerged to be one of the most promising and quite advanced 
therapeutic strategies for the treatment of psychiatric conditions (Jaeschke et al., 2015; Li 
et al., 2013; Lindemann et al., 2015, 2011; Michalon et al., 2014, 2012; Tian et al., 2015; 
Wagner et al., 2014). This approach has demonstrated anti-stress efficacy in a number of 
animal and human studies and studies using mGlu5-deficient mice elegantly support the 
functional role of mGlu5 fear learning (Lu et al., 1997; Xu et al., 2009), acute stress 
physiology (J Brodkin et al., 2002) and depression-related behaviors (Li et al., 2006).  
3-(3-chlorophenyl)-1-(1-methyl-4-oxo-5H-imidazol-2-yl)urea (fenobam), a compound 
shown to be a clinically active anxiolytic already in the early 1980s (Lapierre et al., 1982; 
Pecknold et al., 1982), was recently described to exert its pharmacological effects via 
inverse receptor agonist activity at the mGlu5 receptor (Porter et al., 2005). Moreover, 
allosteric blockade of mGlu5 with the prototypical allosteric receptor antagonist 2-methyl-
6-(2-phenylethynyl)pyridine (MPEP) showed broad anxiolytic and antidepressant-like 
profiles in acute rodent animal models (Gasparini et al., 2008; Li et al., 2006; Liu et al., 
2012; Spooren et al., 2000; Tatarczyńska et al., 2001). Li et al. (2006) reported that 
administration of MPEP and the tricyclic antidepressant (TCA) imipramine resulted in a 
synergistic antidepressant-like effect in the FST and that this effect was even persistent 
after sub-chronic treatment (once daily, for five consecutive days). A further study 
revealed that MPEP remained equally active in reducing the SIH response in mice after 
sub-chronic dosing for five consecutive days, with comparable efficacy as after acute 
administration (Nordquist et al., 2007). Those studies provided the first evidence that 
longer-term administration of mGlu5 blockers may have the potential to ameliorate stress-
induced pathophysiology. Moreover, MPEP’s anxiolytic activity could be confirmed in a 
battery of further acute animal models, such as the EPM, Vogel conflict- and marble 
burying tests and the fear-potentiated startle paradigm (Jesse Brodkin et al., 2002; 
Kłodzińska et al., 2000; Pilc et al., 2002; Spooren et al., 2000; Tatarczyńska et al., 2001). 
Another selective mGlu5 receptor antagonist, 3-[2-(2-methyl-1,3-thiazol-4-
yl)ethynyl]pyridine (MTEP), turned out to be a good pharmacological tool to confirm 
antistress activity in several behavioral models (Cosford et al., 2003; Klodzinska et al., 
2004; Molina-Hernández et al., 2006; Pałucha-Poniewiera et al., 2014a; Pomierny-
Chamioło et al., 2010; Tichá et al., 2011). MTEP showed activity in the FST, TST and 
olfactory bulbectomy (OB) model (Belozertseva et al., 2007; Pałucha et al., 2005). In the 
latter, repeated administration of MTEP attenuated the OB-related hyperactivity of rats in 
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the open field test, a finding that resembles the action of typical antidepressants in the OB 
model of depression (Pałucha et al., 2005). Obviously, both MPEP and MTEP have been 
studied in a wide range of preclinical animal models for different therapeutic indications, 
however, both compounds are not suitable drug candidates for clinical development due to 
pharmacokinetic constraints (Lindsley and Emmitte, 2009). Furthermore, acute 
administration of the recently discovered mGlu5-selective negative allosteric modulator 
(NAM) 2-{2-[2-(difluoromethoxy)-5-({5H,6H,7H-pyrrolo[3,4-b]pyridin-6-
yl}carbonyl)phenyl]ethynyl}pyridine (GRN-529) showed dose-dependent efficacy across a 
broad battery of animal models, including the FST and TST, anxiety tests (attenuation of 
SIH response and increased punished crossings in the four plate test) and pain models 
(reversal of hyperalgesia due to sciatic nerve ligation or inflammation) (Hughes et al., 
2013). Another novel and highly selective mGlu5 receptor antagonist, 
methyl(3aR,4S,7aR)-4-hydroxy-4-[2-(3 methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-
2H-indole-1-carboxylate (AFQ056, mavoglurant), showed an even improved 
pharmacokinetic profile in rodents and better efficacy in SIH tests in mice as compared to 
the prototypic mGlu5 antagonist MPEP (Vranesic et al., 2014). Interestingly, efficacy of 
AFQ056 has been reported also in L-dopa-induced dyskinesia in Parkinson's disease and 
Fragile X syndrome in proof-of-principle clinical studies (Gomez-Mancilla et al., 2014; 
Petrov et al., 2014; Rascol et al., 2014; Vranesic et al., 2014). Recently, the mGlu5-
selective NAM 2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-
yl]ethynyl}pyridine (basimglurant) turned out to be very promising in a phase II clinical 
study as an adjunctive therapy in MDD patients by demonstrating safety and efficacy using 
multiple read-outs. This study showed that a 6-week double-blind treatment of 
basimglurant vs. placebo reached significant improvements in patient-rated Montgomery-
Asberg depression rating scale (MADRS) results, in remission assessment and further 
ratings (Jaeschke et al., 2015; Lindemann et al., 2015; Quiroz et al., 2015). The 
consistency of the efficacy findings combined with good tolerability warrants further 
investigation with basimglurant in depressive disorders. Furthermore, the recently 
discovered mGlu5 NAM 2-chloro- 4-[2-[2,5-dimethyl-1-[4-
(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine (CTEP), a compound chemically 
similar to basimglurant and optimized for utility in rodent studies, was shown to be active 
in acute rodent models, such as the SIH test in mice and the Vogel conflict test in rats 
(Lindemann et al., 2011). CTEP is the first reported mGlu5 inhibitor with both, very long 
half-life of approximately 18 h and high oral bioavailability in rodents, classifying as 
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useful pharmacological tool for long-term treatment. CTEP thus allows the exploration of 
the full therapeutic potential of mGlu5 inhibition for indications requiring chronic receptor 
blockade. Indeed, Michalon et al. (2014, 2012) found out that chronic treatment with 
CTEP in a mouse model of Fragile X rescued learning and memory deficits, elevated 
locomotor activity and increased spine density, suggesting that this mGlu5 NAM treatment 
may be effective in correcting multiple neurological symptoms (Lindemann et al., 2015). 
Furthermore, a very recent study reported that chronic administration of CTEP was able to 
alleviate some CSDS-induced depressive-like symptoms, such as reduced locomotion and 
an anhedonic phenotype, while lacking protective effects on selected physiological 
parameters (Wagner et al., 2014). However, the stress-protective relevance of mGlu5 
particularly under permanent chronic psychosocial stress conditions with respect to a 
broader range of pathologies has not been addressed so far. 
 
2.3.2 Role of group III mGlu receptors in stress physiology – focus on mGlu7 
functional blockade 
Group III mGlu receptors have received somewhat less attention, mostly due to the 
obvious paucity of pharmacological tools available to study them (Flor and Acher, 2012; 
Lavreysen and Dautzenberg, 2008; Mercier and Lodge, 2014; Schoepp et al., 1999). 
Nevertheless, they are thought to be involved in a number of disease states and 
physiological conditions, consistent with their role in the regulation of both glutamatergic 
and GABAergic neurotransmission throughout the brain (Drew et al., 2008; Farazifard and 
Wu, 2010; Guimarães-Souza and Calaza, 2012; Jang, 2014; Macinnes and Duty, 2008; 
Semyanov and Kullmann, 2000; Summa et al., 2013). Much of our current knowledge still 
relies on studies performed by direct central application of compounds and on the 
characterization of genetically manipulated animals under basal and under stress 
conditions. For instance, Tatarczyńska et al. (2002) found out that intraventricular injection 
of the group III mGlu receptor agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-
tricarboxylic acid (ACPT-I) produced both anxiolytic- and antidepressant-like effects. Its 
anxiolytic action was shown in both the SIH and EPM tests in mice, and in the Vogel 
conflict test in rats. Its antidepressant-like action was evaluated in the FST (Stachowicz et 
al., 2009; Tatarczyńska et al., 2002). Interestingly, another study showed that the 
antidepressant-like effects of centrally applied ACPT-I could be reversed by the group III 
mGlu receptor antagonist 2-amino-2-cyclopropyl-2-(4-phosphonophenyl)acetic acid 
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(CPPG) (Pałucha et al., 2004). However, these compounds are not subtype-selective, as 
they act at all members of group III receptors, making it impossible to allocate these effects 
to a specific receptor subtype. Addressing the influence of mGlu4, Kłak et al. (2007) could 
show that the combined administration of the mGlu4-selective PAM 7-hydroxyimino-N-
phenyl-1,7a-dihydrocyclopropa[b]chromene-1a-carboxamide (PHCCC) and a non-
effective dose of ACPT-I produced antidepressant-like efficacy in the rat FST. A further 
study demonstrated that administration of PHCCC into the basolateral amygdala resulted 
in dose-dependent anti-conflict effects in the rat Vogel conflict test, indicating that positive 
allosteric modulation of mGlu4 receptors may be a useful therapeutic approach for anxiety 
(Stachowicz et al., 2004). More recently, the peripheral use of (1R,2S)-2-[(3,5-
dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid (VU0155041), an mGlu4 PAM 
(Niswender et al., 2008), demonstrated anxiolytic action in the elevated zero maze 
(Duvoisin et al., 2011). In addition, the novel mGlu4 PAMs (1S,2R)-2-
[(aminooxy)methyl]-N-(3,4-dichlorophenyl)cyclohexane-1-carboxamide (Lu AF21934) 
and 4-methyl-N-[5-methyl-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-yl]pyrimidin-2-amine 
(ADX88178) have been reported to induce anxiolytic-like effects in acute rodent models 
including SIH, four-plate and marble-burying test, and also to be active in multiple models 
of Parkinson’s disease (Kalinichev et al., 2014; Sławińska et al., 2013). Interestingly, 
mGlu4-deficient mice exerted increased measures of anxiety in acute models, including the 
open field and elevated zero maze, and impaired sensorimotor function on the rotarod test 
(Davis et al., 2012). Consistent with this, they also showed enhanced amygdala-dependent 
cued fear conditioning (Davis et al., 2013). Similar to these findings, mice lacking mGlu8 
showed higher measures of anxiety as compared to control animals (Duvoisin et al., 2005; 
Linden et al., 2002) and when exposed to novel, aversive environments, they exhibit 
greater neuronal activation in stress-related brain regions (Linden et al., 2003). These 
studies suggest enhanced reactivity to stressors in mice deficient for mGlu4 or mGlu8. To 
go on with mGlu8, acute pharmacological stimulation with its agonist 4-[(1S)-1-amino-2 
hydroxy-2-oxoethyl]phthalic acid (DCPG) reduced innate anxiety in the open field and 
EPM tests (Duvoisin et al., 2010) and reduced the expression of contextual fear without 
affecting the acquisition and expression of cued fear (Fendt et al., 2013). Furthermore, 2-
amino-2-(4-phosphonophenyl)acetic acid (RS-PPG), an mGlu8 receptor-preferring agonist, 
induced dose-dependent antidepressant-like effects in the FST after central administration 
(Pałucha et al., 2004). Moreover, the mGlu8-selective PAM 2-{[(4-
bromophenyl)methyl]sulfanyl}-N-[4-(butan-2-yl)phenyl]acetamide (AZ12216052) 
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reduced measures of anxiety in the open field and EPM tests (Duvoisin et al., 2010). 
However, as this anxiolytic effect was still present in mGlu8-KO mice, the effect of 
AZ12216052 on measures of anxiety likely involves molecular targets other than mGlu8, 
too (Duvoisin et al., 2011). Nevertheless, the behavioral data so far suggest that mGlu4 and 
mGlu8 receptor activation may render anxiolytic, anti-stress as well as antidepressant-like 
effects (Raber and Duvoisin, 2014).  
With respect to the mGlu7 subtype, the most widely distributed of the presynaptic mGlu 
receptors, clear evidence for its important role in fear and stress physiology comes from 
studies using mice with genetic ablation of mGlu7 (Cryan et al., 2003; Fendt et al., 2013; 
Masugi et al., 1999). These mice are characterized by reduced amygdala-dependent 
conditioned fear and aversion. Moreover, they display an anti-depressant and anxiolytic-
like phenotype in acute behavioral tests for despair and innate anxiety (Cryan et al., 2003; 
Masugi et al., 1999). In addition, mGlu7-deficient mice have increased hippocampal brain-
derived neurotrophic factor (BDNF) protein levels and show an upregulated GR-dependent 
feedback suppression of the HPA axis (Mitsukawa et al., 2006), further supporting 
mGlu7’s critical role in stress physiology. Regarding pharmacological modulation, only a 
few systemically active allosteric modulators for mGlu7 were identified so far, yielding 
interesting results in acute behavioral paradigms. For instance, the first mGlu7-selective 
allosteric agonist N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082) was 
shown to elevate basal plasma ACTH and CORT levels (Mitsukawa et al., 2005), 
displayed mGlu7-dependent antidepressant-like activity  (Bradley et al., 2012; Palucha et 
al., 2007), and modulated acquisition and extinction of conditioned fear (Fendt et al., 2013, 
2008; Toth et al., 2012). At a first glance, these effects seem to be in contradiction with the 
anxiolytic- and antidepressant-like behavioral changes observed in mice lacking mGlu7 or 
after siRNA-mediated knockdown of the receptor (O’Connor et al., 2013b). However, 
AMN082 has been shown also to induce rapid and lasting mGlu7 internalization, a form of 
functional antagonism and a possible mechanism for the drugs anxiolytic- and 
antidepressant-like activity (Pelkey et al., 2007). A further explanation would be that 
AMN082 not only binds to mGlu7 but with weaker affinity also to monoamine 
transporters, similar to its primary metabolite N-benzhydrylethane-1,2-diamine (Met-1), 
which inhibits serotonin and norepinephrine reuptake transporters with a physiologically 
relevant affinity (Sukoff Rizzo et al., 2011). Altogether, these findings may explain the 
seemingly conflicting results obtained using AMN082 in vivo. Similar to AMN082, two 
systemically active mGlu7 NAMs have also yielded divergent results in behavioral tests, 
Introduction 
39 
 
despite displaying very similar pharmacological properties in vitro. 6-(2,4-
dimethylphenyl)-2-ethyl-4,5,6,7-tetrahydro-1,3-benzoxazol-4-one (ADX71743) was 
shown to have robust anxiolytic effects in the EPM and the marble burying test 
(Kalinichev et al., 2013). In contrast, 6-(4-methoxyphenyl)-5-methyl-3-(pyridin-4-yl)-
4H,5H-[1,2]oxazolo[4,5-c]pyridine-4-one (MMPIP) was reported to have only weak 
anxiolytic activity but reversed antidepressant-like effects of AMN082 in rats (O’Connor 
and Cryan, 2013; Pałucha-Poniewiera and Pilc, 2013). In addition, MMPIP was reported to 
impair cognitive performances in the object recognition and the object location test 
(Hikichi et al., 2010). Like AMN082, both NAMs likely act via allosteric sites in more 
lipophilic domains and, thus, may be associated with desirable off-target effects. 
Furthermore, allosteric ligands have been shown to act in a context-dependent manner and 
not to necessarily affect all downstream signaling pathways of a given GPCR (Niswender 
et al., 2010). The recent discovery and characterization of the mGlu7 antagonist 7-
hydroxy-3-(4-iodophenoxy)-4Hchromen-4-one (XAP044) may have provided a step 
forward in understanding mGlu7’s function. XAP044 was identified as the first mGlu7-
selective full antagonist that binds to the receptor’s VFTD, a mechanism alternative to 
binding to allosteric sites.  
In summary, pharmacological blockade of mGlu7 may represent the most promising mode 
of action in attempting to reverse stress-related pathophysiological states in psychiatric 
illness. In line with this, human genetic studies with depressed siblings and recurrent MDD 
patients pointed at GRM7 (the gene coding for mGlu7 receptors) as a gene potentially 
involved in human depression (Hamilton, 2011; Shyn et al., 2011). Taken together, 
considerable progress has been made in recent years in increasing our understanding of 
particularly the mGlu7 receptor within the CNS, and has remarkably revealed key roles for 
this receptor subtype in acute stress, fear- and depression-related behavior, thereby 
emphasizing the therapeutic potential of group III-directed ligands and asking for future 
studies under chronic stress conditions. 
 
 
3. Concluding introductory remarks 
Encouraging evidence has emerged from both preclinical and clinical research in recent 
years, supporting key roles for the brain glutamatergic neurotransmitter system in the 
physiology of psychiatric disorders. However, only little is known about the contribution 
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of the glutamate system to the pathophysiology following chronic psychosocial stress, 
which is the most acknowledged risk factor for emotion disorders, such as anxiety and 
depression (Caspi et al., 2003; Cryan and Holmes, 2005; Cryan and Slattery, 2007; de 
Kloet et al., 2005; Hammen, 2005; Schneiderman et al., 2005; Virtanen and Kivimäki, 
2012). Moreover, current drug discovery efforts targeting the mGlu receptors led to the 
identification of pharmacological tools with promising efficacy in psychiatric conditions 
(Conn et al., 2009a; Lavreysen and Dautzenberg, 2008; Mercier and Lodge, 2014; Nicoletti 
et al., 2015; Swanson et al., 2005). The potential of these pharmacological tools in the 
manifestation of physiological and behavioral consequences of chronic psychosocial stress 
still needs to be investigated. On a preclinical basis, the CSC paradigm might be an 
appropriate animal model, as it utilizes chronic psychosocial stressor exposure and results 
in decreased GC signaling and concomitant somatic and affective pathologies, such as an 
overall proinflammatory and cancer-prone phenotype and an anxiogenic and substance 
abuse phenotype (Füchsl et al., 2014; Langgartner et al., 2015; Peters et al., 2013, 2012; 
Reber et al., 2007; Schmidt et al., 2010; Uschold-Schmidt et al., 2013, 2012). All these 
consequences are relevant for the development of somatic, e.g. gastrointestinal, and/or 
psychiatric disorders and the question whether mGlu receptors have the potential to modify 
these consequences is of great interest. 
The recent discoveries of CTEP and basimglurant, two compounds with markedly 
improved pharmacokinetic and safety profiles as compared to previous mGlu5 NAMs, 
such as MPEP and MTEP, may be most suitable to study the long-term effects of mGlu5-
blockade in vivo following chronic stress exposure. Most notably, CTEP’s sufficiently long 
half-life amenable for once daily administration in rodents and its high in vivo potency to 
achieve a low application dose makes it a suitable compound for chronic application and 
for the study of mGlu5’s role in chronic stress conditions. Indeed, Wagner et al. (2014) 
demonstrated that sustained mGlu5 receptor blockade via sub-chronic CTEP 
administration was able to recover CSDS-induced behavioral alterations. The finding, that 
CTEP did not have any stress-protective effects on selected physiological parameters, 
requires further investigation. A potentially profitable approach in this regard may be to 
investigate whether chronic CTEP administration can attenuate the various physiological, 
immunological, and also behavioral consequences of chronic psychosocial stress induced 
by CSC exposure. Such studies may suggest future therapeutic avenues for mGlu5 NAMs 
in chronic clinical conditions, including somatoform psychiatric disorders. 
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The mGlu7 receptor is also a promising target in chronic stress physiology, but the 
question still remains, which mechanism of action – its activation or its blockade – might 
be effective in ameliorating the detrimental consequences of chronic psychosocial stress. 
Considerable progress has been made with the discovery of the mGlu7 agonist AMN082 
(Mitsukawa et al., 2005) and the mGlu7 NAM ADX71743 (Kalinichev et al., 2013), two 
compounds that have shown robust efficacy in animal models for anxiety and depression, 
but have not yet been investigated in any context of chronic or even psychosocial stress. Of 
note, the recent discovery of the first orthosteric-like mGlu7 antagonist XAP044 (Gee et 
al., 2014), might provide an additional and suitable tool compound to elucidate the role of 
mGlu7 in chronic psychosocial stress conditions, at least in rodents. Moreover, the use of 
mice lacking mGlu7 might help to dissect the role of mGlu7 in chronic psychosocial stress 
conditions and to suggest which mode and direction of mGlu7 modulation might be 
preferable.  
Taken together, there is emerging evidence that makes it worthwhile to further investigate 
in detail the potentially beneficial roles of especially mGlu5 and mGlu7 subtype-selective 
modulation in the context of chronic psychosocial stress and to provide a better 
understanding of the neural mechanisms involved and regulated by mGlu receptors. 
Besides providing fundamental neurophysiological insights, these investigations will 
hopefully stimulate drug development towards mGlu5- and mGlu7-targeted therapies 
aiming at the large panel of human chronic stress-induced disorders. 
 
 
 
4. Aims of the present thesis 
The present PhD thesis can be separated into two major parts: 
 
1.) In vivo characterization of the first orthosteric-like mGlu7-selective antagonist 
XAP044. 
 
2.) Investigation of molecular changes within the L-glutamate system in response to 
chronic psychosocial stress in mice, with a focus on mGlu receptors. Detailed analysis of 
potentially beneficial roles of selective mGlu5 and mGlu7 receptor subtype modulation on 
chronic psychosocial stress. 
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Ad 1.) 
A very recent study paved the way in advancing our understanding of mGlu7 function and 
its therapeutic implication. Gee et al. (2014) presented XAP044, the first mGlu7-selective 
full antagonist that blocks the receptor’s signaling pathways via binding to its hydrophilic 
VFTD close to the L-glutamate binding site. Thus, XAP044 presumably acts via a novel 
site compared to the allosteric ligands described above (AMN082, ADX717343, MMPIP). 
Moreover, XAP044 was shown to selectively block long-term potentiation (LTP) in the 
lateral amygdala of wildtype but not of mGlu7-deficient mice, further substantiating a role 
for mGlu7 in the cellular physiology of the fear and emotion circuitry. It was part of the 
present PhD thesis to characterize XAP044 in vivo in a broad battery of acute stress tests 
for innate anxiety, depression and conditioned fear tests in mice and thus to demonstrate a 
new mechanism of mGlu7 receptor binding to have potential therapeutic usefulness.  
The results presented here contributed to and are part of the study published by Gee et al. 
(2014) in the Journal of Biological Chemistry. 
 
Ad 2.) 
The L-glutamate system has often been addressed in the context of acute stress, fear- and 
depression-related behavior. A number studies provide striking evidence that both the 
mGlu5 and mGlu7 subtypes are crucially involved in the regulation of physiological 
processes associated with acute stress, fear and depression-related behaviors as well as in 
the regulation of neuroendocrine function. However, only little is known about the role 
these receptors play in chronic psychosocial stress, the most acknowledged risk factor for 
emotion and somatoform disorders. Therefore, at least two main questions emerged: i) 
what are the molecular changes that occur within the mGlu receptor system in response to 
chronic psychosocial stress? ii) Is it possible to ameliorate the chronic stress-induced 
detrimental behavioral, physiological and immunological consequences by genetic and 
pharmacological modulation of the mGlu5 and mGlu7 receptor subtypes? These questions 
were addressed by using the CSC paradigm, an animal model that utilizes chronic 
psychosocial stressor exposure and that results in concomitant affective and somatic 
alterations. Given the crucial role of mGlu5 and mGlu7 in the regulation of acute stress and 
fear as well as of neuroendocrine function, robust alterations were expected in gene 
expression levels of both receptor subtypes after CSC exposure in brain regions involved 
in the control of behavioral and physiological stress responses. Therefore, potential effects 
of CSC were assessed on mGlu receptor mRNA expression particularly in the prefrontal 
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cortex (PFC), the hypothalamus (HT) and the hippocampus (HC). Furthermore, functional 
inhibition of mGlu5 and mGlu7 was predicted to result in a decreased vulnerability to 
chronic psychosocial stress, i.e. lower levels of anxiety and relief of physiological and 
immunological maladaptations. To this end, conventional mGlu7 knockout (KO) mice  and 
corresponding wildtype (WT) mice exposed CSC were assessed with respect to selected 
stress-related behavioral parameters, HPA axis functionality and immune function. On the 
other hand, to reveal a potential stress-protective role of mGlu5 inhibition, conventional 
mGlu5 KO exposed to CSC were analyzed with respect to the same parameters as above 
and compared to corresponding WT mice. Moreover, to extend the findings from the 
mGlu5 KO and to obtain independent evidence for mGlu5 receptor inhibition to be stress-
protective, CTEP was continuously infused via micro-osmotic pumps in mice during CSC 
exposure and selected parameters were analyzed after 19 days of CSC in these mice. 
Material and Methods 
The Material and Methods section includes chapters taken and adapted from one joint first 
author publication and submitted first author manuscripts: 
1.) Gee, C.E.*, Peterlik, D.*, Neuhäuser, C., Bouhelal, R., Kaupmann, K., Laue, G., 
Uschold-Schmidt, N., Feuerbach, D., Zimmermann, K., Ofner, S., Cryan, J.F., van der 
Putten, H., Fendt, M., Vranesic, I., Glatthar, R., Flor, P.J., 2014. Blocking metabotropic 
glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits 
amygdala plasticity, stress, and anxiety-related behavior. J. Biol. Chem. 289, 10975–87. 
doi:10.1074/jbc.M113.542654.* Both authors contributed equally to this work. (J. Biol. 
Chem. permits the author to include published journal articles in full or in part in the 
author’s dissertation) 
2.) Peterlik, D., Stangl, C., Bauer, A., Bludau, A., Keller, J., Grabski, D., Killian, T., 
Schmidt, D., Zajicek, F., Jaeschke, G., Lindemann, L., Reber, S.O., Flor, P.J., Uschold-
Schmidt, N., 2016b. Blocking Metabotropic Glutamate Receptor Subtype 5 Relieves 
Maladaptive Stress Consequences Induced by Chronic Male Subordination. Brain. Behav. 
Immun., doi:10.1016/j.bbi.2016.08.007, in press. (Brain. Behav. Immun. permits the author 
to include published journal articles in full or in part in the author’s dissertation) 
3.) Peterlik, D., Stangl, C., Bludau, A., Grabski, D., Strasser, R., Schmidt, D., Flor, P.J., 
Uschold-Schmidt, N., 2016c. Relief from detrimental consequences of chronic 
psychosocial stress in mice deficient for the metabotropic glutamate receptor subtype 7. 
Neuropharmacology, doi:10.1016/j.neuropharm.2016.04.036, in press. 
(Neuropharmacology permits the author to include published journal articles in full or in 
part in the author’s dissertation) 
 
Peterlik D. is responsible for design and performance of the experiments, data collection, 
analysis and interpretation and writing of the first drafts of the manuscripts. 
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1. Material 
1.1 Drugs 
Drug Chemical structure Manufacturer 
XAP044  http://www.chemspider.c
om/Chemical-
Structure.4558326.html?
rid=bf8d5965-13d8-
47fb-b100-
460b3e813d63 
Novartis 
Pharma AG 
(Basel, 
Switzerland) 
Imipramine  http://www.chemspider.c
om/Chemical-
Structure.3568.html?rid=
870b2d98-2cdb-4bd0-
8f5f-260882edb9cb 
Sigma-Aldrich 
(Deisenhofen, 
Germany) 
Diazepam  http://www.chemspider.c
om/Chemical-
Structure.2908.html?rid=
671408ba-819e-4757-
bc8f-7e8a2519dd5b 
Ratiopharm 
GmbH (Ulm, 
Germany) 
MPEP  http://www.chemspider.c
om/Chemical-
Structure.2291589.html?
rid=5bb4801b-8774-
475f-86a2-
9dcefb25ea73&page_nu
m=0 
Novartis 
Pharma AG 
(Basel, 
Switzerland) 
CTEP  http://www.chemspider.c
om/Chemical-
Structure.9821562.html?
rid=bd3aa80f-3ed3-
4477-9e76-
21d53a6c1811 
F. Hoffmann-
La Roche Ltd. 
(Basel, 
Switzerland) 
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1.2 RNA processing, reverse transcription and quantitative PCR (qPCR) 
Application Product Company 
 
 
 
 
RNA 
isolation 
Trizol reagent (peqGOLD Trifast) Peqlab (Erlangen, Germany) 
Chloroform Acros organics (Geel, Belgium) 
Isopropanol Merck (Darmstadt, Germany) 
Ethanol Mallinckrodt Baker (Griesheim, 
Germany) 
Glycogen (20 mg/ml) Thermoscientific (Braunschweig, 
Germany) 
DEPC (for 0.1 % DEPC water) Carl Roth (Karlsruhe, Germany) 
RNA 
measurement 
Spectrophotometer ND-100 Peqlab (Erlangen, Germany) 
 
 
 
 
Reverse 
transcription 
dNTPs mix (10 mM) Carl Roth (Karlsruhe, Germany) 
Oligo (dT) primer NEB (Frankfurt, Germany) 
DEPC (for 0.1 % DEPC water) Carl Roth (Karlsruhe, Germany) 
FS buffer (5x) Invitrogen (Karlsruhe, Germany) 
MgCl2 (50 mM) Invitrogen (Karlsruhe, Germany) 
DTT (0.1 M) Invitrogen (Karlsruhe, Germany) 
RNase Out (40 U/μl) NEB (Frankfurt, Germany) 
SuperScript® III RT (200 U/μl) Invitrogen (Karlsruhe, Germany) 
RNase H (5.000 U/ml) NEB (Frankfurt, Germany) 
 
qPCR 
SYBR®Green (fast, Master Mix) Applied Biosystems (Darmstadt, 
Germany) 
7500 Fast Real-Time PCR System Applied Biosystems (Darmstadt, 
Germany) 
 
1.3 Oligonucleotides 
The following oligonucleotides were used as primers for gene expression analysis via 
qPCR. All primers were designed using Primer Express 3.0 software (Applied Biosystems, 
Darmstadt, Germany) and were purchased from Metabion (Martinsried, Germany). 
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Gene 5’-3’ Sequence 
GAPDH forward TGTGTCCGTCGTGGATCTGA 
GAPDH reverse CCTGCTTCACCACCTTCTTGA 
mGlu2 forward CGTGTCCGTCAGCCTCAGT 
mGlu2 reverse TGGCTCACCACGACGTTCTTCTG 
mGlu3 forward TGTGATGGTGTCTGTGTGGCT 
mGlu3 reverse GTTTCCCGCTTCTCTGGCA 
mGlu5 forward TGTGTACCTTCTGCCTCATTGC 
mGlu5 reverse GGAGAGAGACCGATGCCAATT 
mGlu7 forward GCAGAAGGAGCCATCACCAT 
mGlu7 reverse GTCCGGGATGTGAAGTAAGCA 
 
1.4 Blood hormone level analysis and adrenal ACTH stimulation in vitro 
Application Product Company 
Blood sampling EDTA-coated tubes Sarstedt (Nürnbrecht, Germany) 
 
 
 
Adrenal ACTH stimulation 
in vitro 
DMEM/F-12 
 
Life Technologies (Darmstadt, 
Germany) 
BSA Sigma-Aldrich (Deisenhofen, 
Germany) 
ACTH 1-24 (100 nM) Sigma-Aldrich (Deisenhofen, 
Germany) 
Saline (0.9 % NaCl) Braun Melsung AG (Melsung, 
Germany) 
Plasma ACTH 
measurement 
ACTH ELISA Kit IBL International (Hamburg, 
Germany) 
Plasma and adrenal 
supernatant CORT 
measurement 
CORT ELISA Kit IBL International (Hamburg, 
Germany) 
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1.5 Analysis of immunological parameters 
Application Product Company 
 
 
 
 
 
 
Mes LNC isolation and 
stimulation in vitro with 
anti-CD3/anti-CD28 
Cell strainer (70 µm) Becton Dickinson Biosciences 
(Heidelberg, Germany) 
RPMI 1640 Sigma-Aldrich (Deisenhofen, 
Germany) 
Fetal bovine serum 
(FBS) superior 
Biochrom AG (Berlin, Germany) 
Penicillin PAA laboratories GmbH (Cölbe, 
Germany) 
Streptomycin PAA laboratories GmbH (Cölbe, 
Germany) 
β-mercaptoethanol PAA laboratories GmbH (Cölbe, 
Germany) 
anti-CD3 antibody BD Biosciences (Heidelberg, 
Germany) 
anti-CD28 antibody eBioscience GmbH (Frankfurt, 
Germany) 
IFN-γ measurement IFN-γ ELISA Kit BioLegend (London, England) 
 
 
 
 
 
Colon processing/staining 
Embedding cassettes Simport Plastics Ltd. (Bernard-
Pilon, 
Beloeil QC, Canada) 
Harris haematoxylin Sigma-Aldrich (Deisenhofen, 
Germany) 
Eosin Y solution Sigma-Aldrich (Deisenhofen, 
Germany) 
Microscope slides 
(SuperFrost) 
Gerhard Menzel GmbH 
(Braunschweig, Germany) 
Mounting solution, 
Roti Histokitt II 
Carl Roth (Karlsruhe, Germany) 
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1.6 Chemicals, enzymes, reagents and technical equipment 
Chemicals, enzymes and reagents used in this thesis were obtained from Beckman Coulter 
(Krefeld, Germany), Biomol (Hamburg, Germany), Bio-Rad (München, Germany), Braun 
(Melsungen, Germany), Carl Roth GmbH (Karlsruhe, Germany), Merck (Darmstadt, 
Germany), Sigma-Aldrich (Deisenhofen, Germany). Cell culture materials, general plastic 
material and other equipment were purchased from BD Biosciences (Heidelberg, 
Germany), Beckman Coulter (Krefeld, Germany), Eppendorf AG (Hamburg, Germany), 
Leica Microsystems (Wetzlar, Germany), Sarstedt (Nürnbrecht, Germany), Thermo 
Scientific (Rockford, USA) and VWR GmbH (Darmstadt, Germany). 
 
1.7 Software 
Application Product Company 
Text and data 
processing 
Microsoft Office 2013 Microsoft 
Graph plotting SigmaPlot 11.0 Systat software 
Reference 
management 
Mendeley 1.15 (freeware) Chip.de/downloads 
EPM analysis Plusmaze (DOS program, ©Ernst 
Fricke, 1993) 
Ernst Fricke 
ELISA analysis FLUOstar OPTIMA BMG Labtech GmbH (Offenbach, 
Germany) 
Statistical 
analysis 
SPSS 22.0 IBM 
 
 
2. Methods 
2.1 Animals 
The in vivo effects of XAP044 were assessed in the TST, the EPM and the cued fear 
conditioning test in individually housed male C57BL/6 WT mice (Charles River, Sulzfeld, 
Germany; see Results, 1). 
The effects of acute and sub-chronic CTEP treatment on SIH response (Results, 4.7) were 
assessed also in individually housed male C57BL/6 WT mice (Charles River, Sulzfeld, 
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Germany). For investigating the consequences of 19 days of CSC exposure on mGlu 
receptor mRNA expression, male C57BL/6 WT mice (Charles River, Sulzfeld, Germany) 
weighing 19-22 g and exposed to 19 days of CSC were used (Results, 2).  
For studying the influence of mGlu7 genetic ablation on the consequences of 19 days of 
CSC (Results, 3.1-3.4), male C57BL/6 mGluR7 KO mice (generated as described 
previously from E14 (129/Ola) embryonic stem cells; Sansig et al., 2001) and their male 
WT littermates (from C57BL/6 heterozygous breeding pairs in the animal facility of the 
University of Regensburg) were used. Aged 6-8 weeks and weighing 19-22 g, these 
experimental mice were individually housed in standard polycarbonate mouse cages (16 x 
22 x 14 cm) for one week before the start of CSC exposure.  
For studying the influence of genetic and pharmacological inhibition of mGlu5 the 
consequences of 19 days of CSC (Results, 4), conventional C57BL/6 mGlu5 KO mice and 
C57BL/6 mice chronically infused with CTEP were used in combination with the CSC 
paradigm. Here, male C57BL/6 mGlu5 KO mice and their male WT littermates (from 
C57BL/6 heterozygous breeding pairs in the animal facility of the University of 
Regensburg), and male C57BL/6 WT mice (Charles River, Sulzfeld, Germany), aged 6-8 
weeks and weighing 19-22 g were used as experimental mice and individually housed in 
standard polycarbonate mouse cages (16 x 22 x 14 cm) for at least one week before starting 
the CSC procedure. Male CD1 mice weighing 30-35 g from our own breeding were used 
as dominants. 
 
In all experiments, mice were kept under standard laboratory conditions (12 h light/dark 
cycle, lights on at 0600 h, 22 °C, 60% humidity) with free access to tap water and standard 
mouse diet (ssniff Spezialdiäten GmbH, Soest, Germany). All experimental protocols were 
approved by the Committee on Animal Health and Care of the local government and 
conformed to the international guidelines on the ethical use of animals. All efforts were 
made to minimize the number of animals used and their suffering. 
 
2.2 Drug treatment and surgical procedure 
Acute application of XAP (i.p.) 
XAP044 (identified by high throughput random drug screening and follow-up chemical 
efforts; Gee et al., 2014), MPEP, diazepam, and imipramine were dissolved in 10% 
Neoral® vehicle (Novartis Pharma AG, Basel, Switzerland) and diluted in 0.4% 
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methylcellulose (AMIMED, Allschwill, Switzerland). Either vehicle (10% Neoral® 
vehicle, 0.4% methylcellulose), XAP044 (10 and 60 mg/kg), imipramine (20 mg/kg), 
diazepam (1 mg/kg) or MPEP (30 mg/kg) were administered i.p. at a volume of 10 ml/kg 
body weight 30 min prior to respective in vivo testing. Imipramine and diazepam served as 
positive controls for the TST and the EPM test, respectively. MPEP was used as positive 
control in the cued fear conditioning experiment. 
 
Chronic application of CTEP via micro-osmotic pumps 
To achieve permanent receptor saturation during CSC exposure, CTEP (F. Hoffmann-La 
Roche, Basel, Switzerland) was administered chronically via Alzet® micro-osmotic pumps 
(pumping rate: 0.11 µl/h, Alzet®, Model 1004, Cupertino, USA). Compound release 
initiated one week prior starting the CSC paradigm (day -6) in order to establish a stable 
baseline receptor occupancy and continued until the end of chronic stressor exposure (day 
20). Micro-suspensions of CTEP were prepared in vehicle (VEH, polyethyleneglycol 400 
(PEG), Sigma Aldrich, Steinheim, Germany) and sonicated (3 x 1.5 min) to ensure a 
continuous substance release of 0.05, 0.5 or 2 mg/kg/day. As reported by Peters et al. 
(2014), a micro-osmotic pump was implanted s.c. in the abdominal region through a 1 cm 
long incision at the lower neck of the mouse under isoflurane anesthesia (Baxter, GmbH, 
Germany). To avoid post-surgical infections, each mouse received 100 µl of antibiotics 
(s.c., Baytril® 2.5% Bayer Vitral GmbH, Leverkusen, Germany), followed by wound 
treatment with betaisodona (Mundipharma GmbH, Limburg, Germany).  
Using micro-osmotic pumps for this purpose was of particular advantage (in terms of 
animal welfare and experimental convenience), as multiple injections associated with 
frequent manipulation of animals have been shown to alter the animal’s phenotype by 
affecting behavioral and other parameters. For example, vehicle or sham injections were 
associated with impairment of the animal’s behavior in the EPM test (Lapin, 1995). 
Moreover, preliminary studies in our group revealed that repeated (daily) i.p. injections of 
vehicle (0.5% methylcellulose) resulted in an increased adrenal and decreased thymus 
weight when compared to non-injected controls (unpublished data) and thus demonstrated 
that daily i.p. injections induced stress effects interfering with the effects of CSC 
procedure. On this background, chronic administration of CTEP via micro-osmotic pumps 
offered the advantage of not requiring daily animal manipulation and the risk of impairing 
sensitive CSC-related parameters. Of note, it was recently demonstrated that i.c.v. 
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administration of drugs via micro-osmotic pump is well compatible with the CSC 
procedure in mice (Peters et al., 2014). 
 
Acute and sub-chronic application of CTEP (i.p.) 
To verify and to extend (with respect to the route and duration of administration) the 
anxiolytic properties of oral CTEP reported by Lindemann et al. (2011), the effect of acute 
and sub-chronic CTEP treatment on the SIH response in naïve C57BL/6 mice was 
assessed. Here, SIH measurement took place 1 h following a single i.p. injection (acute), or 
on day 16 and day 24 following 8 and 12 i.p. injections every 48 h (sub-chronic), 
respectively. CTEP doses were either 0.1, 0.5 or 2 mg/kg with a volume of 2.5 ml/kg body 
weight. 
 
2.3 Acute behavioral tests 
2.3.1 The TST 
The TST was carried out in a gray Plexiglas box containing three compartments separated 
by gray Plexiglas walls, each compartment measuring 38 x 38 x 80 cm, between 0800 h 
and 1100 h. To evaluate the effects of systemic XAP044 administration on depressive-like 
behavior, mice were injected i.p. with vehicle (10% Neoral® vehicle, 0.4% 
methylcellulose), imipramine (20 mg/kg) as positive control, or XAP044 (10 and 60 
mg/kg). After 30 min they were individually suspended by the tail to a vertical ring-stand 
bar (distance from floor: 40 cm) using adhesive tape (distance from tip of tail: 2 cm). 
Typically, the animals demonstrated several phases of escape-oriented behavior with 
temporally increasing periods of immobility. A 6-min test session was employed, which 
was videotaped and subsequently analyzed for the time the mice spent immobile (Results, 
1.1) by a trained observer blind to the treatment. 
 
2.3.2 Cued fear conditioning and fear expression 
To assess conditioned freezing response in mice, a computerized fear-conditioning system 
(TSE, Bad Homburg, Germany) was used as described previously (Fendt et al., 2013; Toth 
et al., 2012). The cued fear experiments were performed in two different contexts, A and 
B, that differed in visual, tactile, and olfactory cues. On day 1, fear acquisition was 
assessed in context A, which consisted of a transparent perspex box (45 x 45 x 40 cm) with 
a transparent lid. The floor was made up of 45 x 0.4 m stainless steel bars set 0.5 cm apart, 
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which served as conductors of mild foot shocks. The boxes were located in a wooden 
chamber to reduce external noise and visual stimulation, provided with loudspeakers for 
the acoustic stimuli, and ventilation fans producing a low background noise. Illumination 
(300 lx for context A and 20 lx for context B) was provided by four white LEDs. To 
evaluate the effects of systemic XAP044 administration on conditioned freezing response, 
mice were individually placed into the conditioning chamber (context A) and, after a 5-min 
adaptation period, exposed to five CS-US pairings 30 min after i.p. injection of vehicle 
(10% Neoral® vehicle, 0.4% methylcellulose), MPEP (30 mg/kg) as positive control, or 
XAP044 (10 and 60 mg/kg). The conditioned stimulus (CS) was a white noise (80 db, 8 
kHz, 30 s), which co-terminated with a mild electric food shock (US, 0.6 mA, 2 s) with a 2 
min inter-trial interval (Results, 1.3). After the CS-US pairings, mice were left in the 
conditioning chamber for 5 min before they were returned to their home cage. The 
conditioning chamber was cleaned with a neutral smelling detergent before each trial. On 
day 2, fear expression was evaluated in context B, which consisted of a black box (45 x 45 
x 40 cm) with a smooth floor. After a 5 min adaptation period, the animals received two 
CS presentations (80 db, 8 kHz, 30 s) with an inter-stimulus interval of 30 s (Results, 1.3). 
Context B was cleaned with a lemon-scented detergent before each trial. Animal 
movement was detected with infrared sensors. In both the fear acquisition and the fear 
expression phases, the time spent freezing (immobility, no infrared beam crosses for more 
than 1 s) relative to the total time (set to 100%) was automatically recorded and defined as 
freezing response (%) (Fanselow, 1980). 
 
2.3.3 The EPM test 
The EPM consisted of two bight, open (130-140 lx, 6 cm  x 30 cm) and two dark, closed 
(10-20 lx, 6 cm x 30 cm x 17 cm) arms radiating from a central platform (6 cm x  6 cm) to 
form a plus-shaped figure elevated 130 cm above the floor. The open arm edges were 0.3 
cm in height to prevent mice from falling. Each mouse was placed on the central platform 
facing a closed arm (CA). The maze was cleaned thoroughly before each test. EPM testing 
period was 5 min and took place between 0800 h and 1100 h. Animal movement on the 
EPM was monitored by a camera and subsequently analyzed using the program Plus-maze 
(DOS program, Ernst Fricke, 1993, Munich, Germany) by an observer blind to the 
animal’s treatment/genotype/housing condition. The percentage of time spent on open 
arms of the EPM was used as a measure of anxiety. In addition, the number of closed-arm 
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entries was taken as an indicator for locomotor activity. In all experiments, mice were 
transported to the EPM room one day prior to testing. 
To evaluate the effects of systemic XAP044 administration on innate anxiety-related 
behavior, each mouse was tested 30 min after i.p. injection of vehicle (10% Neoral® 
vehicle, 0.4% methylcellulose), diazepam (1 mg/kg) as positive control, or XAP044 (10 
and 60 mg/kg) (Results, 1.2). 
In order to assess genotype- (Results, 3 and 4) or treatment-specific (Results, 4) effects of 
CSC on innate anxiety-related behavior, mice were tested on the EPM day 18 of CSC 
exposure. After testing, CSC mice were put back in their respective CSC colony and SHC 
mice were kept single-housed. Different to what was previously described (Füchsl et al., 
2014; Peters et al., 2014; Reber et al., 2007), day 18 instead of day 19 of CSC was chosen 
for assessing innate anxiety-related behavior on the EPM in the present thesis, as mice 
were additionally tested for their physiological anxiety in the more stressful SIH test on 
day 19. 
  
2.3.4 The SIH test 
The SIH test was performed as described elsewhere (Gee et al., 2014; O’Connor et al., 
2013b; Peterlik et al., 2016a) between 0800 h and 1000 h in a room different from where 
the animals were housed before in order to avoid any confounding influence of housing on 
test performance and vice versa. Rectal temperature was recorded twice at T1 and T2 (15 
min later) using a digital thermometer (2.5 mm diameter, Amarell GmbH and Co KG, 
Kreuzwertheim, Germany). In order to avoid any rectal injuries the thermometer was 
covered with vaseline before inserting it 1.5 cm into the rectum. Recording of T1 indicated 
baseline temperature and served as stressor at the same time. Recording of T2 allowed 
determination of the SIH response defined as the difference between T2 and T1. SIH 
measurement was performed on day 19 of CSC exposure in CSC and SHC mice (Results, 
4.1) or after acute and sub-chronic treatment (Results, 4.7) in naïve mice, with all mice 
individually housed between the two temperature recordings at T1 and T2. In CSC-related 
experiments, SIH measurement was established in order to complement potential effects of 
CSC on physiological anxiety, in addition to the well characterized effects on (innate) 
anxiety-related behavior (Langgartner et al., 2015; Reber et al., 2007; Slattery et al., 2012). 
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2.4 The CSC paradigm 
The CSC paradigm was conducted as described previously (Langgartner et al., 2015; 
Peterlik et al., 2016a; Reber et al., 2007). Briefly, experimental mice were assigned to the 
SHC or CSC group in a genotype- , treatment- as well as weight-matched manner. Four 
CSC mice of the same genotype or the same treatment were housed together with a 
dominant male for 19 consecutive days in order to induce chronic psychosocial stress. To 
avoid habituation during chronic stressor exposure, each dominant male was replaced by a 
novel one on days 8 and 15 (Figure 2a). As appropriate controls, SHC mice were used 
(Singewald et al., 2009), in line with previous studies demonstrating single-housing to be 
less stressful in male mice as compared to group housing (Bartolomucci et al., 2003; 
Chourbaji et al., 2005; Gasparotto et al., 2005). SHC mice remained undisturbed in their 
home cage except for change of bedding once a week. On day 18 and 19 of CSC, animals’ 
innate and physiological anxiety were assessed on the EPM (day 18) and in the SIH test 
(day 19), respectively. After testing, stressed mice were placed back into their respective 
CSC colony and SHC mice remained single-housed. On day 20, all mice were rapidly 
decapitated between 0800 h and 1100 h and trunk blood was collected for quantification of 
plasma CORT and plasma ACTH levels, and pituitary, adrenal, thymus and spleen 
weights, as well as the in vitro ACTH responsiveness of adrenal explants were assessed. In 
addition, the histological damage score of the colon, the number of viable mesenteric 
lymph node cells (mesLNC) and anti-CD3/anti-CD28-stimulated IFN-γ production of 
mesLNC in vitro were determined (detailed description see below). 
 
2.5 Trunk blood sampling 
To determine the effects of CSC exposure on basal morning plasma ACTH and CORT 
concentrations, mice were rapidly killed by decapitation under CO2 anesthesia within 3 
minutes after entering the animal room between 0800 h and 1100 h on day 20. Trunk blood 
was collected in EDTA-coated tubes (Sarstedt, Nuembrecht, Germany) on ice and 
centrifuged at 4 °C (5000 rpm for 5 min). Plasma was isolated and samples were stored at -
20 °C until assayed. 
In addition, the concentration of CTEP in plasma (day 20) of CSC and SHC animals 
treated with CTEP at different doses (Discussion, 4.2) was determined. Analysis was 
performed by F. Hoffmann-La Roche Ltd. (Basel, Switzerland) using a combined high-
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performance liquid chromatography/mass spectrometry (HPLC/MS) method as described 
in Lindemann et al. (2011). 
 
2.6 Determination of body and organ weight and brain dissection 
On day 20, mice were weighed immediately before decapitation to assess the effects of 
CSC on body weight. Afterwards, the pituitary, left and right adrenal glands, thymus and 
spleen of each animal were removed, pruned from fat and weighed separately. In addition, 
the sum of left and right absolute adrenal weights was calculated for each animal. Until all 
mice were killed and all adrenals removed, the latter were stored in ice-cold DMEM 
(DMEM/F-12, Life Technologies, Darmstadt, Germany) containing 0.1% bovine serum 
albumin (BSA). Values represent absolute measurements (in mg) of respective organs. 
The brain was carefully removed from the cranium (with careful removal of the dura 
mater), followed by immediate dissecting in PFC, HT and HC as described in the 
following: The PFC was extracted by vertical cutting off 1-2 mm of the frontal part of the 
brain. Subsequently, the hypothalamus was carefully cut using micro-scissors. At last, the 
hippocampi were removed after separating the two hemispheres by a median cut of the 
cortex and pulling out both the left and the right hippocampus by means of forceps and 
razor blade. All brain regions were immediately stored in Trizol reagent (Peqlab, Erlangen, 
Germany; for total RNA isolation) or snap-frozen in liquid nitrogen (for mGlu5 protein 
analysis performed by F. Hoffmann-La Roche Ltd., Basel, Switzerland). 
 
2.7 ACTH stimulation of adrenal explants in vitro 
Stimulation of adrenal explants with ACTH (100 nM) in vitro was performed as previously 
described (Füchsl et al., 2014; Peters et al., 2014; Uschold-Schmidt et al., 2012). Briefly, 
left and right adrenals were stored in ice-cold DMEM/F-12 (Life Technologies, Darmstadt, 
Germany) containing 0.1% BSA until all mice were killed and adrenals removed. 
Afterwards, each left and right adrenal gland was cut into two halves each containing 
cortical and medullary tissue. The halves were weighed and pre-incubated in 200 ml 
DMEM/F-12 for 4 h (37 °C, 5% CO2) prior to any further treatment. Culture medium was 
then replaced, and each half of one adrenal was incubated with medium containing either 
0.9% saline (basal) or 0.9% saline plus ACTH (100 nM) for 6 h (37 °C; 5% CO2). After 
incubation, supernatants were carefully removed and stored at -20 °C until being analyzed 
using a commercially available ELISA for CORT (IBL International, Hamburg, Germany). 
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CORT concentrations were calculated in relation to the weight of the respective adrenal 
explants (i.e. relative CORT secretion). To illustrate the in vitro adrenal CORT secretion in 
relation to the whole organism, relative CORT secretion from the left and right adrenal 
gland of each mouse was summed up. 
 
2.8 ELISA for CORT and ACTH 
Plasma and supernatant samples were analyzed using a commercially available ELISA for 
CORT (analytical sensitivity ˂ 1.631 nmol/l and intra-assay and inter-assay coefficients of 
variation (CV) ≤ 6.35%; IBL International, Hamburg, Germany) and ACTH (plasma 
samples only; analytical sensitivity 0.22 pg/ml and intra-assay and inter-assay CV ≤ 7.1%; 
IBL International, Hamburg, Germany).  
 
2.9 Isolation and incubation of mesLNC 
To determine housing-, genotype- and treatment-specific effects of CSC on the IFN-γ 
secretion of anti-CD3 and anti-CD28-stimulated mesLNC in vitro, mesenteric lymph nodes 
were isolated from each animal as described previously (Füchsl et al., 2014; Reber et al., 
2007). Mesenteric lymph nodes were stored in ice-cold RPMI medium (RPMI 1640, 10% 
FCS, 100 U/ml Penicillin, 100 µg/ml Streptomycin and 3 x 10-5 M β-mercaptoethanol) 
until all mice were killed and mesenteric lymph nodes removed. Afterwards, mesenteric 
lymph nodes were mechanically homogenized and filtered through a cell strainer (70 μm 
nylon, Falcon; Becton Dickinson Biosciences, Heidelberg, Germany). The cell suspension 
was centrifuged for 15 min (16000 rpm, 4°C, Allegra X-12R, Beckman Coulter) and 
supernatant was discarded. In turn, cell pellet was re-suspended in 5 ml RPMI medium and 
(viable) cell number was assessed using a cell viability analyzer (Vi-Cell XR; Beckman 
Coulter, Krefeld, Germany). Then, 5 x 105 (100 µl) mesLNC were transferred to 2 wells of 
a 96-well plate pre-coated with anti-CD3 antibody (2.5 µg/ml) and were additionally 
stimulated with anti-CD28 antibody (0.5 µg/well, 100 µl). After incubation for 24 h (37 
°C, 5% CO2; Results, 4.1) or 48 h (37 °C, 5% CO2; Results, 3.4 and 4.5), IFN-γ levels 
were measured in the supernatants of two wells per animal by ELISA (BioLegend, San 
Diego, USA) and averaged per animal and group. 
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2.10 Determination of the histological damage score in the colon 
The histological damage score of colonic tissue was determined as described previously 
(Obermeier et al., 2003; Reber et al., 2007). The colon was removed and mechanically 
cleaned from feces. Afterwards, 1 cm of the distal third was cut longitudinally, laid on a 
filter paper, and fixed in 5% paraformaldehyde overnight. The next day, the fixed tissue 
was embedded in paraffin and cut. For each animal two longitudinal 3 µm sections were 
taken at 100 µm distance and stained with hematoxylin and eosin according to the 
following staining procedure: 
Xylol 2 x 5 min  100% EtOH 2 x 1 min  90% EtOH 1 min  70% EtOH 1 min  
distilled H2O 1 min  hematoxylin 10-15 min  hot H2O 3 min  cold H2O 3 min  
eosin 0.5-2 min  distilled H2O brief rinsing  70% EtOH 2 x 1 min  90% EtOH 1 min 
 100% EtOH 2 x 1 min  Xylol 2 x 5 min 
 
Mice were scored individually, each score representing the mean of the two sections. 
Histological scoring was evaluated by an investigator blind to housing/treatment/genotype 
conditions, according to the following scheme: 
Epithelium Infiltration 
0, normal morphology 0, no infiltration 
1, loss of goblet cells 1, infiltrate around crypt basis 
2, loss of goblet cells in large areas 2, infiltrate reaching to lamina muscularis 
mucosae 
3, loss of crypts 3, extensive infiltration reaching and 
thickening of the mucosa with abundant 
oedema 
4, loss of crypts in large areas 4, infiltration of the lamina submucosa 
 
The total histological score of each mouse represents the sum of the epithelium and 
infiltration score within a range from 0 to 8. The scores were than averaged per animal and 
group. Respective SHC values were set to 100%. 
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2.11 Relative quantification of mGlu receptor mRNA via quantitative PCR 
(qPCR) 
The effect of 19 days of CSC on mGlu2 and mGlu3, mGlu5, and mGlu7 mRNA in PFC, 
HT and HC was determined relative to the expression of the housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in comparison to respective SHC 
controls (set at 100%). Here, total RNA was isolated using Trizol reagent according to 
manufacturer's instructions (Peqlab, Erlangen, Germany).  RNA was re-suspended in 20 µl 
of RNase free water and its concentration and quality were analyzed 
spectrophotometrically (NanoDrop Spectrophotometer, Peqlab, Erlangen, Germany).  
cDNA was prepared from 500 ng of total RNA in a 20 µl final reverse transcription 
reaction mixture (using Superscript III; Invitrogen, Karlsruhe, Germany).  Quantitative 
PCR was performed using SYBR® Green Master Mix and an ABI 7500 Fast Sequence 
Detection System (Applied Biosystems, Darmstadt, Germany), with a cycling profile of 
95°C (20 sec), followed by 40 cycles of 95°C (3 sec), 60°C (30 sec). Samples were 
prepared in triplicates and changes in gene expression were determined according to the 2-
ΔΔCT method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008) by using GAPDH 
for normalization and SHC as control. 
 
2.12 Receptor saturation analysis of mGlu5 
Briefly, analysis of mGlu5 receptor binding sites (Discussion, 2) was performed by F. 
Hoffmann-La Roche Ltd. (Basel, Switzerland) using a tritiated version of the mGlu5 PET 
tracer ABP688 ([3H]ABP688; Hintermann et al., 2007) as described elsewhere (Lindemann 
et al, 2011, 2015). 
 
2.13 Statistics 
All data represent the mean + or ± S.E.M. and were analyzed using the software IBM 
SPSS 22.0.  
TST and EPM test data obtained from XAP044 experiments (Results, 1.1, 1.2) were 
analyzed using a Kruskal-Wallis analysis of variance (ANOVA) followed by a post hoc 
Dunnett’s test when appropriate. Fear acquisition and fear expression data (Results, 1.3) 
were analyzed using repeated measures ANOVA followed by a post hoc Fisher’s least 
significant difference (LSD) test when appropriate. 
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Data obtained from CSC experiments depending on one factor (housing) were analyzed 
using an independent Student’s t-test (Results, 2 and 3.1). Data depending on two factors 
(i.e. housing and genotype, housing and treatment, housing and stimulation) were analyzed 
using two-way ANOVA. Significant main and interaction effects were followed by 
Bonferroni post hoc analysis when appropriate or an independent Student’s t-test (Results, 
3.2-3.4 and 4.1, 4.3-4.6). 
Data obtained from acute CTEP experiments depending on one factor (housing or 
treatment; Results, 4.7) were analyzed using independent Student’s t-test or one-way 
ANOVA followed by LSD post hoc testing.  
Data obtained from sub-chronic CTEP experiments depending on each other (Results, 4.7) 
were analyzed using repeated measures ANOVA followed by Bonferroni or LSD post hoc 
testing or an independent Student’s t-test. 
In all cases, statistical significance was accepted at p ≤ 0.05. 
Results  
The Results section includes chapters taken and adapted from different (joint) first author 
publications and submitted first author manuscripts: 
1.) Peterlik, D., Flor, P.J., Uschold-Schmidt, N., 2016a. The Emerging Role of 
Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related 
Disorders. Curr. Neuropharmacol., 14(5), 514–39. (Curr Neuropharmacol permits the 
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1. Acute pharmacological blockade of mGlu7 inhibits depressive-, 
anxiety-like and fear-related behavior 
The role of mGlu7 in anxiety and acute stress-related behavior and physiology is well 
documented (see Introduction), and several studies investigating mGlu7’s role in emotional 
behavior suggest receptor blockade as a promising mechanism for the treatment of various 
disorders in man. However, systemically active allosteric ligands so far have yielded only 
disparate results in behavioral paradigms. In a previous experiment at the Novartis 
Institutes for BioMedical Research (Basel, Switzerland; under the supervision of Prof. 
Peter J. Flor) it was already shown that XAP044 treatment dose-dependently reduced the 
stress-induced rise in rectal body temperature in the mouse SIH test. Importantly, XAP044 
did not show any significant effects on basal body temperature at any of the tested doses 
(10, 30 and 60 mg/kg, data not shown; see Gee et al., 2014). In the present study, the 
effects of XAP044 were further assessed in a broader range of behavioral tests including 
the TST, the EPM and the cued fear conditioning test. 
 
1.1 Attenuation of depressive-like behavior in the TST 
XAP044 treatment decreased immobility in the TST (H(3) = 32.2, p ≤ 0.001). Both 10 
mg/kg (p ≤ 0.01) and 60 mg/kg (p ≤ 0.001) of XAP044 significantly reduced the time the 
mice spent immobile compared to vehicle-treated animals 30 min following i.p. injection. 
Administration of the TCA imipramine (20 mg/kg; p ≤ 0.001), used as positive control, 
also reduced the immobility time compared to the vehicle group (Figure 4). 
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Figure 4. XAP044 attenuates depressive-like 
behavior in the tail suspension test (TST). 
Immobility time (s) in the TST 30 min following i.p. 
injection of imipramine (20 mg/kg; positive control), 
vehicle, or XAP044 (10 and 60 mg/kg) in mice. Data 
represent the mean + S.E.M.; **, p ≤ 0.01 vs. vehicle 
group; Kruskal-Wallis ANOVA followed by a post 
hoc Dunnett’s test; n = 8-14 per treatment group. 
IMI, imipramine; XAP, XAP044. Adapted from Gee 
et al. (2014). 
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1.2 Relief of innate anxiety in the EPM test 
XAP044 treatment decreased innate anxiety-related behavior in the EPM (H(3) = 19.4, p ≤ 
0.001; Figure 5). At a dose of 60 mg/kg, the i.p.-injected XAP044 significantly increased 
the ratio of open/total arm entries on the EPM (p = 0.006) compared to vehicle-treated 
mice, indicative of a decrease in anxiety-related behavior (Figure 5a). The same effect was 
seen in mice treated with the benzodiazepine diazepam (1 mg/kg; p ≤ 0.001; Figure 5a), 
used as positive control. Importantly, the number of total arm entries as an indicator of 
locomotor activity was neither affected by XAP044 nor by diazepam treatment (H(3) = 
3.2, p = 0.361; Figure 5b). 
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Figure 5. XAP044 relieves innate anxiety in the elevated plus-maze (EPM) test. (a) Ratio open/total arm 
entries and (b) number of total arm entries on the EPM 30 min following i.p. injection of diazepam (1 mg/kg; 
positive control), vehicle, or XAP044 (10 and 60 mg/kg) in mice. Data represent the mean + S.E.M.; **, p ≤ 
0.01 vs. vehicle group; Kruskal-Wallis ANOVA followed by a post hoc Dunnett’s test; n = 8-14 per 
treatment group. DZP, diazepam; XAP, XAP044. Adapted from Gee et al. (2014). 
 
1.3 Reduction of cued fear conditioning/learned fear without affecting fear 
expression 
Freezing of the mice during the fear conditioning session on day 1 was found to be 
significantly affected by the factor treatment (F3,35 = 16.992, p ≤ 0.001). Furthermore, the 
level of freezing increased across CS-US pairings (F5,175 = 154.599, p ≤ 0.001). Also, 
XAP044 injected i.p. at a dose of 60 mg/kg resulted in less freezing during the fear 
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acquisition session compared to the vehicle group, which was statistically significant when 
CS-US pairings were presented for the third time (p = 0.030; Figure 6a) and a trend was 
observed at the fifth CS-US pairing (p = 0.077; Figure 6a). This is indicative of delayed 
short-term fear acquisition by XAP044. As a positive control for delayed fear acquisition, 
the allosteric mGlu5 antagonist MPEP was used (30 mg/kg), which resulted in a significant 
reduction of the freezing response across all trials (p ≤ 0.032 for all pairings). Additionally, 
fear expression was assessed 24 h following conditioning session. However, neither 
XAP044 nor MPEP had any effect on the freezing response compared to vehicle-treated 
animals at CS presentations (F3,35 = 1.040, p = 0.387; Figure 6b). The effect of XAP044 to 
delay short-term fear acquisition in vivo corresponds well with XAP044’s mGlu7-
dependent inhibition of LTP in the lateral amygdala (Gee et al., 2014), an assay that is 
considered an in vitro electrophysiological correlate of fear learning. 
 
Figure 6. XAP044 reduces freezing during the acquisition session of fear conditioning. (a) Freezing 
response (% of time during conditioned stimulus presentation) during the acquisition of cued fear starting 30 
min following i.p. injection of either MPEP (30 mg/kg; positive control), vehicle, or XAP044 (10 and 60 
mg/kg) and (b) expression test on learned fear 24 h following conditioning session in mice. Data represent 
the mean ± S.E.M.; * p ≤ 0.05; **, p ≤ 0.01 vs. vehicle group; repeated measures ANOVA followed by a post 
hoc LSD test; n = 8-14 per treatment group. CS, conditioned stimulus; US, unconditioned stimulus; XAP, 
XAP044. Adapted from Gee et al. (2014). 
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2. Chronic psychosocial stress in mice affects mGlu5 and mGlu7, but not 
mGlu2/3 mRNA expression in distinct brain regions 
Although there is evidence for the involvement of the L-glutamate receptor system, e.g. the 
mGlu5 and mGlu7 receptors, in acute stress and fear regulation, possible molecular 
changes within the brain mGlu receptor system in response to chronic stress have been 
addressed only less so far. To extend and to specify the range of recent reports from 
chronic stress-induced mGlu receptor gene dysregulation, the gene expression profile of 
certain mGlu receptors was investigated upon chronic psychosocial stressor exposure in 
mice. Using the CSC animal model, the consequences of chronic psychosocial stressor 
exposure on mRNA expression of the mGlu2, -3, -5 and -7 subtypes in the PFC, HT and 
HC were assessed.  
Except for a trend towards upregulated mGlu3 mRNA levels in the HT (t16 = -2.042, p = 
0.058), no significant CSC-induced changes of mGlu2- or mGlu3 mRNA expression were 
found in either brain region investigated (Figure 7a, b), indicating that group II mGlu 
receptors may play a less prominent role in CSC-induced pathophysiology. Next, CSC 
resulted in a trend towards increased mGlu5 mRNA expression in the HT (t16 = -1.931, p = 
0.071; see also Peterlik et al. (2016b)), but not in the PFC or in the HC when compared to 
SHC mice (Figure 7c). In addition, mGlu7 mRNA levels were significantly reduced only 
in the PFC of CSC compared to SHC mice (HT, t17 = 2.456, p = 0.025; Figure 7d; see also 
Peterlik et al. (2016c)), suggesting that the mGlu7 receptor subtype is potentially involved 
in PFC-mediated emotional and/or cognitive processes that could be altered by CSC 
exposure. 
However, the present data display only mRNA expression changes of mGlu receptors – 
and no changes at the protein level. Together, the data at least suggest regulation of 
specific mGlu receptor subtypes in certain brain regions in response to chronic 
psychosocial stressor exposure. 
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Figure 7. Selective changes in relative mRNA expression of distinct mGlu receptors in the PFC, HT 
and HC in response to 19 days of CSC. mGlu2, mGlu3, mGlu5 and mGlu7 mRNA levels were assessed in 
CSC mice relative to the expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and in comparison to respective SHC mice (set at 100%). No significant effects of 19 days of CSC 
on (a) mGlu2 and (b) mGlu3 mRNA levels were found in either of the three brain regions. (c) 19 days of 
CSC resulted in an increase by trend of relative mGlu5 receptor mRNA expression in the HT (p = 0.071), 
whereas no changes were observed in the PFC and HC (adapted from Peterlik et al. (2016b)). (d) mGlu7 
mRNA levels were significantly reduced only in the PFC, but not in the HT and HC, after 19 days of CSC 
(adapted from Peterlik et al. (2016c)). White bar, SHC (n = 6); black bar, CSC (n = 9-11). Data represent 
mean + S.E.M. *p ≤ 0.05 vs. respective SHC mice, Student’s t-test; PFC, prefrontal cortex; HT, 
hypothalamus; HC, hippocampus. 
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3. Chronic psychosocial stress-protective phenotype in mice lacking 
mGlu7 
In order to evaluate a functional role of mGlu7 in chronic psychosocial stress-induced 
affective and somatic consequences, different behavioral, physiological, and 
immunological parameters were assessed in male mGlu7 KO mice and their WT 
littermates following 19 days of CSC exposure and compared to SHC mice. 
 
3.1 CSC-induced changes do not differ between C57BL/6J and C57BL/6N mice 
Prior to starting experiments with mGlu7 KO mice in the context of CSC, it was essential 
to show that CSC-induced behavioral and physiological changes described for C57BL/6N 
WT mice also occur in C57BL/6J mice, the background on which the mGlu7 mutant allele 
has been backcrossed for more than 14 generations (Cryan et al., 2003; Sansig et al., 2001). 
Therefore, C57BL/6J WT mice were exposed to 19 days of CSC and compared to SHC 
littermates. CSC exposure significantly increased innate anxiety on the EPM on day 19 
(reduced percentage of time on open arms; p = 0.026; Figure 8a) without altering 
locomotor activity (Figure 8b). Next, selected physiological parameters, exemplified by 
absolute adrenal and thymus weights, were also affected in response to CSC exposure. In 
detail, absolute adrenal weight was significantly increased (p = 0.004; Figure 8c), whereas 
absolute thymus weight was significantly decreased (p = 0.024; Figure 8d) in CSC 
compared to SHC mice.  
Together, these findings are well in agreement with the published literature on C57BL/6N 
mice (Langgartner et al., 2015; Reber et al., 2007) and thus provide a solid basis to 
continue with CSC experiments using KO mice that have been generated on the C57BL/6J 
background. 
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Figure 8. Effects of 19 days of CSC exposure on anxiety-related behavior and selected physiological 
parameters in C57BL/6J WT mice. In accordance with previously published findings in C57BL/6N mice 
(Langgartner et al., 2015; Reber et al., 2007), CSC induced an (a) increased anxiety-related behavior, 
indicated by a reduced percentage of time spent on the open arms (time ratio OA/TA (%) when compared to 
SHC mice. (b) Importantly, the number of closed arm (CA) entries (n) was comparable between both groups, 
reflecting an unaffected locomotor activity following CSC exposure. Moreover, (c) absolute adrenal weight 
(sum of both adrenals; mg) was increased and (c) absolute thymus weight (mg) was decreased in CSC 
compared to SHC mice. White bar, SHC (n = 7-8); black bar, CSC (n = 6-8). Data represent the mean + 
S.E.M, Student’s t-test; * p ≤ 0.05, ** p ≤ 0.01 vs. respective SHC mice. 
 
3.2 mGlu7 genetic ablation protects against the CSC-induced anxiety-prone 
phenotype  
mGlu7 KO mice were repeatedly shown to have a stress-protective phenotype with respect 
to acute stressor exposure. For example, they show a reduced hyperthermic response in the 
SIH test as well as reduced anxiety-related behavior when tested on the EPM compared to 
their WT littermates (Callaerts-Vegh et al., 2006; Cryan et al., 2003; Stachowicz et al., 
2008). The present study assessed whether mGlu7 genetic ablation also influences the 
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behavioral outcome of chronic psychosocial stressor exposure, more precisely the CSC-
induced anxiety-prone phenotype (Füchsl et al., 2014; Peters et al., 2014; Reber et al., 
2007). Assessment of anxiety-related behavior in the EPM test revealed a main effect of 
the factors housing (F1,88 = 13.658, p ≤ 0.001) and genotype (F1,88 = 5.741, p = 0.019), 
with a significantly decreased percentage of time spent on the open arms in CSC compared 
to SHC mice of the WT group (p ≤ 0.001; Figure 9a). This finding is in accordance with 
the literature and indicative for a CSC-induced increase in anxiety-related behavior. 
Interestingly, this CSC-induced decreased percentage of time spent on the open arms was 
absent in the KO group. Bonferroni post hoc analysis further revealed a significantly 
higher percentage of time spent on the open arms in CSC KO compared to CSC WT mice 
(p = 0.012; Figure 9a). Importantly, the number of CA entries, indicative for locomotor 
activity, was neither affected by CSC exposure nor by genotype (Figure 9b). Together, the 
present findings suggest that mice lacking mGlu7 are protected against developing the 
CSC-induced anxiety-prone phenotype. 
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Figure 9. Stress-protective effects of mGlu7 deficiency on the CSC-induced anxiety-prone phenotype. 
To assess chronic psychosocial stress effects on anxiety-related behavior, SHC and CSC mice of the wildtype 
(WT) and knockout (KO) group were exposed to the EPM on day 19 of CSC. (a) The percentage of time 
spent on the open arms (time ratio OA/TA in %) on the EPM was decreased in CSC compared to SHC mice 
only of the WT group, indicative for an increase in innate anxiety. Moreover, the percentage of time spent on 
the open arms was significantly higher in CSC KO compared to CSC WT mice. (b) The number of closed 
arm (CA) entries was neither affected by CSC nor by genotype, indicating unaffected locomotor activity. 
White bar, SHC (WT); black bar, CSC (WT); grey bar, SHC (KO); dashed bar, CSC (KO). n = 19-26 per 
genotype and housing group. Data represent mean + S.E.M. **p ≤ 0.01 vs. respective SHC group; #p ≤ 0.05 
vs. respective WT group; two-way ANOVA followed by Bonferroni post hoc analysis. Adapted from Peterlik 
et al. (2016c). 
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3.3 mGlu7 genetic ablation protects against CSC-induced physiological and 
neuroendocrine alterations 
Exposure to 19 days of CSC has been shown to result also in profound physiological and 
neuroendocrine changes (Füchsl et al., 2014; Reber et al., 2007; Uschold-Schmidt et al., 
2012; Veenema et al., 2008). In the present study, different relevant parameters following 
CSC exposure were assessed in detail in mGlu7 KO mice and their WT littermates to 
evaluate a potential involvement of mGlu7 in CSC-induced HPA axis dysfunction and 
other physiological parameters. First of all, assessing body weight gain revealed no effects 
of CSC exposure in WT mice, which is in line with the literature (Füchsl et al., 2014; 
Slattery et al., 2012; Veenema et al., 2008). In addition, no effects were also found in the 
mGlu7 KO group (Figure 10a). Absolute pituitary weight was found to be dependent on 
both the factor housing (F1,70 = 4.596, p = 0.036) and the factor genotype (F1,70 = 10.613, p 
= 0.002), with a significant increase in pituitary weight in WT animals exposed to CSC 
compared to respective SHC mice (p = 0.003). Interestingly, this CSC effect was absent in 
mGlu7 KO animals. Moreover, pituitary weight was significantly lower in CSC KO 
compared to CSC WT mice (p ≤ 0.001; Figure 10b). Analysis of absolute adrenal weight 
also revealed a main effect of both the factor housing (F1,69 = 56.725, p ≤ 0.001) and the 
factor genotype (F1,69 = 14.080, p ≤ 0.001). Bonferroni post hoc analysis showed a 
significant increase in weight in CSC compared to SHC mice of the WT group (p ≤ 0.001). 
This CSC effect was also present in the KO group, but less pronounced (p = 0.002). 
Therefore, adrenal weight was also significantly lower in CSC KO compared to CSC WT 
mice (p ≤ 0.001; Figure 10c). 
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Figure 10. Stress-protective effects of mGlu7 deficiency on CSC-induced physiological alterations. (a) 
Body weight gain during 19 days of CSC was neither affected by CSC nor by genotype. (b) 19 days of CSC 
induced a significant increase in absolute pituitary weight in the wildtype (WT) but not in the knockout (KO) 
group. In addition, pituitary weight was significantly lower in CSC KO compared to CSC WT mice. (c) CSC 
exposure also induced a significant increase in absolute adrenal weight in WT mice and a less pronounced 
increase also in KO mice. Hence, adrenal weight was significantly lower in CSC KO compared to CSC WT 
mice. White bar, SHC (WT); black bar, CSC (WT); grey bar, SHC (KO); dashed bar, CSC (KO). n = 14-23 
per genotype and housing group. Data represent mean + S.E.M. **p ≤ 0.01 vs. respective SHC group; ##p ≤ 
0.01 vs. respective WT group; two-way ANOVA followed by Bonferroni post hoc analysis. Adapted from 
Peterlik et al. (2016c). 
 
Furthermore, basal morning plasma ACTH levels were dependent on the factor housing 
(F1,68 = 6.462, p = 0.013), with significantly higher basal morning plasma ACTH levels in 
CSC compared to SHC mice of the WT group (p = 0.004). This stress effect was absent in 
the KO group (Figure 11a). Basal morning plasma CORT levels were neither dependent on 
the factor housing nor on the factor genotype (Figure 11b). It was further analyzed whether 
there were potential genotype-dependent effects of CSC exposure on adrenal ACTH 
responsiveness in vitro. In the WT group, there was a main effect of the factors housing 
(F1,48 = 15.587, p ≤ 0.001) and stimulation (F1,48 = 43.881, p ≤ 0.001), as well as a housing 
x stimulation interaction (F1,48  = 11.160, p = 0.002) on adrenal CORT secretion in vitro. In 
contrast, adrenal CORT secretion from explants of mGlu7 KO mice were only dependent 
on the factor stimulation (F1,44 = 31.576, p ≤ 0.001). Adrenal explants from both SHC (p ≤ 
0.001 for each genotype) and CSC (WT: p = 0.025; KO: p ≤ 0.001) mice showed an 
increased CORT secretion in response to ACTH compared to basal (saline) stimulation. 
However, adrenal CORT secretion in response to ACTH was significantly lower in CSC 
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compared to SHC mice of the WT group (p ≤ 0.001). This CSC-induced attenuation of 
adrenal in vitro ACTH responsiveness was absent in mGlu7 KO mice (Figure 11c).  
Together, these findings indicate that mGlu7 genetic ablation protects against developing 
CSC-induced HPA axis dysfunction. 
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Figure 11. Stress-protective effects of mGlu7 deficiency on CSC-induced alterations in HPA axis 
functionality. (a) The CSC-induced increase in basal morning plasma ACTH levels in wildtype (WT) mice 
was absent in knockout (KO) mice. (b) There was neither an effect of housing nor genotype on basal morning 
plasma CORT levels. (c) 19 days of CSC resulted in an impaired adrenal in vitro ACTH responsiveness in 
WT mice (left panels), an effect absent in KO mice (right panels). White bar, SHC (WT); black bar, CSC 
(WT); grey bar, SHC (KO); dashed bar, CSC (KO). n = 15-23 (a, b) and n = 11-13 (c) per genotype and 
housing group. Data represent mean + S.E.M. **p ≤ 0.01 vs. respective SHC group; #p ≤ 0.05, ##p ≤ 0.01 vs. 
respective basal stimulation (c); two-way ANOVA followed by Bonferroni post hoc analysis. Adapted from 
Peterlik et al. (2016c). 
Results 
75 
 
 
3.4 mGlu7 genetic ablation protects against CSC-induced immunological 
alterations 
Reliable immunological alterations induced by CSC exposure include splenomegaly and 
the development of spontaneous colitis (Füchsl et al., 2014; Langgartner et al., 2015; Reber 
et al., 2007). In the present study, absolute spleen weight was dependent on both the factor 
housing (F1,22 = 11.069, p = 0.003) as well as the factor genotype (F1,22 = 12.917, p = 
0.002). In line with the literature (Füchsl et al., 2014; Reber et al., 2007), Bonferroni post 
hoc analysis revealed a significant increase in spleen weight in CSC compared to SHC 
mice of the WT group (p = 0.001). This CSC effect was absent in the KO group. In 
addition, spleen weight was significantly lower in CSC KO compared to CSC WT mice (p 
≤ 0.001; Figure 12a). Beneficial effects of mGlu7 genetic ablation were also found with 
respect to CSC-induced colonic inflammation. In vitro IFN-γ secretion from isolated and 
anti-CD3/anti-CD28-stimulated mesLNC were found to be dependent on the factors 
housing (F1,19 = 5.476, p = 0.030) and genotype (F1,19 = 12.358, p = 0.002), as well as a 
factor housing x genotype interaction (F1,19 = 5.632, p = 0.028). Bonferroni post hoc 
analysis revealed significantly increased IFN-γ secretion in CSC compared to SHC mice of 
the WT group (p = 0.004). This CSC effect was again absent in mGlu7 KO mice. 
Moreover, IFN-γ secretion was significantly lower in the CSC KO group compared to CSC 
WT mice (p ≤ 0.001; Figure 12b). In support of colonic inflammation, the histological 
damage score was found to be dependent on the factors housing (F1,49 = 6.332, p = 0.015) 
and genotype (F1,49 = 6.967, p = 0.011), as well as a factor housing x treatment interaction 
(F1,49 = 6.967, p = 0.011). Bonferroni post hoc analysis revealed a significantly increased 
damage score in CSC compared to SHC mice of the WT group (p ≤ 0.001; Figure 12c), 
reflected by an increased epithelial damage and a more severe inflammatory infiltration 
(Figure 12d). This CSC effect was again absent in the mGlu7 KO group. Furthermore, the 
damage score was significantly lower in CSC KO compared to CSC WT mice (p ≤ 0.001; 
Figure 12c).  
Together, these findings suggest that mGlu7 genetic ablation also protects against 
developing CSC-induced immunological alterations including colonic inflammation. 
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Figure 12. Stress-protective effects of mGlu7 deficiency on CSC-induced immunological alterations. (a) 
Absolute spleen weight was significantly increased in CSC compared to SHC mice of the wildtype (WT) but 
not of the knockout (KO) group. In addition, spleen weight was significantly lower in CSC KO compared to 
CSC WT mice. (b) 19 days of CSC resulted in a significantly increased secretion of IFN-γ from isolated and 
anti-CD3/anti-CD28 stimulated mesenteric lymph node cells (mesLNC). This effect was absent in KO mice. 
Hence, IFN-γ secretion was also significantly lower in CSC KO compared to CSC WT mice. (c) CSC 
exposure induced a significant increase in the histological damage (HD) score of colonic tissue in the WT 
group, whereas this damage was not present in KO mice. Furthermore, HD score was significantly lower in 
CSC KO compared to CSC WT mice. (d) Representative colonic sections stained with hematoxylin and eosin 
from SHC WT (left; normal colon histology) and CSC WT (right; goblet cell loss and crypt loss in locally 
restricted areas and infiltration of cells reaching the Lamina muscularis mucosae) mice. White bar, SHC 
(WT); black bar, CSC (WT); grey bar, SHC (KO); dashed bar, CSC (KO). n = 5-8 (a), n = 4-8 (b) and n = 
11-15 (c) per genotype and housing group. Data represent mean + S.E.M. **p ≤ 0.01 vs. respective SHC 
group; ##p ≤ 0.01 vs. respective WT group; two-way ANOVA followed by Bonferroni post hoc analysis. 
Adapted from Peterlik et al. (2016c). 
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4. mGlu5 functional blockade relieves maladaptive stress consequences 
induced by CSC 
In order to investigate the functional role of the mGlu5 receptor in modulating somatic as 
well as affective consequences of CSC exposure, genetic and pharmacological approaches 
were designed. First, mGlu5 KO mice exposed to CSC were analyzed with respect to 
selected physiological, immunological and behavioral parameters. Second, the effects of 
chronic systemic pharmacological blockade of mGlu5 were assessed on a broader range of 
physiological, immunological and behavioral consequences of CSC. For this purpose, 
C57Bl/6N WT mice, separated into CSC and SHC groups, were chronically infused with 
the allosteric mGlu5 receptor antagonist CTEP at different doses; vehicle infusions were 
used as control. 
 
4.1 Chronic stress-protective phenotype in mice lacking mGlu5 
To evaluate a functional role of mGlu5 in chronic psychosocial stress-induced somatic and 
affective alterations, different selected physiological, immunological, and behavioral 
parameters were assessed in male mGlu5 KO mice and their WT littermates after CSC 
exposure. Absolute adrenal weight was found to be dependent on the factor housing (F1,46 
= 22.717, p ≤ 0.001) and a factor housing x genotype interaction (F1,46 = 5.516, p = 0.023), 
with a significant increase in weight in WT animals exposed to CSC compared to 
respective SHC mice (p ≤ 0.001). This CSC effect was absent in mGlu5 KO animals. 
Moreover, adrenal weight was significantly lower in CSC mGlu5 KO compared to CSC 
WT mice (p = 0.010; Figure 13a). Next, a potential influence of chronic stressor exposure 
on the number of viable mesLNC was analyzed and it was found a main effect of the factor 
genotype (F1,47 = 18.228, p ≤ 0.001). Bonferroni post hoc analysis indicated a significantly 
lower number of viable mesLNC in CSC mGlu5 KO mice compared to their CSC WT 
littermates (p ≤ 0.001). Moreover, an independent Student’s t-test revealed an increase by 
trend in the number of viable mesLNC in CSC compared to SHC mice of the WT group 
(t28 = -1.868, p = 0.072; Figure 13b). In addition, stimulated IFN-γ secretion of mesLNC in 
vitro was dependent on a factor housing x genotype interaction (F1,43 = 4.116, p = 0.049), 
with a significantly increased secretion in CSC compared to SHC mice of the WT group (p 
= 0.003). This effect was again absent in the mGlu5 KO group (Figure 13c). Moreover, 
there was a significantly lower IFN-γ secretion in CSC KO compared to CSC WT mice (p 
= 0.043; Figure 13c). To assess genotype-specific effects of CSC on anxiety-related 
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behavior, especially physiological anxiety, the SIH response on day 19 of CSC exposure 
was evaluated. A main effect was found of the factor housing (F1,44 = 23.754, p ≤ 0.001) 
and of the factor housing x genotype interaction (F1,44 = 5.002, p = 0.030). Bonferroni post 
hoc analysis revealed a significantly increased SIH response in CSC compared to SHC 
mice of the WT group (p ≤ 0.001); this CSC effect was again absent in the mGlu5 KO 
group (Figure 13d). Notably, it was shown for the first time that CSC exposure – in 
addition to the typical increase in innate anxiety – also increased physiological anxiety in 
WT mice. Unfortunately, innate anxiety on the EPM could not be evaluated due to 
technical limitations in experimental setups at the time the experiments was performed. 
Together, the present findings indicate a stress-protective phenotype in mice lacking the 
mGlu5 receptor, at least with respect to the selected parameters assessed. 
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Figure 13. Physiological, immunological, and behavioral profile of WT mice and their mGlu5 KO 
littermates exposed to 19 days of CSC. (a) CSC exposure induced a significant increase in absolute adrenal 
weight in WT mice; this CSC effect was absent in KO mice. In addition, CSC KO mice showed a 
significantly lower adrenal weight compared to CSC WT mice. (b) In WT mice, CSC exposure resulted in a 
strong trend towards an increased number of viable mesenteric lymph node cells (mesLNC; p = 0.072), 
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whereas it remained unaffected in KO mice. In addition, the number of viable mesLNC was significantly 
lower in CSC KO compared to CSC WT mice. (c) The CSC-induced increased IFN-γ secretion of stimulated 
mesLNC in vitro, as observed in WT mice, was not present in KO mice. Furthermore, IFN-γ secretion in 
vitro was significantly lower in CSC KO compared to CSC WT mice. (d) CSC exposure significantly 
increased the hyperthermic response in the SIH test in WT mice. This CSC effect was again not present in 
KO mice. White bar, SHC (WT); black bar, CSC (WT); grey bar, SHC (KO); striped bar, CSC (KO). n = 9-
16 per genotype and housing group. Data represent mean + S.E.M. **p ≤ 0.01 vs. respective SHC mice; #p ≤ 
0.05, ##p ≤ 0.01 vs. respective WT genotype; two-way ANOVA followed by Bonferroni post hoc analysis or 
independent Student’s t-test. WT, wildtype; KO, knockout. Adapted from Peterlik et al. (2016b). 
 
4.2 Pilot-study: Chronic application of vehicle (PEG) and CTEP in naïve mice 
precludes any undesirable effects on typical CSC-affected parameters 
In preparation for the pharmacological approach of studying mGlu5’s functional role in 
CSC-induced consequences, it was essential to provide experimental evidence for the 
compatibility of chronic vehicle (PEG) administration via micro-osmotic pumps with 
typical CSC-affected parameters. Therefore, it was tested whether chronic administration 
of the vehicle (PEG) and CTEP (2 mg/kg/day) s.c. via micro-osmotic pumps had any 
undesirable effects under non-stress conditions on parameters typically assessed after CSC 
exposure (Figure 14a). Importantly, there was no effect of either vehicle or CTEP 
treatment (2 mg/kg/day) in comparison to chronic saline administration (Figure 14b) in 
non-stressed mice after 26 days. This is in line with a previous study conducted by Peters 
et al. (2014), where they revealed no confounding influence of either the surgical 
procedure or the chronic i.c.v. administration of vehicle (in this case Ringer’s solution) via 
micro-osmotic pumps. 
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Experimental designa
1 19 20 days-6
Saline/ VEH/ CTEP (2 mg/kg/day)
s.c. micro-osmotic
pump implantation
Behavior
Innate anxiety (EPM)/
learned fear (fear conditioning; FC)
Physiology
b
Saline VEH 
(PEG)
CTEP 
(2 mg/kg/day)
innate anxiety (EPM, time ratio OA/TA (%)), n = 4-6 49.88 ± 14.50 64.72 ± 7.60 69.51 ± 13.16
locomotion (EPM, CA entries), n = 4-6 7.83 ± 2.17 6.17 ± 1.35 4.5 ± 1.26
fear acquisition (cued FC, freezing response (%) after 5 
CS-US pairings), n = 5-6
67.14 ± 9.94 47.62 ± 9.96 57.14 ± 7.93
fear expression (+ 24 h, freezing response (%) after 2 CS 
presentations), n = 5-6
65.33 ± 5.73 50.56 ± 5.67 54.44 ± 6.59
body weight gain (g), n = 11-12 3.3 ± 0.5 2.9 ± 0.2 2.9 ± 0.4
thymus weight (mg), n = 11-12 44.81 ± 2.59 41.91 ± 1.99 40.91 ± 2.19
pituitary weight (mg), n = 11-12 1.63 ± 0.10 1.55 ± 0.05 1.53 ± 0.07
adrenal weight (mg), n = 11-12 3.69 ± 0.15 3.64 ± 0.05 3.54 ± 0.10
plasma ACTH (pg/ml), n = 11-12 10.68 ± 0.73 12.66 ± 1.92 10.41 ± 0.40
plasma CORT (ng/ml), n = 8-12 37.43 ± 4.32 38.43 ± 3.15 31.29 ± 3.00
 
Figure 14. Chronic application of vehicle (PEG) and CTEP via micro-osmotic pumps in naïve mice 
precludes any undesirable effects on typical CSC-affected parameters. (a) Schematic illustration of the 
experimental design of chronic (i.e. 26 days) administration of saline, VEH (polyethylene glycol, PEG), and 
CTEP at a dose of 2 mg/kg/day via micro-osmotic pumps (s.c.) in unstressed mice to test for possible 
undesirable effects on the parameters typically assessed following CSC exposure. (b) Neither VEH nor CTEP 
treatment had any effects on the parameters assessed compared to mice treated with saline only. Adapted 
from Peterlik et al. (2016b). 
 
4.3 Chronic pharmacological mGlu5 blockade reverses the CSC-induced decrease 
in body weight 
To further address the functional involvement of the mGlu5 receptor in chronic 
psychosocial stress physiology, it was assessed whether chronic pharmacological blockade 
of the mGlu5 receptor interferes with the well-known CSC-induced somatic and affective 
changes. It was found a main effect of the factor treatment (F3,125 = 3.352; p = 0.021) and a 
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factor housing x treatment interaction (F3,125 = 3.017; p = 0.032) on body weight gain, with 
a decrease in CSC compared to SHC mice of the vehicle group (p = 0.028). This stress 
effect was abolished by CTEP at all three doses applied (Figure 15a). Moreover, body 
weight gain was significantly higher in CSC mice treated with CTEP at a dose of 0.05 
mg/kg/day (p = 0.011) and 0.5 mg/kg/day (p = 0.003) compared to CSC mice of the 
vehicle group. A closer look on body weight development of mice treated with vehicle and 
2 mg/kg/day of CTEP (exemplary for all CTEP doses) during CSC procedure revealed a 
main effect of the factors housing (F3,75 = 3.373, p = 0.023), time (F6,450 = 41.282, p ≤ 
0.001) and a factor housing x time interaction (F18,450 = 1.658, p = 0.044). Mice from all 
treatment/housing groups showed a positive body weight development over a period of 19 
days. Moreover, an independent Student’s t-test revealed a decreased body weight in CSC 
compared to SHC mice of the vehicle group on day 10 (t42 = 2.062, p = 0.045), day 15 (t42 
= 2.186, p = 0.034) and day 17 (t42 = 2.116, p = 0.040). This CSC effect was blocked in 
mice treated with CTEP at a dose of 2 mg/kg/day (Figure 15b). 
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Figure 15. Stress-protective effects of chronic CTEP treatment on CSC-induced changes in body 
weight gain and body weight development. (a) CSC induced a significant decrease in body weight gain 
(day 1 to day 20) in VEH-treated mice. This stress effect was blocked by chronic CTEP treatment. Also, 
body weight gain was significantly higher in CSC mice treated with CTEP at the doses of 0.05 and 0.5 
mg/kg/day compared to CSC VEH-treated mice. (b) In VEH-treated mice, CSC resulted in a significantly 
lower absolute body weight on days 10, 15, and 17; this effect was blocked with chronic CTEP treatment (2 
mg/kg/day). White bar, SHC; black bar, CSC. n = 8-24 per treatment and housing group. Data represent 
mean ± S.E.M. *p ≤ 0.05 vs. respective SHC mice; #p ≤ 0.05, ##p ≤ 0.01 vs. respective VEH group; two-way 
ANOVA followed by Bonferroni post hoc analysis (a) or independent Student’s t-test (b). Adapted from 
Peterlik et al. (2016b). 
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4.4 Chronic pharmacological mGlu5 blockade corrects CSC-induced alterations 
in HPA axis functionality in a dose-dependent manner 
As CSC exposure has been shown to result in profound physiological and neuroendocrine 
changes (Füchsl et al., 2014; Reber et al., 2007; Uschold-Schmidt et al., 2012; Veenema et 
al., 2008), further focused was placed on different HPA axis-related parameters. It was 
found a main effect of the factor housing (F1,127 = 7.366, p = 0.008) on absolute pituitary 
weight with an increased weight in CSC compared to SHC mice treated with vehicle (p = 
0.008) and CTEP at a dose of 0.05 mg/kg/day (by trend; p = 0.057). This increase could be 
reversed with the two higher doses of CTEP (Figure 16a). Basal morning plasma ACTH 
levels were found to be dependent on the factors housing (F1,123 = 3.873, p = 0.051) and 
treatment (F3,123 = 3.356, p = 0.021). Bonferroni post hoc analysis showed a significant 
stress-induced increase only in basal morning plasma ACTH in mice treated with CTEP at 
a dose of 0.05 mg/kg/day, but failed to show any differences between mice treated with 
CTEP in comparison to respective vehicle groups. In addition, an independent Student’s t-
test revealed a significant increase in plasma ACTH in CSC compared to SHC mice treated 
with vehicle (t42 = -2.297, p = 0.027; Figure 16b). Analysis of absolute adrenal weight 
revealed a main effect of the factor housing (F1,128 = 96.834, p ≤ 0.001) and a factor 
housing x treatment interaction (F3,128 = 9.646, p ≤ 0.001). CSC exposure induced an 
increase in adrenal weight in mice treated with vehicle and CTEP at a dose of 0.05 and 0.5 
mg/kg/day (p ≤ 0.001 for each). This effect was abolished by treatment with CTEP at a 
dose of 2 mg/kg/day, and consequently, adrenal weight was significantly lower in stressed 
mice treated with the high dose of CTEP compared to CSC mice of the vehicle group (p ≤ 
0.001; Figure 16c). Basal morning plasma CORT levels were neither influenced by the 
factor housing nor by the factor treatment (Figure 16d).  
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Figure 16. Stress-protective effects of chronic CTEP treatment on CSC-induced physiological and 
neuroendocrine alterations. (a) Absolute pituitary weight was significantly increased in CSC compared to 
SHC mice treated with VEH and increased by trend in mice treated with 0.05 mg/kg/day (p = 0.057). CTEP 
at doses of 0.5 and 2 mg/kg/day were able to abolish this increase. (b) The CSC-induced increase in basal 
morning plasma ACTH levels found in VEH-treated mice was still present in mice treated with CTEP at a 
dose of 0.05 mg/kg/day, but completely abolished in mice treated with 0.5 and 2 mg/kg/day of CTEP. (c) 
CSC resulted in an increased absolute adrenal weight in VEH-treated mice; this CSC effect was still present 
in mice treated with CTEP at doses of 0.05 and 0.5 mg/kg/day, but completely abolished with 2 mg/kg/day of 
CTEP. In addition, adrenal weight was significantly lower in CSC mice treated with 2 mg/kg/day of CTEP 
compared to CSC mice of the VEH group. (d) Neither CSC nor chronic CTEP treatment significantly 
affected basal morning plasma CORT levels. White bar, SHC; black bar, CSC. n = 8-24 per treatment and 
housing group. Data represent mean + S.E.M. *p ≤ 0.05, **p ≤ 0.01 vs. respective SHC mice; ##p ≤ 0.01 vs. 
respective VEH group; two-way ANOVA followed by Bonferroni post hoc analysis or independent Student’s 
t-test (b). Adapted from Peterlik et al. (2016b). 
 
Next, the effects of CSC on adrenal in vitro ACTH responsiveness and potential effects of 
CTEP treatment were analyzed. In mice treated with vehicle and 0.05 mg/kg/day of CTEP, 
there was a main effect of the factors housing (vehicle: F1,86 = 8.660, p = 0.004; 0.05 
CTEP: F1,32 = 14.705, p ≤ 0.001), stimulation (vehicle: F1,86 = 42.362, p ≤ 0.001; 0.05 
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CTEP: F1,32 = 37.689, p ≤ 0.001) and a factor housing x stimulation interaction (vehicle: 
F1,86 = 8.282, p = 0.005; 0.05 CTEP: , F1,32 = 5.313, p = 0.028) on adrenal CORT secretion 
in vitro (Figure 17). In contrast, adrenal CORT secretion from explants of mice treated 
with 0.5 and 2 mg/kg/day of CTEP were only dependent on the factor stimulation (0.5 
CTEP: F1,64 = 108.316, p ≤ 0.001; 2 CTEP: F1,58 = 60.518, p ≤ 0.001). In all groups, 
adrenal explants from both SHC (p ≤ 0.001 for each) and CSC (vehicle: p = 0.013; 0.05 
CTEP: p = 0.015; 0.5 and 2 CTEP: p ≤ 0.001) mice showed an increased CORT secretion 
in response to ACTH compared to basal (saline) stimulation (Figure 17). However, in mice 
treated with vehicle and 0.05 mg/kg/day of CTEP, adrenal CORT secretion in response to 
ACTH was significantly lower in CSC compared to SHC mice (p ≤ 0.001 for each). This 
CSC-induced attenuation of adrenal in vitro ACTH responsiveness was absent in mice 
treated with CTEP at doses of 0.5 and 2 mg/kg/day (Figure 17). Together, these findings 
indicate that HPA axis functionality is generally less vulnerable to chronic psychosocial 
stressor exposure in mice with pharmacological mGlu5 receptor inhibition. 
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Figure 17. Stress-protective effects of chronic CTEP treatment on CSC-induced reduction of adrenal 
in vitro ACTH responsiveness. CSC resulted in an impaired adrenal in vitro ACTH responsiveness in VEH-
treated mice as well as in mice treated with CTEP at a dose of 0.05 mg/kg/day. This CSC effect was absent in 
mice treated with 0.5 and 2 mg/kg/day of CTEP. White bar, SHC; black bar, CSC. n = 8-24 per stimulation 
and housing group. Data represent mean + S.E.M. **p ≤ 0.01 vs. respective SHC mice; #p ≤ 0.05, ##p ≤ 0.01 
vs. respective basal stimulation; two-way ANOVA followed by Bonferroni post hoc analysis. Adapted from 
Peterlik et al. (2016b). 
 
Results 
85 
 
4.5 Chronic pharmacological mGlu5 blockade dose-dependently prevents CSC-
induced immunological alterations 
CSC housing represents an established model to also assess immunological consequences 
of chronic psychosocial stress (Füchsl et al., 2014; Langgartner et al., 2015; Peters et al., 
2012; Reber et al., 2007) and has been shown to result in thymic atrophy and splenomegaly 
(Füchsl et al., 2014; Reber et al., 2007) and to cause spontaneous colitis (Reber et al., 
2007). In the present study, assessment of absolute thymus weight revealed a main effect 
of the factor housing (F1,128 = 19.837, p ≤ 0.001)  and a factor housing x treatment 
interaction (F3,128 = 3.296, p = 0.023), with a decreased thymus weight in CSC compared 
to SHC mice treated with vehicle (p ≤ 0.001) and 0.05 mg/kg/day of CTEP (p = 0.021). 
This CSC-induced thymic atrophy was blocked by treatment with CTEP at the doses of 0.5 
and 2 mg/kg/day. Furthermore, Bonferroni post hoc analysis also revealed a lower thymus 
weight in CSC mice treated with CTEP at a dose of 0.5 (p = 0.005) and 2 mg/kg/day (p = 
0.047) compared to CSC mice of the vehicle group (Figure 18a). Absolute spleen weight 
was dependent on the factor housing (F1,95 = 30.239, p ≤ 0.001) and a factor housing x 
treatment interaction (F3,95 = 7.527, p ≤ 0.001). CSC exposure induced an increase in 
spleen weight in mice treated with vehicle (p ≤ 0.001) and CTEP at the doses of 0.05 (p = 
0.037) and 0.5 mg/kg/day (p = 0.002). This effect was blocked by treatment with 2 
mg/kg/day of CTEP. In addition, spleen weight was lower in CSC mice of all CTEP 
groups compared to stressed vehicle-treated animals (0.05 CTEP: p = 0.017; 0.5 CTEP: p 
= 0.002; 2 CTEP: p ≤ 0.001; Figure 18b).  
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Figure 18. Stress-protective effects of chronic CTEP on CSC-induced weight changes in organs of the 
immune system. (a) CSC exposure induced a significant decrease in absolute thymus weight in VEH-treated 
mice as well as in mice treated with CTEP at a dose of 0.05 mg/kg/day. This stress effect was blocked in 
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mice treated with CTEP at the doses of 0.5 and 2 mg/kg/day. In addition, thymus weight was significantly 
higher in CSC mice treated with CTEP at the doses of 0.5 and 2 mg/kg/day compared to CSC mice of the 
VEH group. (b) The CSC-induced increase in absolute spleen weight found in VEH-treated mice was still 
present in mice treated with CTEP at doses of 0.05 and 0.5 mg/kg/day, but prevented by 2 mg/kg/day of 
CTEP. In addition, spleen weight was significantly lower in CSC mice of all CTEP groups compared to CSC 
mice of the VEH group. White bar, SHC; black bar, CSC. n = 8-24 per treatment and housing group. Data 
represent mean + S.E.M. *p ≤ 0.05, **p ≤ 0.01 vs. respective SHC mice; #p ≤ 0.05, ##p ≤ 0.01 vs. respective 
VEH group; two-way ANOVA followed by Bonferroni post hoc analysis. Adapted from Peterlik et al. 
(2016b). 
 
Beneficial effects of chronic mGlu5 receptor blockade were also found with respect to 
CSC-induced colonic inflammation. The number of viable mesLNC was dependent on the 
factor housing (F1,93 = 36.841, p ≤ 0.001) and a factor housing x treatment interaction (F3,93 
= 3.424, p = 0.020). Bonferroni post hoc analysis revealed an increased number in CSC 
compared to SHC mice treated with vehicle and CTEP at doses of 0.05 and 0.5 mg/kg/day 
(p ≤ 0.001 for each). This increase was blocked by 2 mg/kg/day of CTEP. Moreover, the 
number of viable mesLNC was significantly lower in CSC mice treated with CTEP at a 
dose of 2 mg/kg/day compared to CSC mice of the vehicle group (p = 0.015; Figure 19a). 
Analysis of the IFN-γ secretion of mesLNC in vitro revealed a main effect of the factors 
housing (F1,89 = 7.708, p = 0.007), treatment (F3,89 = 3.401, p = 0.021) as well as a housing 
x treatment interaction (F3,89 = 4.555, p = 0.005). Bonferroni post hoc tests showed a 
significantly increased IFN-γ secretion in CSC compared to SHC mice treated with vehicle 
(p ≤ 0.001). This CSC effect was blocked by CTEP-treatment independent of the dose 
applied. Furthermore, in vitro IFN-γ secretion was lower in CSC mice of all CTEP groups 
compared to CSC mice of the vehicle group (0.05 CTEP: p = 0.006; 0.5 CTEP: p = 0.001; 
2 CTEP: p = 0.003; Figure 19b). In support of CSC-induced development of colonic 
inflammation, the histological damage score was dependent on the factor housing (F1,82 = 
34.776, p ≤ 0.001), the factor treatment (F3,82 = 5.075, p = 0.003), as well as a factor 
housing x treatment interaction (F3,82 = 5.075, p = 0.003). It was found an increased score 
in CSC compared to SHC mice treated with vehicle (p ≤ 0.001; Figure 19d), indicated by 
an increased epithelial damage and more severe inflammatory infiltration (Figure 19c). 
This CSC effect was also present in mice treated with CTEP at the doses of 0.05 (p = 
0.035) and 0.5 mg/kg/day (p = 0.003), but absent in mice treated with 2 mg/kg/day of 
CTEP (Figure 19d). Moreover, histological damage was significantly higher in CSC mice 
treated with vehicle compared to CSC mice of all CTEP groups (for each p ≤ 0.014). 
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Together, these findings suggest a dose-dependent reduction of the vulnerability to chronic 
stressor exposure with respect to immunological consequences including colonic 
inflammation in CTEP-treated mice. 
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Figure 19. Prevention of CSC-induced colonic inflammation by chronic CTEP. (a) In a similar fashion, 
the CSC-induced increase in the number of viable mesLNC in the VEH group was also present in mice 
treated with CTEP at doses of 0.05 and 0.5 mg/kg/day, but abolished with 2 mg/kg/day of CTEP. In addition, 
CSC mice treated with 2 mg/kg/day of CTEP had a significant lower number of viable mesLNC compared to 
CSC mice of the VEH group. (b) Stimulated IFN-γ secretion in vitro was significantly increased in VEH-
treated animals after CSC exposure. All CTEP doses applied were able to reverse this CSC effect. Also, IFN-
γ secretion was significantly lower in CSC mice of all CTEP groups compared to CSC mice treated with 
VEH. (c) Representative colonic sections stained with hematoxylin and eosin from SHC (left; normal colon 
histology) and CSC (right; goblet cell loss and crypt loss in locally restricted areas and infiltration of cells 
reaching the Lamina muscularis mucosae) mice of the VEH group. (d) CSC exposure induced a significant 
increase in the histological damage (HD) score of colonic tissue in mice treated with VEH as well as CTEP at 
doses of 0.05 and 0.5 mg/kg/day. This damage was blocked by treatment with 2 mg/kg/day of CTEP. White 
bar, SHC; black bar, CSC. n = 8-24 per treatment and housing group. Data represent mean + S.E.M. *p ≤ 
0.05, **p ≤ 0.01 vs. respective SHC mice; #p ≤ 0.05, ##p ≤ 0.01 vs. respective VEH group; two-way ANOVA 
followed by Bonferroni post hoc analysis. Adapted from Peterlik et al. (2016b). 
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4.6 Chronic pharmacological mGlu5 blockade has no influence on the CSC-
induced anxiety-prone phenotype 
As CSC exposure reliably increases anxiety-related behavior in mice  (Langgartner et al., 
2015; Reber and Neumann, 2008), possible beneficial effects were evaluated of CTEP-
treatment on CSC-induced physiological and innate anxiety with the SIH and EPM test, 
respectively. It was found a main effect of the factor housing (F1,129 = 32.902, p ≤ 0.001) 
on the stress-induced hyperthermic response. Bonferroni post hoc analysis revealed an 
increased SIH response in CSC compared to SHC mice treated with vehicle (p = 0.002) as 
well as CTEP at a dose of 0.5 and 2 mg/kg/day (p ≤ 0.001 for each). In addition, an 
independent Student’s t-test also revealed a CSC-induced increase in the SIH response in 
mice treated with 0.05 mg/kg/day of CTEP (t16 = -2.645, p = 0.018; Figure 20).  
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Figure 20. Chronic CTEP has no influence on CSC-
induced increase in physiological anxiety. CSC 
exposure induced an increased hyperthermic response 
in the SIH test independent of treatment, indicative for 
an increase in physiological anxiety. White bar, SHC; 
black bar, CSC. Data represent mean + S.E.M. **p ≤ 
0.01 vs. respective SHC mice. n = 8-24 per treatment 
and housing group; two-way ANOVA followed by 
Bonferroni post hoc analysis or independent Student’s 
t-test (0.05 mg/kg/day). Adapted from Peterlik et al. 
(2016b). 
 
The time the mice spent on the open arms of the EPM, indicative for their level of innate 
anxiety, was also dependent on the factor housing (F1,92 = 31.780, p ≤ 0.001), with a 
decreased percentage of time spent on the open arms in CSC compared to SHC mice of the 
vehicle group (p ≤ 0.001). This CSC-induced decrease was still present in mice treated 
with CTEP independent of the dose applied (Bonferroni post hoc analysis, 0.05 CTEP: by 
trend p = 0.065; 0.5 CTEP: by trend p = 0.057; 2 CTEP: p ≤ 0.001), suggesting also no 
beneficial effects of CTEP on CSC-induced increase in innate anxiety (Figure 21a). 
Although there was a main effect of the factor housing on the number of CA entries (F1,92 
= 4.501, p = 0.037), Bonferroni post hoc analysis did not show any significant differences 
of CA entries within and between all groups, indicating comparable locomotor activity 
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(Figure 21b). Together, these findings indicate that chronic CTEP treatment had no 
influence on the CSC-induced increase in physiological and innate anxiety. 
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Figure 21. Chronic CTEP has no influence on CSC-induced increase in innate anxiety. (a) The 
percentage of time spent on the open arms (time ratio OA/TA in %) on the EPM was decreased in CSC mice 
of all treatment groups (in the groups of 0.05 and 0.5 mg/kg/day of CTEP by trend, p ≤ 0.057; significance 
was reached in the 2 mg/kg/day group, p ≤ 0.01), indicating CSC-induced increase in innate anxiety 
independent of treatment. (b) The number of closed arm (CA) entries were not different within and between 
all groups, indicating comparable locomotor activity. White bar, SHC; black bar, CSC. Data represent mean 
+ S.E.M. **p ≤ 0.01 vs. respective SHC mice. n = 8-16 per treatment and housing group; two-way ANOVA 
followed by Bonferroni post hoc analysis. Adapted from Peterlik et al. (2016b). 
  
4.7 Acute and sub-chronic pharmacological mGlu5 blockade induce anxiolytic-
like effects in the SIH test 
Pharmacological inhibition of the mGlu5 receptor by CTEP-treatment already 
demonstrated robust activity in the SIH test in mice, with a minimal effective oral dose of 
0.1 mg/kg. In addition, unspecific effects of CTEP such as sedation or general changes in 
overall health and body temperature were absent in a dose range of up to 2 mg/kg 
(Lindemann et al., 2011). In the present study, these findings were extended towards a 
different administration route of CTEP (i.p.) and CTEP’s in vivo activity was verified in 
the SIH test upon acute and sub-chronic treatment at the doses of 0.1, 0.5, and 2 mg/kg 
(see experimental design, Figure 22a). 
The SIH response following acute CTEP-treatment was found to be dependent on the 
factor treatment (one-way ANOVA; F3,23 = 8.464, p = 0.001), with a reduced stress-
induced hyperthermic response 1 h after a single i.p. injection in mice treated with 0.5 (p = 
0.008) and 2 mg/kg (p ≤ 0.001) of CTEP compared to vehicle treatment (Figure 22b). 
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Furthermore, the SIH response following sub-chronic CTEP-treatment (injected i.p. every 
48 h) was dependent on the factors treatment (repeated measures ANOVA; F3,70 = 2.858, p 
= 0.043) and time (repeated measures ANOVA; F1,70 = 4.631, p = 0.035). LSD post hoc 
analysis revealed a reduced stress-induced hyperthermic response in mice treated with 
CTEP at a dose of 2 mg/kg compared to the respective vehicle group on day 16 (p = 0.007) 
and on day 24 (p = 0.035; Figure 22c). These findings indicate that acute and sub-chronic 
treatment with CTEP given i.p. every 48 h is able to induce anxiolytic-like effects in the 
SIH test.  
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Figure 22. Acute and sub-chronic CTEP (i.p.) induces anxiolytic effects in the SIH test. (a) Schematic 
illustration of the experimental design of acute (1 h following single i.p. injection) and sub-chronic (day 16 
and day 24 following 8x and 16x i.p. injections every 48 h, respectively) CTEP treatment assessed in the SIH 
test. (b) Acute CTEP (1 h after single i.p. injection) was dose-dependently active in reducing the SIH response 
compared to VEH. (c) Sub-chronic CTEP injected i.p. every 48 h was dose-dependently active in reducing the 
SIH response compared to VEH on day 16 and day 24. White bar, VEH; light grey bar, CTEP 0.1 mg/kg; dark 
grey bar, CTEP 0.5 mg/kg; black bar, CTEP 2 mg/kg. Data represent mean + S.E.M. * p ≤ 0.05, **p ≤ 0.01 
vs. respective VEH group. n = 6-7 for acute and n = 18-19 for sub-chronic treatment per group; one-way 
ANOVA followed by LSD post hoc analysis (b) or two-way ANOVA followed by Bonferroni post hoc 
analysis (c). Adapted from Peterlik et al. (2016b). 
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1. Acute pharmacological blockade of mGlu7 inhibits depressive-, 
anxiety-like and fear-related behavior 
Gee et al. (2014) recently identified and thoroughly characterized XAP044, the first 
mGlu7-selective full antagonist that blocks the receptor’s signaling pathways via binding 
to the large extracellular VFTD region. Thus, XAP044 presumably acts via a novel site 
compared to known selective allosteric ligands that were often associated with off-target 
effects. XAP044 was furthermore shown to selectively block LTP in the lateral amygdala 
in an mGlu7-dependent manner, i.e. it blocked LTP only in WT but not mGlu7-KO mice. 
In support of the literature, this further substantiates a role for mGlu7 in the cellular 
physiology of the fear and emotion circuitry. In addition, XAP044 treatment reduced in a 
dose-dependent manner the stress-induced rise in rectal body temperature in the mouse 
SIH test without affecting basal body temperature, a finding that gave the first hint of 
XAP044’s systemic in vivo activity. 
It was now an essential part of the present PhD thesis to further characterize XAP044 in 
vivo in a battery of behavioral tests including innate anxiety, depression and conditioned 
fear tests in mice. These experiments should a.) add further knowledge to and support 
studies that have investigated mGlu7’s role in emotional behavior suggesting receptor 
blockade as a promising pharmacotherapeutic approach and b.) proof and specify systemic 
in vivo activity of mGlu7 receptor blockade with a compound that binds via a new 
mechanism, i.e. to the receptor’s VFTD. 
Systemic application of XAP044 in the present study slightly reduced immobility in the 
TST and an increased ratio of open/total arm entries in the EPM test (Figures 4, 5), 
indicative of decreased depression- and anxiety-related behavior, respectively. XAP044 
furthermore resulted in less freezing during the acquisition session of Pavlovian fear 
conditioning (Figures 6). All these findings are well consistent with published data on the 
behavior of mGlu7-deficient mice and with mGlu7 siRNA-mediated knockdown studies 
using several paradigms to assess anxiety-, depression- and fear-related behavior 
(Callaerts-Vegh et al., 2006; Cryan et al., 2003; Dobi et al., 2013; Fendt et al., 2013, 2008; 
Goddyn et al., 2008; Mitsukawa et al., 2006; O’Connor et al., 2013b; Stachowicz et al., 
2008). Interestingly, the effects of XAP044 are also, at least in part, similar to those 
previously reported for the allosteric agonist AMN082 (Palucha et al., 2007; Stachowicz et 
al., 2008). However, as discussed above, this apparent discrepancy can potentially be 
explained by the rapid AMN082-induced mGlu7 internalization or effects of active 
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metabolites (Pelkey et al., 2007; Sukoff Rizzo et al., 2011). It is worth noting that despite 
widespread efficacy of XAP044 in tests of anxiety and stress, the magnitudes of such 
effects were less than those of either benzodiazepines, the mGlu5 antagonist MPEP, or 
mGlu7 deficient mice. This difference in efficacy might be explained by the low 
concentration of free compared to total XAP044 in brain and plasma (see pharmacokinetic 
studies reported in Gee et al. (2014)), a drawback of XAP044 that can likely be overcome 
with future chemical derivatives. Nonetheless, the present results with XAP044 further 
substantiate an important role for mGlu7 in the behavioral physiology of acute stress, fear, 
and anxiety.  
In conclusion, Gee et al. (2014) have identified XAP044 as an mGlu7-selective antagonist 
that acts via binding to the VFTD of this class C GPCR. The present in vivo findings 
indicate that XAP044’s novel molecular mode of pharmacological blockade carries 
significant application potential for the treatment of stress-related pathologies. Moreover, 
modeling the mechanism of binding of XAP044 within the VFTD of mGlu7, followed by 
computer-assisted drug design, could possibly facilitate future drug development. 
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2. Chronic psychosocial stress in mice induces changes of specific mGlu 
receptors in the mouse brain 
Despite well-established links between acute stress, fear and depression-related behaviors 
and specific mGlu receptor subtypes (Kew and Kemp, 2005; Swanson et al., 2005), only 
little is known about their role(s) in chronic psychosocial stress in rodents and even much 
less in humans. Therefore, it was part of the present PhD thesis to investigate the molecular 
changes that occur within the brain mGlu receptor system with a focus on mRNA 
expression of selected mGlu receptor subtypes in response to chronic psychosocial stress. 
To this end, the CSC model was used, a valuable animal model whose diverse effects on 
behavioral, physiological and immunological parameters are well characterized (Füchsl et 
al., 2014; Peterlik et al., 2016a; Peters et al., 2012; Reber and Neumann, 2008; Reber et al., 
2007; Schmidt et al., 2010; Uschold-Schmidt et al., 2013, 2012; Veenema et al., 2008). 
Given the crucial involvement of in particular mGlu5 and mGlu7 subtypes in the 
regulation of fear and acute stress and anxiety (see Introduction), robust CSC-induced 
alterations in the mRNA expression of these two receptor subtypes were expected to occur 
in brain regions relevant for the regulation of emotion and stress-related behaviors, namely 
the prefrontal cortex, the hypothalamus and the hippocampus. 
A trend towards a CSC-induced increase of mGlu5 mRNA levels was detected specifically 
in the hypothalamus (Peterlik et al., 2016b). In order to assess whether these changes also 
reflect changes at the protein level, mGlu5 protein binding sites were measured using the 
[3H]ABP688 radioligand binding assay (performed by F. Hoffmann-La Roche, Basel, 
Switzerland). Interestingly, mGlu5 protein levels were specifically increased in the 
hippocampus of CSC compared to SHC mice (Figure 23). Together, these findings suggest 
a prominent and region-specific activation of the mGlu5 receptor system during chronic 
psychosocial stress in the hippocampus. 
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Figure 23. Selective changes in brain mGlu5 
receptor binding sites in response to 19 days of 
CSC. Saturation analysis using the highly mGlu5-
selective radioligand [3H]-ABP688 (performed by F. 
Hoffmann-La Roche, Basel, Switzerland) revealed 
significantly increased mGlu5 receptor binding sites 
(Bmax) in HC after 19 days of CSC exposure, whereas 
mGlu5 receptor binding sites in the PFC and HT 
remained unaffected. White bar, SHC (n = 3); black 
bar, CSC (n = 3). Data represent mean + S.E.M. **p ≤ 
0.01 vs. respective SHC mice, Student’s t-test; PFC, 
prefrontal cortex; HT, hypothalamus; HC, 
hippocampus. Adapted from Peterlik et al. (2016b).  
 
This finding is in line with previous reports on alterations of mGlu5 protein expression 
following chronic stressor exposure. Employing the CMS model, Wierońska et al. (2001) 
showed changes in hippocampal mGlu5 receptor protein expression with an increase in the 
CA1 and a decrease in the CA3 region, paralleled by an increase in depressive-like 
behavior. In contrast, mice exposed to CSC typically show an increased anxiety-related 
behavior without changes of depressive-like behavior (Slattery et al., 2012). Thus, different 
qualities of chronic stressors (i.e. a continuous psychosocial stressor with only repeated 
physical interaction vs. continuous exposure to a combination of physical and 
psychological stress) may have different effects on brain mGlu5 expression and/or 
signaling. Further supporting the functional relevance of hippocampal mGlu5 in stress 
physiology, Yim et al. (2012) revealed in a recent study a link between hippocampal 
mGlu5 and behavioral coping strategy in response to inescapable and unpredictable 
footshock stress. They could demonstrate that mGlu5 protein expression was increased in 
rats that showed helpless behavior and a lack of adaptation in a novel environment, 
whereas it was decreased in those that did not. These results suggested that hippocampal 
mGlu5 has a pivotal role in the controllability-based coping strategy. Translated to the 
CSC-induced changes found in the present study, i.e. increase in hippocampal mGlu5 
protein expression and increase in anxiety-related behavior, this would also suggest mGlu5 
to be critically involved in the development of the chronic stress-related anxiety-prone 
phenotype found in CSC mice. At least, the present data suggest an increased mGlu5 
activity in stress-sensitive brain regions involved in the regulation of behavior and HPA 
axis functionality following CSC exposure.  
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With respect to the mGlu7 receptor subtype, downregulated mGlu7 transcript levels were 
found specifically in the prefrontal cortex. Of course, these transcript data may not 
necessarily reflect functional relevance of mGlu7 in chronic psychosocial stress-induced 
pathology. However, due to the poor quality of antibodies raised against the mGlu7 
protein, measuring selective mGlu7 protein levels is still a challenge to many different 
laboratories worldwide (O’Connor et al., 2013; O’Connor et al., 2013a). Presumed that 
also mGlu7 protein levels are reduced specifically in the prefrontal cortex, the following 
speculation can be made: The specific reduction of the primarily presynaptically located 
mGlu7 in the prefrontal cortex might lead to a reduction in the negative feedback at the 
synapses of glutamatergic neurons, which in turn could result in excessive L-glutamate 
release. The consequent hyperexcitability in the prefrontal cortex might, at least in part, 
contribute to the CSC-induced anxiety-prone phenotype (Bi et al., 2013; Bruening et al., 
2006). In support, anxiety-inducing stimuli have been reported to be associated with 
increased neuronal activation in prefrontal cortical areas (Singewald et al., 2003). 
Furthermore, the fact that mGlu7 is also presynaptically located on inhibitory GABAergic 
neurons (Kinoshita et al., 1998; Somogyi et al., 2003), where the receptor negatively 
regulates inhibitory neurotransmitter release (Klar et al., 2015; Schrader and Tasker, 1997), 
adds further complexity. Given that anxiety disorders are often viewed as a result of an 
imbalance between L-glutamate and GABA (Wierońska and Pilc, 2009), mGlu7 is in a 
prime position to act as a key regulator of this imbalance in such disorders. In view of this, 
the L-glutamate/GABA balance might be disturbed due to the CSC-induced dysregulation 
of mGlu7 in the prefrontal cortex.  
Interestingly, no changes of mGlu2 and mGlu3 mRNA levels were found in response to 
CSC in each of the three brain regions, possibly suggesting that group II mGlu receptors 
may play a less prominent role in CSC-induced pathophysiology. As it would have gone 
beyond the scope of the present thesis, the determination of a possible functional relevance 
of group II mGlu receptors in CSC-induced maladaptations may be part of future 
investigation. 
Overall, the present findings represent very early evidence towards a role of specific mGlu 
receptor subtypes in chronic psychosocial stress-induced pathophysiology. At least, the 
data suggest that there are dysregulated activities and thus possibly controlling roles of the 
mGlu5 and mGlu7 receptor subtypes in the hippocampus and the prefrontal cortex, 
respectively, two brain regions involved in the regulation of behavior and HPA axis 
functionality. Together, these findings may indicate that these receptor subtypes should be 
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pursued as further research topics in chronic stress-induced conditions. The functional 
relevance of these receptor subtypes can be further addressed by the investigation of their 
associated intracellular proteins like Homer1, Calmodulin, Norbin, Tamalin and protein 
interacting with PKC alpha (PICK1), which have important regulatory functions (Enz, 
2007; Niswender and Conn, 2010). 
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3. Chronic psychosocial stress-protective phenotype of mGlu7 KO mice 
The present study provides first evidence for the involvement of mGlu7 in mediating 
behavioral, physiological and immunological consequences of chronic psychosocial stress 
in mice using CSC as a male subordination paradigm. Genetic ablation of mGlu7 relieved 
multiple chronic stress-induced maladaptations: in addition to protection against the CSC-
induced anxiety-prone phenotype, mGlu7 deficient mice were also less vulnerable to CSC 
with respect to reliable physiological and immunological consequences such as HPA axis 
dysfunction and colonic inflammation. Together, these findings evidence the involvement 
of the mGlu7 subtype in a wide range of affective and somatic alterations that emerge upon 
chronic psychosocial stressor exposure and suggest that mGlu7 pharmacological blockers 
could be a relevant option for the treatment of chronic stress-related emotional and somatic 
dysfunctions in man. 
Genetic ablation of mGlu7 has been demonstrated to be associated with several selective 
changes in molecular targets that participate in the acute stress response and in 
psychopathological states (Cryan et al., 2003; Mitsukawa et al., 2006). In particular, 
increased GR levels in the hippocampus combined with an increased GR-mediated 
feedback suppression of the HPA axis, as well as elevated hippocampal BDNF and 5-HT1A 
receptor levels in mGlu7 KO mice suggest selective dysregulation of stress response 
integration opposite to that found in humans suffering from chronic stress-related 
pathologies (Holsboer and Barden, 1996; Webster et al., 2002). Moreover, these changes 
correlate well with the previously identified acute antistress, antidepressant- and 
anxiolytic-like phenotype in mice with genetic mGlu7 ablation (Callaerts-Vegh et al., 
2006; Cryan et al., 2003), with pharmacological mGlu7 blockade  (Gee et al., 2014; 
Kalinichev et al., 2013) as well as with siRNA-mediated knockdown of mGlu7 (Fendt et 
al., 2008; O’Connor et al., 2013b). 
The present study demonstrated a stress-protective phenotype in mice with genetic ablation 
of mGlu7 in the context of chronic psychosocial stress. First of all, in support of previous 
findings (Füchsl et al., 2014; Peters et al., 2013; Reber and Neumann, 2008; Reber et al., 
2007; Slattery et al., 2012; Uschold-Schmidt et al., 2012), CSC exposure resulted in 
increased anxiety-related behavior in mice of the WT group tested on the EPM. However, 
this CSC-induced anxiety-prone phenotype was not present in mGlu7 KO mice, suggesting 
a stress-protective effect of genetic mGlu7 ablation with respect to the chronic stress-
induced increase in innate anxiety. Of note, this lack of CSC-induced anxiety observed in 
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mGlu7 KO mice was not due to changes in locomotor activity. This is an important 
consideration as mGlu7 genetic ablation has been associated with an increased 
susceptibility to sensory stimulus-induced seizures (Sansig et al., 2001). Interestingly, the 
previously described anxiolytic-like effect of genetic mGlu7 ablation could not be 
reproduced in the present study, as innate anxiety levels on the EPM were comparable 
between mGlu7 KO and WT mice in the SHC group. However, the findings are still in line 
with the study of Cryan et al. (2003) who showed a significant anxiolytic-like effect of 
genetic ablation of mGlu7 in mice using the light-dark box (LDB) test, but couldn’t easily 
confirm this effect with the EPM test. Thus, it seems that the detection of the anxiolytic-
like phenotype of mGlu7 KO mice depends on the exact behavioral test employed. 
A stress-protective effect of genetic mGlu7 ablation was also found regarding HPA axis 
functionality. In mGlu7 KO mice, no CSC-induced increase in absolute pituitary weight 
and associated basal morning plasma ACTH levels were detected, which are reliable 
indicators for chronic psychosocial stress induced by CSC exposure (Füchsl et al., 2013; 
Langgartner et al., 2015) and could be confirmed in the WT group of the current study. 
Furthermore, mGlu7 KO, in contrast to WT mice, did not develop the previously shown 
CSC-induced increase in absolute adrenal weight accompanied by a reduction in adrenal 
ACTH responsiveness in vitro (Uschold-Schmidt et al, 2012). These findings suggest that 
the HPA axis of mGlu7-deficient mice is less vulnerable to chronic psychosocial stressor 
exposure.  
Analysis of immunological parameters further supported a stress-protective phenotype in 
mGlu7 KO mice. First, the previously described CSC-induced splenomegaly (Füchsl et al., 
2014), which was confirmed in the WT group of the present study, appears completely 
abolished in mGlu7 KO mice. Given the suggested role for mGlu7 in the regulation of 
gastrointestinal function (Julio-Pieper et al., 2010), it was also of great interest to assess 
whether genetic ablation of mGlu7 is protective against CSC-induced development of 
spontaneous colitis. Indeed, an increased IFN-γ secretion from isolated and anti-CD3/anti-
CD28-stimulated mesLNC and an increased histological damage of colonic tissue, 
indicating development of mild colonic inflammation (Füchsl et al., 2014; Reber et al., 
2007), were detected in CSC mice of the WT group but not in mGlu7 KO mice.  
Together, the present findings indicate that mice with genetic ablation of mGlu7 are less 
vulnerable to various behavioral, physiological as well as immunological consequences of 
chronic psychosocial stressor exposure. The mechanisms underlying these stress-protective 
effects of genetic mGlu7 ablation might be explained by the role of mGlu7 in regulating 
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neurotransmitter release: The presynaptically located mGlu7 is thought to act as an auto- 
and heteroreceptor on glutamatergic and GABAergic neurons in key limbic brain regions 
involved in the regulation of the stress response. Thus, a complete lack of mGlu7 might 
induce region-specific changes in excitatory and inhibitory neurotransmitter release 
through altered negative feedback regulation eventually leading to a stress-resilient 
phenotype. Moreover, downstream effects on other neurotransmitter systems such as the 
dopamine and serotonin (5-HT) systems (Müller and Schwarz, 2007) that are known to 
alter e.g. anxiety-related behavior (Lucki, 1998) and/or altered neurodevelopmental 
mechanisms due to mGlu7 deficiency may also account for stress resilience observed in 
mGlu7 KO mice. 
The finding of above demonstrated that 19 days of CSC lead to a decrease of mGlu7 
mRNA levels in the PFC in WT mice is possibly well consistent with the 
physiological/behavioral observations: A downregulation of mGlu7 and hence an L-
glutamate/GABA imbalance in a specific brain region, namely the PFC, may account for 
an increase in anxiety-related behavior following CSC. This would be in line with studies 
suggesting that hyperexcitability in the PFC contributes to an anxiety-prone phenotype (Bi 
et al., 2013; Bruening et al., 2006; Singewald et al., 2003). Conversely, altered inhibition 
and/or excitation in several brain regions at the same time, due to the complete lack of 
mGlu7, may compensate CSC-induced changes in neurotransmitter release via complex 
circuitry adaptations and thereby account for the stress-protective phenotype of mGlu7 KO 
mice. In addition, mGlu7 is known to be expressed in endocrine organs like adrenal glands 
and also in the gastrointestinal tract (Julio-Pieper et al., 2011). Therefore, peripheral 
mechanisms may also contribute to the stress-protective phenotype in mice lacking mGlu7, 
at least with respect to immunological/inflammatory parameters. In support of this, 
glutamatergic activation of colonic mGlu7 was recently associated with the 
pathophysiology of secretory disorders (Julio-Pieper et al., 2010). 
In conclusion, the present results demonstrate a stress-protective phenotype of mice 
lacking mGlu7 in the context of chronic psychosocial stress, and thus clearly indicate a 
role for mGlu7 in mediating affective as well as somatic consequences induced by chronic 
psychosocial stressor exposure. 
Discussion 
103 
 
4. mGlu5 functional blockade relieves maladaptive stress consequences 
induced by CSC 
The present thesis could reveal that also the mGlu5 receptor is crucially involved in 
mediating physiological, immunological, and behavioral consequences of chronic 
psychosocial stress in mice using CSC as a male subordination paradigm. First, it was 
shown that genetic ablation of mGlu5 decreases the vulnerability to selected CSC-induced 
alterations. Second, it was demonstrated that chronic treatment of WT mice with CTEP, a 
systemically active mGlu5 NAM, is in a dose-dependent manner protective against the 
physiological and immunological consequences of CSC. These findings suggest for mGlu5 
to be a valuable and novel target for the treatment of chronic stress-induced pathologies in 
man.  
 
4.1 Stress-protective phenotype in mice lacking mGlu5 
In line with previous reports (Füchsl et al., 2014; Reber et al., 2007; Uschold-Schmidt et 
al., 2012) and the findings described above, WT littermates of mGlu5 KO mice showed a 
CSC-induced increase in adrenal weight. Moreover, CSC compared to SHC WT mice 
showed a trend towards an increased number of isolated viable mesLNC as well as an 
increased secretion of the pro-inflammatory cytokine IFN-γ from these cells following in 
vitro anti-CD3/anti-CD28 stimulation. Both findings are in agreement with previous 
reports and indicative for the development of spontaneous colonic inflammation 
(Langgartner et al., 2015; Reber et al., 2007). However, these reliable physiological and 
immunological CSC-induced alterations were not present in mice lacking mGlu5. CSC 
exposure also reliably results in an increased anxiety-related behavior, recorded e.g. in the 
EPM, in the elevated platform (EPF), in the LDB, and in the open-field tests (Reber and 
Neumann, 2008; Reber et al., 2007; Slattery et al., 2012; Uschold-Schmidt et al., 2012). In 
the present study, CSC versus SHC mice were exposed to the SIH test, an animal model 
addressing the physiological component of anxiety and sensitive to anxiolytic drugs 
(Adriaan Bouwknecht et al., 2007; Borsini et al., 1989). Interestingly, it could be shown for 
the first time that 19 days of CSC, in addition to innate anxiety, also increases 
physiological anxiety levels, indicated by a CSC-induced increased hyperthermic response 
in WT mice in the SIH test. Again, this chronic stress effect was absent in mGlu5 KO 
mice, suggesting a stress-protective effect of genetic mGlu5 ablation also with respect to 
physiological anxiety. Unfortunately, the previously reported anxiolytic-like effect of 
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mGlu5 receptor depletion in the SIH test (J Brodkin et al., 2002) was not reproduced as a 
lower SIH response was not found in KO compared to WT mice within the SHC group. 
This might be due to genetic differences between mouse strains (B6;129-Gprc1etm1Rod vs. 
C57/BL6 mice) and differences in the experimental setup (measurement of T2 30 min vs. 
15 min after T1 in the SIH test).  
Taken together, the present findings suggest that mice deficient for mGlu5 are protected 
from important CSC-induced physiological, immunological, and behavioral (at least with 
respect to physiological anxiety) alterations, and thus, seem to be resilient to a variety of 
maladaptive consequences of chronic psychosocial stressor exposure. 
 
4.2 Stress-protective effects of chronic CTEP treatment 
Given the promising stress-protective phenotype of mGlu5 KO mice, a further step was 
analyze the effects of pharmacological mGlu5 inhibition in mice exposed to CSC. The 
typical CSC-affected parameters were assessed in even more detail after chronic (during 
CSC) administration of the mGlu5 NAM CTEP. Different doses of CTEP (0.05, 0.5, and 2 
mg/kg/day) were used to evaluate a possible dose-dependency. These doses were chosen 
according to previously published data showing sufficient plasma and brain exposure and 
sustained receptor occupancy as well as activity in animal models of anxiety (SIH, Vogel 
conflict test; Lindemann et al. (2011)), with minimal effective oral doses between 0.1 and 
0.3 mg/kg. Of note, the in vivo experiments reported by Lindemann et al. (2011) did not 
reveal any unspecific effects of CTEP like sedation or general changes in overall health, 
body temperature, and body weight, in a dose range of up to 2 mg/kg. 
In a pilot study, it was imperative to provide experimental evidence for the compatibility of 
chronic vehicle administration via micro-osmotic pumps with typical CSC-related 
parameters. Importantly, no effects of either vehicle or CTEP treatment (2 mg/kg/day) 
were found in comparison to chronic saline administration (Figure 14) in unstressed mice. 
This was in line with the study conducted by Peters et al. (2014), where they revealed no 
confounding influence of either the surgical procedure or the chronic i.c.v. administration 
of vehicle (in that case Ringer’s solution) via micro-osmotic pumps. 
In line with previous studies using untreated mice (Reber et al., 2007; Veenema et al., 
2008), vehicle-treated CSC vs. SHC mice of the present study showed a reduced body 
weight gain. This effect was absent in chronically stressed mice treated with CTEP at all 
doses. A stress-protective effect of CTEP is further supported by findings assessing HPA 
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axis functionality. Absolute pituitary weight and associated basal morning plasma ACTH 
levels, typically increased in mice exposed to CSC (Füchsl et al., 2013; Langgartner et al., 
2015), were also increased in CSC vs. SHC mice of the vehicle group, but not in mice 
treated with the two higher doses of CTEP. Furthermore, in vehicle-treated mice, CSC 
exposure resulted in enlarged adrenals accompanied by a reduced adrenal CORT response 
to ACTH in vitro, fully in accordance with previous reports (Uschold-Schmidt et al, 2012). 
CTEP dose-dependently prevented these CSC-induced changes, together with pituitary and 
plasma ACTH findings indicating that the HPA axis is generally less vulnerable to chronic 
psychosocial stressor exposure in mice with pharmacological mGlu5 inhibition. These 
findings seem to be in contrast to the study by Wagner et al. (2014), showing no beneficial 
effects of oral CTEP (2 mg/kg; every 48 h) on the dysregulated HPA axis activity in mice 
exposed to CSDS. These discrepancies might be due to differences in the chronic stress 
paradigms likely resulting in different changes in the mGlu5 system in the brain and/or 
periphery and, thus, different CTEP-mediated effects. Moreover, it cannot be excluded that 
the stress induced by repeated oral applications of CTEP interfered with possible beneficial 
effects of mGlu5 blockade on the CSDS-induced dysregulation of HPA axis activity. 
The assessed immunological parameters suggest that pharmacological blockade of mGlu5 
by CTEP attenuates or even abolishes the vulnerability also to CSC-induced 
immunological alterations. In accordance with previous studies (Füchsl et al., 2014; Reber 
et al., 2007), CSC mice of the vehicle group showed a decrease in absolute thymus weight 
and an increase in absolute spleen weight. These effects were dose-dependently reduced 
with CTEP. Anti-stress effects of mGlu5 blockade were also found with respect to colonic 
inflammation. Although an increased number of isolated viable mesLNC found in vehicle-
treated CSC mice was still detectable in the groups with the two lower CTEP doses, it was 
absent in mice treated with 2 mg/kg/day of CTEP. Furthermore, CTEP in contrast to 
vehicle treatment abolished the CSC-induced increase in in vitro IFN-γ secretion from 
isolated viable mesLNC and, at least at a dose of 2 mg/kg/day, in the histological damage 
score of the colon. Thus, CTEP is protective against two reliable CSC consequences 
indicative for colonic inflammation (Reber et al., 2011, 2007). 
In line with previous data (Reber and Neumann, 2008; Reber et al., 2007) and the above 
mentioned data from WT mice, CSC exposure of vehicle-treated mice in the present study 
increased innate and physiological anxiety measured on the EPM and in the SIH test, 
respectively. Unexpectedly, however, CTEP treatment did not normalize the CSC-induced 
anxiety-prone phenotype, despite the above reported attenuated SIH response of mGlu5 
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KO CSC mice and the recovery of behavioral alterations by chronic oral CTEP 
administration in CSDS mice reported in a recent study (Wagner et al., 2014). This raises 
the suspicion that in the present study the mGlu5 receptor saturation upon chronic CTEP 
administration via micro-osmotic pumps was not sufficient to induce any behavioral 
effects – at least on the days of behavioral testing (EPM and SIH tests on days 18 and 19, 
respectively). Indeed, subsequent drug exposure analysis (performed by F. Hoffmann-La 
Roche Ltd., Basel, Switzerland) revealed only low plasma CTEP concentrations within a 
range of approximately 1.0 ng/ml up to 1.5 ng/ml (Figure 24), far below the expected 
values.  
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Figure 24. Plasma CTEP exposure after chronic (26 days) drug dosing via micro-osmotic pumps. 
Plasma samples were collected after 26 days of chronic CTEP (1 and 2 day(s) after SIH and EPM testing, 
respectively) at doses of 0.05, 0.5 and 2 mg/kg/d. Chronic CTEP administration at the two lower doses 
resulted in significantly increased CTEP plasma concentrations (ng/ml) compared to VEH (CTEP .05: p = 
0.001 and CTEP .5: p = 0.016). Unexpectedly, chronic application of CTEP at a dose of 2 mg/kg/d did not 
result in significantly increased CTEP plasma concentrations compared to VEH (CTEP 2: p = 0.159). White 
bar, VEH; light grey bar, CTEP 0.05 mg/kg; dark grey bar, CTEP 0.5 mg/kg; black bar, CTEP 2 mg/kg. As 
drug exposure levels were not different between the SHC and CSC group (raw data not shown), data of SHC 
and CSC mice was averaged per data set. CTEP plasma concentration values obtained from VEH-treated 
animals were ≤ 0.25 ng/ml and therefore averaged to 0.25 ng/ml. Data represent mean + S.E.M. * p ≤ 0.05, 
**p ≤ 0.01 vs. respective VEH group. n = 8 per group (n = 4 SHC and n = 4 CSC mice); independent 
Student’s t-test. 
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In a recent study, Michalon et al. (2012) reported a minimal CTEP plasma concentration of 
98 ± 14 ng/ml following two weeks of chronic oral dosing at 2 mg/kg every 48 h, 
corresponding to an estimated mean receptor occupancy level of 81%.  
Of course, by comparing the study conducted by Michalon et al. (2012) with the present 
study, possible differences in CTEP plasma exposure due to different route and duration of 
drug administration seem very likely. However, the low plasma CTEP levels on day 20 of 
CSC yielded in the present study strongly suggest only inadequate mGlu5 receptor 
saturation insufficient to induce any beneficial effects on behavior, but apparently 
sufficient to prevent CSC-induced physiological and immunological alterations. It could 
also be (which is even quite likely), that CTEP plasma exposure was actually higher at an 
earlier time point during CSC exposure when physiological (Uschold-Schmidt et al., 2012) 
and immunological changes (Reber et al., 2007) start to develop, but declined due to 
improper functioning of micro-osmotic pumps and eventually resulted in a lack of 
behavioral effects. In view of this, it will be part of future experiments to determine the 
actual levels of mGlu5 receptor saturation at various earlier time points during chronic 
administration of CTEP via micro-osmotic pumps. If the assessed CTEP plasma exposure 
rate will be found on a low level also at earlier time points, the present findings suggest 
that CSC-induced physiological and immunological alterations are more sensitive to 
mGlu5 inhibition compared to the behavioral consequences of CSC. Together with the 
stress-protective phenotype of mGlu5 KO CSC mice seen in the SIH test, this also suggests 
that a higher dose of CTEP and subsequently a higher receptor saturation in relevant brain 
regions might correct the CSC-induced anxiety-prone phenotype. Unfortunately, attempts 
to use a higher CTEP dose (6 mg/kg/day; data not shown) failed due to plugging of the 
pumps and resultant loss of pump functioning and, thus, one can only speculate about 
potential results of experiments using higher drug doses. However, if this hypothesis 
proves correct, this would make CTEP a powerful tool for the independent treatment of 
stress-induced somatic and affective diseases in man depending on the dose applied. 
A further explanation for the missing behavioral effects in the present study could be that 
chronic CTEP administration caused an upregulation of mGlu5 receptor expression 
accompanied by functional changes in specific brain regions, which possibly compensated 
for any potential effects on behavior. Indeed, antagonist-induced upregulation and 
concomitant functional supersensitivity has been reported for 5-HT3A-, opioid- and NMDA 
receptors (Follesa and Ticku, 1996; Morton et al., 2015; Yoburn, 1988; Yoburn et al., 
1994). Therefore, and especially in view of the close physical and functional interaction 
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between NMDA and mGlu5 receptors, an antagonist-induced upregulation of mGlu5 upon 
chronic CTEP dosing may have occurred and confounded any behavioral effects in the 
present study. However, this is only part of speculation at the moment and has to be 
investigated in future projects. 
Of note, the proposed anxiolytic-like efficacy of CTEP could be verified in a further 
experiment with naïve mice i.p.-administered with CTEP at doses of 0.5 and 2 mg/kg in an 
acute and of 2 mg/kg/day in a sub-chronic design. Therefore, the anti-stress/anxiolytic-like 
effect of CTEP reported in the literature (Lindemann et al., 2011) could be confirmed and 
extended (with respect to the route and the duration of administration). Future experiments 
will be needed to resolve the underpinnings of the discrepancies in the behavioral effects of 
CTEP obtained in the present study (chronic s.c. vs. sub-chronic i.p. treatment). 
 
With respect to the molecular mechanisms underlying the beneficial anti-stress effects of 
mGlu5 receptor blockade, one so far can only speculate based on findings reported in the 
literature: 
First of all, it’s interesting to consider that the selective mGlu5 antagonist MPEP has been 
shown to dose-dependently induce c-Fos neuronal activation in stress-related brain areas 
including the PVN of the hypothalamus, CeA and BNST (Inta et al., 2012), similar to the 
activation pattern induced by imipramine (Sumner et al., 2004) and/or diazepam (Salminen 
et al., 1996) treatment. This would implicate that functional mGlu5 blockade might result 
in neuronal activation of stress-sensitive brain areas that are also stimulated by 
antidepressant and anxiolytic drugs. Whether CTEP does the same as MPEP remains to be 
tested. 
Given the synergistic reciprocal interaction between mGlu5 and NMDA receptors, mGlu5 
inhibition may reduce glutamatergic transmission at NMDA receptors (O’Leary et al., 
2000), thereby shifting the balance towards inhibitory GABAergic neurotransmission in 
brain regions regulating behavioral and physiological responses to stress (Palucha and Pilc, 
2007). On the other hand, similar to the proposed mechanisms underlying the effects of the 
clinically active CTEP analogue basimglurant (Fuxe and Borroto-Escuela, 2015), CTEP 
may preferentially target mGlu5 heteroreceptor complexes of cortical limbic GABA 
interneurons, especially those inhibiting the glutamate projection neurons of the circuits of 
stress-related mood and emotion pathways. These glutamate neurons may therefore be 
activated by being set free from GABA inhibition, which in turn restores activity in 
relevant brain circuits. Moreover, concurrent increased AMPA receptor activation might 
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involve increased glutamate release (Thomas et al., 2000) as well as increased BDNF 
levels and release associated with increased TrkB signaling (Chaki et al., 2013; Pilc et al., 
2008). Subsequent activation of the PI3-kinase/Akt/mTOR pathway might improve the 
formation of synaptic proteins and/or the return of stress-induced loss of synaptic function 
(as briefly discussed by Fuxe and Borroto-Escuela (2015)). In support of this, activation of 
mTOR signaling has recently been shown to be associated with the antidepressant-like 
activity of the mGlu5 antagonist MTEP and the NMDA antagonist ketamine (Li et al., 
2010; Pałucha-Poniewiera et al., 2014a; Tang et al., 2015). Interestingly, recent studies 
showed reduced phosphorylation levels of mTOR and its downstream signaling 
components in the amygdala in rats (Chandran et al., 2013) and the prefrontal cortex in 
mice (Tang et al., 2015) following CUS exposure. Whether also CSC exposure actually 
induces dysregulation of mTOR and whether this dysregulation can be corrected by CTEP 
treatment remains to be assessed in future studies. 
Other reports suggest the involvement of the serotonergic system in the action of mGlu5 
blockade. The existence of mGlu5-5-HT2A/2C heteroreceptor complexes implicates specific 
functional interaction between the glutamate and serotonin systems. Stachowicz et al. 
(2007) supposed that the anxiolytic effect of mGlu5 blockade via MTEP in the Vogel 
conflict drinking test observed in rats occurs due to an increased release of serotonin in the 
PFC with subsequent activation of 5-HT2A/2C receptors and, therefore, changes in the 
balance between the glutamatergic and serotonergic system in specific brain regions. 
Moreover, it was recently shown that MPEP-induced blockade of mGlu5 exerted 
anxiolytic-like effects in the novelty-suppressed feeding test in a 5-HT2A/2C receptor-
dependent manner (Fukumoto and Chaki, 2015).  
Others suggest an interaction with neuropeptides that are crucial for modulating stress 
responses, such as neuropeptide Y (NPY, Heilig, 2004), in the stress-protective action of 
mGlu5 blockade. Wierońska et al. (2004) showed that NPY neurons that are highly 
expressed in the amygdala are critically involved in MPEP’s anxiolytic action. The 
concrete investigation of an involvement of NPY and its receptors in CTEP’s stress-
protective effects is part of future studies. 
Furthermore, as the mGlu5 expression is also abundant in peripheral endocrine organs like 
the adrenal glands (Pokusa et al., 2014), in the gastrointestinal tract (Julio-Pieper et al., 
2011) and in immune cells (Storto et al., 2000), also peripheral mechanism have to be 
considered to play a role in mGlu5’s involvement in chronic psychosocial stress 
conditions. For example, although a clear functional role is not much explored, Nasser et 
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al. (2007) found that chemically induced colitis was associated with redistribution of 
mGlu5 and that a mouse model of spontaneous chronic intestinal inflammation showed 
dysregulated glial mGlu5 expression in colon myenteric plexus, suggesting involvement of 
mGlu5 in inflammatory processes. 
In conclusion, the present studies employing genetic and pharmacological inhibition of 
mGlu5 activity suggest a stress-protective effect of mGlu5 functional blockade. Moreover, 
the results suggest that the stress-protective effects are due to acute mGlu5 inhibition as 
opposed to potential neurodevelopmental effects of mGlu5 ablation in the KO mice. 
Together, these findings strongly indicate a role for mGlu5 in mediating at least somatic 
consequences induced by chronic psychosocial stressor exposure and, thus, substantiate 
that the approach of mGlu5 receptor blockade represents a very promising strategy towards 
future treatment of chronic stress-induced pathologies in man. 
 
Future Outlook 
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Given the promising stress-protective phenotype of mice lacking mGlu7, pharmacological 
blockade of mGlu7 might represent a relevant option for the treatment of chronic stress-
induced affective and somatic maladaptations. Future studies will encompass chronic 
application of selective mGlu7 antagonists, such as XAP044 (see characterization above) 
and/or related compounds, at different doses, aiming to reverse CSC-induced emotional 
and physiological dysfunctions, and thus, extend the findings obtained from mGlu7 
deficient mice to pharmacological approaches. Moreover, given that functional expression 
of mGlu7 in specific brain regions, such as PFC and HT, is expected to be necessary and 
possibly sufficient to exert regulatory effects on certain consequences of CSC, viral vectors 
for selective and regions-specific knockdown (or overexpression) of mGlu7 will help to 
reveal region-specific functional relevance of mGlu7 in mediating CSC-induced 
alterations. Furthermore, detailed behavioral analysis will be performed to assess whether 
the animal’s stress coping style (active vs. passive; which is regulated by the PFC) during 
CSC exposure is altered in mGlu7 KO compared to WT mice and also in mGlu7 
antagonist-treated compared to vehicle-treated mice. In view of the present data, mGlu7 
blockade is expected to be associated with rather active stress coping behavior which 
might contribute to and explain the overall stress-protective phenotype observed in mGlu7 
KO mice. The potentially beneficial influence of mGlu7 blockade on CSC-induced basal 
evening hypocorticism (and subsequent impaired GC signaling), a phenomenon that is also 
seen in humans suffering from chronic stress (see Introduction), will also be addressed. In 
addition, future studies will aim at analyzing mGlu7’s impact on the development of CSC-
induced somatic alterations (HPA axis dysfunction, colonic inflammation and damage, 
etc.); CSC time-course experiments (10 h, 48 h, 7 d, 19 d) will be conducted to find the 
earliest point-in-time when stress protection in mGlu7 KO mice emerges. Furthermore, 
detailed immunohistochemistry for mGlu7 protein distribution needs to be conducted in 
sections of organs such as the pituitary, adrenal glands and colonic tissue, in order to reveal 
whether alterations in peripheral mGlu7 might contribute to the development of CSC-
induced somatic dysfunctions, or if they are solely centrally mediated.  
 
Genetic and pharmacological mGlu5 inhibition was shown to exert beneficial effects on a 
broad range of CSC-induced maladaptations. Thus, mice lacking mGlu5 were protected 
against a variety of CSC-induced alterations, including the newly established CSC-induced 
increase in SIH response. Future studies will address also behavioral analysis of the stress 
coping styles of mGlu5 KO mice compared to their WT littermates. 
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Interestingly, chronic application of CTEP relieved only somatic, but not the typical 
behavioral alterations induced by CSC exposure. This lack of effect on behavioral aspects 
might be due to relatively low plasma CTEP levels assessed on day 20 of CSC, strongly 
suggesting only insufficient mGlu5 receptor saturation. It is quite likely that CTEP plasma 
exposure was actually higher at earlier time points of CSC exposure. Future experiments 
will be needed to determine the actual levels of mGlu5 receptor saturation at various earlier 
time points during chronic administration of CTEP via micro-osmotic pumps and to study 
its possibly stress-protective effects on CSC-induced increased physiological and innate 
anxiety (e.g. SIH and EPM test, respectively). Thus, these experiments will reveal whether 
CTEP (or close analogues such as basimglurant) can be used for the independent treatment 
of stress-induced somatic and affective pathologies depending on the dose applied. 
Given that CSC exposure increased mGlu5 protein expression specifically in the HC, the 
application of CTEP (and/or related compounds) locally into the HC (or into other stress-
sensitive brain regions) in combination with CSC exposure and its functional analysis will 
help to find out whether mGlu5 in the HC (or in other brain regions) might have functional 
relevance for any CSC-induced behavioral and/or somatic alterations. 
 
Summary 
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Etiology and pharmacotherapy of stress-related psychiatric conditions and comorbid 
somatic pathologies are nowadays areas of high unmet medical need and intense research. 
It is widely accepted that stressors holding a chronic and psychosocial component 
represent the most acknowledged risk factor. The L-glutamatergic system represents the 
primary excitatory neurotransmitter system of the mammalian brain and mGlu receptors 
acting as important pre- and postsynaptic regulators of neurotransmission provide a 
mechanism by which fast synaptic responses through iGlu receptors can be fine-tuned. 
During the last decades, research on mGlu receptors advanced remarkably and much 
attention was given to the mGlu5 and mGlu7 subtypes in acute stress, fear and depression-
related behavior and physiology (see Introduction). As the most widely distributed 
throughout the mammalian brain, the presynaptic mGlu7 receptor is an important regulator 
of glutamatergic function and postulated to be critical for both normal CNS functioning 
and a range of stress-related disorders. Although genetic and pharmacological approaches 
have helped to understand mGlu7’s function in a host of behavioral and physiological 
processes, available allosteric ligands have often yielded disparate results despite 
displaying similar pharmacological properties in vitro. The recent discovery of XAP044 
raised great hope to resolve this discrepancy. XAP044 was characterized as the first 
mGlu7-selective full antagonist that blocks the receptor’s signaling pathways by binding to 
its large VFTD, but not to allosteric sites within the transmembrane domain. Thus, 
XAP044 presumably binds via a novel mechanism compared to that from known selective 
ligands. It was part of the present PhD thesis to characterize this novel compound XAP044 
in vivo in a broad battery of acute stress tests for depression, fear and anxiety in mice. It 
was shown that XAP044 is systemically active and demonstrates a wide spectrum of anti-
stress, antidepressant and anxiolytic-like efficacy, strongly supporting pharmacological 
blockade of mGlu7 as a promising mode of action for future treatment of stress-related 
disorders of emotion in man.  
Also the mGlu5 subtype has become a recent focus for drug discovery efforts (see 
Introduction). Due to its physical and functional association with the postsynaptic NMDA 
receptor the mGlu5 subtype is considered as a good target to modulate NMDA receptor 
function. This is an important consideration as, for instance, the NMDA receptor 
antagonist ketamine – despite showing rapid and sustained efficacy in clinical depression 
trials – is also associated with severe cognition-altering and dissociative effects. To date, 
several mGlu5 NAMs have been reported to have therapeutic potential for numerous 
conditions including clinical depression and anxiety disorders. A recent study revealed the 
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mGlu5 NAM basimglurant as a promising antidepressant drug with the potential to also 
alleviate comorbidities such as anxiety and pain. 
Despite the overall well-established link between mGlu5 and mGlu7 and acute stress-
related behavior and physiology, the roles these receptors play in chronic stress-related 
conditions is only little explored. The CSC paradigm represents a powerful animal model 
as it displays harmful behavioral, physiological and immunological changes induced by 
chronic psychosocial stress. Those consequences are relevant for the development of 
psychiatric, somatic and/or gastrointestinal disorders in humans and the question whether 
mGlu5 and mGlu7 have the potential to exert control on these pathological consequences 
is of great interest, and it may suggest future therapeutic strategies for the treatment of 
chronic stress-related disorders in humans, i.e. a wide clinical application spectrum. In a 
first step of the present PhD thesis, the molecular changes were assessed that occur within 
the mGlu receptor system in response to CSC exposure. Here, an increase by trend of 
mGlu5 mRNA was found in the hypothalamus. Additional saturation binding analysis 
revealed increased mGlu5 protein binding specifically in the hippocampus. Furthermore, 
robust downregulation of mGlu7 mRNA was found specifically in the PFC. In contrast, 
mGlu2 and mGlu3 were not dysregulated upon CSC exposure. Taken together, the present 
results indicate specific CSC-induced alterations of mGlu5 and mGlu7 expression in 
stress-sensitive brain regions involved in the regulation of behavior and HPA axis 
functionality, and thus provide early evidence towards a role of specific mGlu receptor 
subtypes in chronic psychosocial stress-induced pathophysiology.  
In a next step, the influence of genetic ablation of mGlu7 on behavioral, physiological and 
immunological consequences of CSC was analyzed to reveal the potential role of the 
endogenous mGlu7 receptor during chronic psychosocial stress. Indeed, genetic ablation of 
mGlu7 relieved multiple CSC induced alterations; mGlu7 deficient mice were protected 
against the CSC-induced anxiety-prone phenotype as well as against several CSC-induced 
physiological and immunological consequences such as HPA axis dysfunction and colonic 
inflammation, respectively. These findings point to a distinct role of mGlu7 in modulating 
a wide range of affective and somatic alteration that occur upon CSC exposure. Moreover, 
the stress-protective phenotype of genetic mGlu7 ablation suggests mGlu7 
pharmacological blockade to be a possible treatment strategy for chronic stress-related 
emotional and somatic conditions in man.  
In the last part of the present thesis, the potentially beneficial role of genetic and 
pharmacological mGlu5 inhibition on CSC-induced alterations (the same broad range as 
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presented above) was analyzed. Interestingly, also mGlu5 deficient mice were protected 
against a variety of CSC-induced physiological and behavioral changes, including the 
newly established CSC-induced increase in SIH response. Moreover, the effects of the 
mGlu5 NAM CTEP, a close analogue to the clinically active drug basimglurant with long 
half-life in rodents, were studied on a wider range of CSC-affected parameters. Here, 
CTEP relieved in a dose-dependent manner various CSC-induced consequences such as 
HPA axis dysfunction, immunological alterations and colonic inflammation, suggesting 
that mGlu5 is a relevant mediator for a wide range of alterations induced by chronic 
psychosocial stress and a potentially valuable drug target for the treatment of stress-related 
somatic pathologies. 
In conclusion, the present PhD thesis provides clear evidence for the importance of 
especially the mGlu5 and mGlu7 subtypes in the regulation of acute and chronic stress-
related behavior and physiology, lending further support towards future development of 
mGlu5- and mGlu7-selective antagonists and their administration as therapy for stress-
related psychiatric and somatic disorders in humans. 
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Die Ursachenforschung und Therapiemöglichkeiten stressbedingter psychischer und 
somatischer Erkrankungen sind heutzutage von großer medizinischer Bedeutung. Es ist 
allgemein anerkannt, dass Stressoren mit chronischer und psychosozialer Komponente 
dabei den stärksten Risikofaktor darstellen. Das L-Glutamatsystem mit seinen ionotropen 
und metabotropen Rezeptoren ist das primäre exzitatorische Neurotransmittersystem im 
Säugergehirn, wobei die prä- und postsynaptischen metabotropen Glutamatrezeptoren die 
Feinmodulation der schnellen synaptischen Signalweiterleitung der ionotropen 
Glutamatrezeptoren ermöglicht. In den letzten Jahrzehnten waren erstaunliche Fortschritte 
in der Forschung an metabotropen Glutamatrezeptoren festzustellen. Ein besonderes 
Augenmerk wurde hier auf die Rolle der Subtypen mGlu5 und mGlu7 in akutem stress-, 
furcht- und depressionsbezogenem Verhalten gesetzt (siehe Einleitung). Im Säugergehirn 
ist der mGlu7 Subtyp der am weitesten verbreitete Glutamatrezeptor und spielt somit 
vermutlich eine bedeutende Rolle im zentralen Nervensystem, unter normalen sowie 
pathologischen Zuständen. Obwohl genetische und pharmakologische Ansätze hilfreich 
dafür waren, die Funktionsweise des mGlu7 in vielen verhaltensbedingten und 
physiologischen Prozessen zu verstehen, sind die Ergebnisse von Studien mit verfügbaren 
allosterischen Liganden trotz ähnlicher pharmakologischer Eigenschaften in vitro nicht 
immer eindeutig. Vor kurzem hat die Entdeckung von XAP044 große Hoffnung geweckt, 
um dieses Dilemma zu lösen. Charakteristisch für XAP044 ist, dass diese Substanz die 
Signalwege des mGlu7 durch Bindung an dessen Venusfliegenfalle-Domäne blockiert, und 
nicht wie die bisher bekannten selektiven Liganden durch Bindung an allosterische 
Transmembranstellen. XAP044 verwendet also vermutlich einen neuartigen 
Regulationsmechanismus. Ein Abschnitt der vorliegenden Doktorarbeit hat nun darauf 
abgezielt, diese neue Substanz XAP044 in verschiedenen Tests für Depression, Furcht und 
Angst in der Maus in vivo zu charakterisieren. Mir gelang es nachzuweisen, dass XAP044 
systemisch aktiv ist und eine antistress, antidepressive und anxiolytische Wirkung 
aufweist. Diese Ergebnisse unterstützen die pharmakologische Blockade von mGlu7 als 
vielversprechenden therapeutischen Ansatz für die Behandlung von stressbedingten 
emotionalen Erkrankungen des Menschen. 
Ebenso steht der mGlu5 Subtyp im Fokus der aktuellen Arzneimittelforschung (siehe 
Einleitung). Aufgrund seiner physikalischen und funktionellen Wechselwirkung mit dem 
postsynaptischen NMDA Rezeptor bietet der mGlu5 eine vielversprechende Möglichkeit, 
die Funktion des NMDA Rezeptors zu modulieren. Dies ist insofern von besonderer 
Bedeutung, da z.B. der NMDA Rezeptor Antagonist Ketamin – trotz schneller und 
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langanhaltender Wirkung in klinischen Depressionsstudien – sich ernsthaft auf die 
Wahrnehmung und Psyche auswirkt. Bis heute sind einige mGlu5 negative allosterische 
Modulatoren (NAM) bekannt, die z.B. bei Depressions- oder Angsterkrankungen 
therapeutisches Potential besitzen. Eine Studie hat vor kurzem gezeigt, dass der mGlu5-
selektive NAM Basimglurant eine vielversprechende Substanz mit antidepressiver 
Wirkung ist, die zugleich Angst-und Schmerzzustände lindert. 
Trotz der gut etablierten Rolle von mGlu5 und mGlu7 in akutem stressbezogenen 
Verhalten und Physiologie, ist deren Beteiligung bei chronischem Stress nur sehr gering 
erforscht. Das CSC-Modell stellt ein geeignetes Tiermodell dar, um genau dies näher zu 
untersuchen. Durch chronisch psychosoziale Stressor-Exposition werden hier 
verhaltensbedingte, physiologische und immunologische Veränderungen bei Mäusen 
induziert, welche vergleichbar sind mit den psychischen, somatischen und/oder 
gastrointestinalen Erkrankungen bei chronisch gestressten Menschen. Dabei stellte sich die 
Frage, ob die Glutamatrezeptorsubtypen mGlu5 und mGlu7 das Potential haben, diese 
pathologischen Veränderungen zu kontrollieren und womöglich therapeutische Ansätze für 
die Behandlung verschiedener chronisch stressbedingter Erkrankungen im Menschen zu 
liefern. Im Zuge dieser Doktorarbeit wurden zuerst mögliche Effekte von CSC auf das 
metabotrope Glutamatrezeptorsystem untersucht. Dabei wurde herausgefunden, dass im 
Hypothalamus die mGlu5 mRNA tendenziell hochreguliert ist. Eine zusätzliche 
Saturationsanalyse hat gezeigt, dass die Proteinbindung des mGlu5 spezifisch im 
Hippocampus erhöht ist. Des Weiteren ergab sich eine deutliche Abnahme der mGlu7 
mRNA spezifisch im präfrontalen Cortex. Im Gegensatz dazu waren weder mGlu2 noch 
mGlu3 nach CSC-Exposition beeinflusst. Zusammenfassen waren nun als Folge von CSC-
Exposition spezifische Expressionsänderungen der Subtypen mGlu5 und mGlu7 in 
stresssensitiven Gehirnregionen festzustellen, welche für die Regulation von Verhalten und 
der HPA-Achsen Funktion bedeutend sind. Somit konnten erste Hinweise auf eine 
mögliche wichtige Rolle dieser Rezeptoren in chronisch psychosozialem Stress geliefert 
werden. 
Im nächsten Schritt wurden die Effekte der genetischen Blockade des mGlu7 auf 
verhaltensbiologische, physiologische und immunologische Konsequenzen der CSC-
Exposition untersucht. Dabei wurde herausgefunden, dass das genetische Entfernen des 
mGlu7 viele CSC-induzierte Veränderungen abschwächt oder sogar verhindert; mGlu7-
defiziente Mäuse entwickelten keine Angst und waren auch vor den physiologischen und 
immunologischen Folgen von CSC geschützt. Diese Ergebnisse deuten auf eine wichtige 
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Rolle des mGlu7 in der Modulation einer großen Bandbreite der affektiven und 
somatischen Veränderungen nach CSC-Exposition hin. Sie suggerieren darüber hinaus, 
dass die pharmakologische Blockade des mGlu7 eine mögliche Behandlungsstrategie bei 
chronisch gestressten Menschen darstellt. 
Im letzten Teil der vorliegenden Doktorarbeit wurden mögliche positive Effekte der 
genetischen sowie pharmakologischen Blockade des mGlu5 Subtyps auf CSC-induzierte 
Veränderungen (dieselbe Bandbreite an Parametern wie oben beschrieben) analysiert. 
Interessanterweise waren mGlu5-defiziente Mäuse vor einigen Folgen von CSC, u.a. vor 
dem von mir neu etablierten CSC-induzierten Anstieg stressbedingter Hyperthermie, 
geschützt. Des Weiteren wurden die Effekte des mGlu5 NAM CTEP, welcher chemisch 
gesehen der klinisch aktiven Substanz Basimglurant sehr ähnlich ist und eine 
vergleichsweise hohe Halbwertszeit bei Nagern hat, auf eine größere Bandbreite CSC-
induzierter Veränderungen untersucht. CTEP hat dosisabhängig tatsächlich viele 
Konsequenzen von CSC gelindert, wie z.B. die Dysfunktion der HPA-Achse und die 
Darmentzündung. Dies deutet darauf hin, dass auch der mGlu5 Subtyp einen relevanten 
Mediator für viele stress-induzierten Veränderungen darstellt und ein mögliches 
Zielprotein für die Behandlung stressbedingter somatischer Pathologien ist. 
Somit konnte die vorliegende Doktorarbeit einen deutlichen Beweis dafür liefern, dass 
besonders die mGlu5- und mGlu7-Subtypen eine wichtige Rolle in der Regulation akut- 
und chronisch-stressbedingter Veränderungen im Verhalten und der Physiologie spielen. 
Womöglich kann dadurch auch die Entwicklung mGlu5- und mGlu7-gerichteter 
Therapieansätze für stress-bedingte psychische und somatische Erkrankungen beim 
Menschen unterstützt werden. 
 
References 
References 
130 
 
Aas, M., Steen, N.E., Agartz, I., Aminoff, S.R., Lorentzen, S., Sundet, K., Andreassen, 
O.A., Melle, I., 2012. Is cognitive impairment following early life stress in severe 
mental disorders based on specific or general cognitive functioning? Psychiatry Res. 
198, 495–500. doi:10.1016/j.psychres.2011.12.045 
Abe, T., Sugihara, H., Nawa, H., Shigemoto, R., Mizuno, N., Nakanishi, S., 1992. 
Molecular characterization of a novel metabotropic glutamate receptor mGluR5 
coupled to inositol phosphate/Ca2+ signal transduction. J. Biol. Chem. 267, 13361–8. 
Adriaan Bouwknecht, J., Olivier, B., Paylor, R.E., 2007. The stress-induced hyperthermia 
paradigm as a physiological animal model for anxiety: a review of pharmacological 
and genetic studies in the mouse. Neurosci. Biobehav. Rev. 31, 41–59. 
doi:10.1016/j.neubiorev.2006.02.002 
Aguilera, G., 1994. Regulation of pituitary ACTH secretion during chronic stress. Front. 
Neuroendocrinol. 15, 321–50. doi:10.1006/frne.1994.1013 
Akiba, Y., Watanabe, C., Mizumori, M., Kaunitz, J.D., 2009. Luminal L-glutamate 
enhances duodenal mucosal defense mechanisms via multiple glutamate receptors in 
rats. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G781–91. 
doi:10.1152/ajpgi.90605.2008 
Albeck, D.S., McKittrick, C.R., Blanchard, D.C., Blanchard, R.J., Nikulina, J., McEwen, 
B.S., Sakai, R.R., 1997. Chronic social stress alters levels of corticotropin-releasing 
factor and arginine vasopressin mRNA in rat brain. J. Neurosci. 17, 4895–903. 
Antflick, J.E., Hampson, D.R., 2012. Modulation of glutamate release from parallel fibers 
by mGlu4 and pre-synaptic GABA(A) receptors. J. Neurochem. 120, 552–63. 
doi:10.1111/j.1471-4159.2011.07611.x 
Armario, A., Lopez-Calderon, A., Jolin, T., Balasch, J., 1986. Response of anterior 
pituitary hormones to chronic stress. The specificity of adaptation. Neurosci. 
Biobehav. Rev. 10, 245–50. 
Arnsten, A.F.T., 2009. Stress signalling pathways that impair prefrontal cortex structure 
and function. Nat. Rev. Neurosci. 10, 410–22. doi:10.1038/nrn2648 
Avgustinovich, D.F., Kovalenko, I.L., Kudryavtseva, N.N., 2005. A model of anxious 
depression: persistence of behavioral pathology. Neurosci. Behav. Physiol. 35, 917–
24. doi:10.1007/s11055-005-0146-6 
Balsevich, G., Namendorf, C., Gerlach, T., Uhr, M., Schmidt, M. V, 2014. The bio-
distribution of the antidepressant clomipramine is modulated by chronic stress in 
mice: effects on behavior. Front. Behav. Neurosci. 8, 445. 
doi:10.3389/fnbeh.2014.00445 
Bartolomucci, A., 2007. Social stress, immune functions and disease in rodents. Front. 
Neuroendocrinol. 28, 28–49. doi:10.1016/j.yfrne.2007.02.001 
References 
131 
 
Bartolomucci, A., Palanza, P., Sacerdote, P., Ceresini, G., Chirieleison, A., Panerai, A.E., 
Parmigiani, S., 2003. Individual housing induces altered immuno-endocrine responses 
to psychological stress in male mice. Psychoneuroendocrinology 28, 540–58. 
Bartolomucci, A., Palanza, P., Sacerdote, P., Panerai, A.E., Sgoifo, A., Dantzer, R., 
Parmigiani, S., 2005. Social factors and individual vulnerability to chronic stress 
exposure. Neurosci. Biobehav. Rev. 29, 67–81. doi:10.1016/j.neubiorev.2004.06.009 
Battaglia, G., Busceti, C.L., Molinaro, G., Biagioni, F., Storto, M., Fornai, F., Nicoletti, F., 
Bruno, V., 2004. Endogenous activation of mGlu5 metabotropic glutamate receptors 
contributes to the development of nigro-striatal damage induced by 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci. 24, 828–35. 
doi:10.1523/JNEUROSCI.3831-03.2004 
Battaglia, G., Riozzi, B., Bucci, D., Di Menna, L., Molinaro, G., Pallottino, S., Nicoletti, 
F., Bruno, V., 2014. Activation of mGlu3 metabotropic glutamate receptors enhances 
GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the 
SOD-1 mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 74C, 126–136. 
doi:10.1016/j.nbd.2014.11.012 
Belozertseva, I. V, Kos, T., Popik, P., Danysz, W., Bespalov, A.Y., 2007. Antidepressant-
like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse 
tail suspension tests. Eur. Neuropsychopharmacol. 17, 172–9. 
doi:10.1016/j.euroneuro.2006.03.002 
Belzung, C., Griebel, G., 2001. Measuring normal and pathological anxiety-like behaviour 
in mice: a review. Behav. Brain Res. 125. 
Bennett, E.J., Tennant, C.C., Piesse, C., Badcock, C.A., Kellow, J.E., 1998. Level of 
chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 43, 256–
61. 
Bergink, V., van Megen, H.J.G.M., Westenberg, H.G.M., 2004. Glutamate and anxiety. 
Eur. Neuropsychopharmacol. 14, 175–83. doi:10.1016/S0924-977X(03)00100-7 
Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., 
Krystal, J.H., 2000. Antidepressant effects of ketamine in depressed patients. Biol. 
Psychiatry 47, 351–4. 
Berton, O., McClung, C.A., Dileone, R.J., Krishnan, V., Renthal, W., Russo, S.J., Graham, 
D., Tsankova, N.M., Bolanos, C.A., Rios, M., Monteggia, L.M., Self, D.W., Nestler, 
E.J., 2006. Essential role of BDNF in the mesolimbic dopamine pathway in social 
defeat stress. Science 311, 864–8. doi:10.1126/science.1120972 
Bi, L.-L., Wang, J., Luo, Z.-Y., Chen, S.-P., Geng, F., Chen, Y., Li, S.-J., Yuan, C., Lin, S., 
Gao, T.-M., 2013. Enhanced excitability in the infralimbic cortex produces anxiety-
like behaviors. Neuropharmacology 72, 148–56. 
doi:10.1016/j.neuropharm.2013.04.048 
References 
132 
 
Bitton, A., Sewitch, M.J., Peppercorn, M.A., deB Edwardes, M.D., Shah, S., Ransil, B., 
Locke, S.E., 2003. Psychosocial determinants of relapse in ulcerative colitis: a 
longitudinal study. Am. J. Gastroenterol. 98, 2203–8. doi:10.1111/j.1572-
0241.2003.07717.x 
Blanchard, E.B., Rowell, D., Kuhn, E., Rogers, R., Wittrock, D., 2005. Posttraumatic stress 
and depressive symptoms in a college population one year after the September 11 
attacks: the effect of proximity. Behav. Res. Ther. 43, 143–50. 
doi:10.1016/j.brat.2003.12.004 
Blanchard, M.S., Eisen, S.A., Alpern, R., Karlinsky, J., Toomey, R., Reda, D.J., Murphy, 
F.M., Jackson, L.W., Kang, H.K., 2006. Chronic multisymptom illness complex in 
Gulf War I veterans 10 years later. Am. J. Epidemiol. 163, 66–75. 
doi:10.1093/aje/kwj008 
Boger, K.D., Auerbach, R.P., Pechtel, P., Busch, A.B., Greenfield, S.F., Pizzagalli, D.A., 
2014. Co-Occurring Depressive and Substance Use Disorders in Adolescents: An 
Examination of Reward Responsiveness During Treatment. J. Psychother. Integr. 24, 
109–121. doi:10.1037/a0036975 
Bordi, F., Ugolini, A., 1999. Group I metabotropic glutamate receptors: implications for 
brain diseases. Prog. Neurobiol. 59, 55–79. 
Borsini, F., Lecci, A., Volterra, G., Meli, A., 1989. A model to measure anticipatory 
anxiety in mice? Psychopharmacology (Berl). 98, 207–11. 
Borsini, F., Meli, A., 1988. Is the forced swimming test a suitable model for revealing 
antidepressant activity? Psychopharmacology (Berl). 94, 147–60. 
Boyce-Rustay, J.M., Holmes, A., 2006. Ethanol-related behaviors in mice lacking the 
NMDA receptor NR2A subunit. Psychopharmacology (Berl). 187, 455–66. 
doi:10.1007/s00213-006-0448-6 
Bradley, S.R., Uslaner, J.M., Flick, R.B., Lee, A., Groover, K.M., Hutson, P.H., 2012. The 
mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by 
modulating glutamatergic signaling. Pharmacol. Biochem. Behav. 101, 35–40. 
doi:10.1016/j.pbb.2011.11.006 
Brice, N.L., Varadi, A., Ashcroft, S.J.H., Molnar, E., 2002. Metabotropic glutamate and 
GABA(B) receptors contribute to the modulation of glucose-stimulated insulin 
secretion in pancreatic beta cells. Diabetologia 45, 242–52. doi:10.1007/s00125-001-
0750-0 
Brinkborg, H., Michanek, J., Hesser, H., Berglund, G., 2011. Acceptance and commitment 
therapy for the treatment of stress among social workers: a randomized controlled 
trial. Behav. Res. Ther. 49, 389–98. doi:10.1016/j.brat.2011.03.009 
Brodkin, J., Bradbury, M., Busse, C., Warren, N., Bristow, L.J., Varney, M.A., 2002. 
Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur. J. Neurosci. 
16, 2241–4. 
References 
133 
 
Brodkin, J., Busse, C., Sukoff, S.J., Varney, M.A., 2002. Anxiolytic-like activity of the 
mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol. 
Biochem. Behav. 73, 359–66. 
Bruening, S., Oh, E., Hetzenauer, A., Escobar-Alvarez, S., Westphalen, R.I., Hemmings, 
H.C., Singewald, N., Shippenberg, T., Toth, M., 2006. The anxiety-like phenotype of 
5-HT receptor null mice is associated with genetic background-specific perturbations 
in the prefrontal cortex GABA-glutamate system. J. Neurochem. 99, 892–9. 
doi:10.1111/j.1471-4159.2006.04129.x 
Bruno, V., Battaglia, G., Copani, A., Cespédes, V.M., Galindo, M.F., Ceña, V., Sánchez-
Prieto, J., Gasparini, F., Kuhn, R., Flor, P.J., Nicoletti, F., 2001a. An activity-
dependent switch from facilitation to inhibition in the control of excitotoxicity by 
group I metabotropic glutamate receptors. Eur. J. Neurosci. 13, 1469–78. 
Bruno, V., Battaglia, G., Copani, A., D’Onofrio, M., Di Iorio, P., De Blasi, A., Melchiorri, 
D., Flor, P.J., Nicoletti, F., 2001b. Metabotropic glutamate receptor subtypes as 
targets for neuroprotective drugs. J. Cereb. Blood Flow Metab. 21, 1013–33. 
doi:10.1097/00004647-200109000-00001 
Bruno, V., Battaglia, G., Kingston, A., O’Neill, M.J., Catania, M. V, Di Grezia, R., 
Nicoletti, F., 1999. Neuroprotective activity of the potent and selective mGlu1a 
metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine 
(LY367385): comparison with LY357366, a broader spectrum antagonist with equal 
affinity for mGlu1a and mGlu5 recept. Neuropharmacology 38, 199–207. 
Cairns, S.R., Scholefield, J.H., Steele, R.J., Dunlop, M.G., Thomas, H.J.W., Evans, G.D., 
Eaden, J.A., Rutter, M.D., Atkin, W.P., Saunders, B.P., Lucassen, A., Jenkins, P., 
Fairclough, P.D., Woodhouse, C.R.J., 2010. Guidelines for colorectal cancer 
screening and surveillance in moderate and high risk groups (update from 2002). Gut 
59, 666–89. doi:10.1136/gut.2009.179804 
Callaerts-Vegh, Z., Beckers, T., Ball, S.M., Baeyens, F., Callaerts, P.F., Cryan, J.F., 
Molnar, E., D’Hooge, R., 2006. Concomitant deficits in working memory and fear 
extinction are functionally dissociated from reduced anxiety in metabotropic 
glutamate receptor 7-deficient mice. J. Neurosci. 26, 6573–82. 
doi:10.1523/JNEUROSCI.1497-06.2006 
Caplan, R.D., Cobb, S., French, J.R., 1979. White collar work load and cortisol: disruption 
of a circadian rhythm by job stress? J. Psychosom. Res. 23, 181–92. 
Cartmell, J., Schoepp, D.D., 2000. Regulation of neurotransmitter release by metabotropic 
glutamate receptors. J. Neurochem. 75, 889–907. 
Caspi, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., Harrington, H., McClay, J., 
Mill, J., Martin, J., Braithwaite, A., Poulton, R., 2003. Influence of life stress on 
depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386–9. 
doi:10.1126/science.1083968 
References 
134 
 
Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., Pilc, A., 2013. mGlu2/3 and 
mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 66, 
40–52. doi:10.1016/j.neuropharm.2012.05.022 
Chandran, A., Iyo, A.H., Jernigan, C.S., Legutko, B., Austin, M.C., Karolewicz, B., 2013. 
Reduced phosphorylation of the mTOR signaling pathway components in the 
amygdala of rats exposed to chronic stress. Prog. Neuropsychopharmacol. Biol. 
Psychiatry 40, 240–5. doi:10.1016/j.pnpbp.2012.08.001 
Chang, H.J., Yoo, B.C., Lim, S.-B., Jeong, S.-Y., Kim, W.H., Park, J.-G., 2005. 
Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its 
prognostic significance. Clin. Cancer Res. 11, 3288–95. doi:10.1158/1078-0432.CCR-
04-1912 
Charmandari, E., Tsigos, C., Chrousos, G., 2005. Endocrinology of the stress response. 
Annu. Rev. Physiol. 67, 259–84. doi:10.1146/annurev.physiol.67.040403.120816 
Chourbaji, S., Zacher, C., Sanchis-Segura, C., Spanagel, R., Gass, P., 2005. Social and 
structural housing conditions influence the development of a depressive-like 
phenotype in the learned helplessness paradigm in male mice. Behav. Brain Res. 164, 
100–6. doi:10.1016/j.bbr.2005.06.003 
Christopoulos, A., Kenakin, T., 2002. G protein-coupled receptor allosterism and 
complexing. Pharmacol. Rev. 54, 323–74. 
Chrousos, G.P., 2009. Stress and disorders of the stress system. Nat. Rev. Endocrinol. 5, 
374–81. doi:10.1038/nrendo.2009.106 
Ciceroni, C., Mosillo, P., Mastrantoni, E., Sale, P., Ricci-Vitiani, L., Biagioni, F., Stocchi, 
F., Nicoletti, F., Melchiorri, D., 2010. mGLU3 metabotropic glutamate receptors 
modulate the differentiation of SVZ-derived neural stem cells towards the astrocytic 
lineage. Glia 58, 813–22. doi:10.1002/glia.20965 
Cohen, S., Janicki-Deverts, D., Miller, G.E., 2007. Psychological stress and disease. 
JAMA 298, 1685–7. doi:10.1001/jama.298.14.1685 
Collett, V.J., Collingridge, G.L., 2004. Interactions between NMDA receptors and mGlu5 
receptors expressed in HEK293 cells. Br. J. Pharmacol. 142, 991–1001. 
doi:10.1038/sj.bjp.0705861 
Conn, P.J., 2003. Physiological roles and therapeutic potential of metabotropic glutamate 
receptors. Ann. N. Y. Acad. Sci. 1003, 12–21. 
Conn, P.J., Christopoulos, A., Lindsley, C.W., 2009a. Allosteric modulators of GPCRs: a 
novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41–54. 
doi:10.1038/nrd2760 
Conn, P.J., Jones, C.K., Lindsley, C.W., 2009b. Subtype-selective allosteric modulators of 
muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30, 
148–55. doi:10.1016/j.tips.2008.12.002 
References 
135 
 
Conn, P.J., Pin, J.P., 1997. Pharmacology and functions of metabotropic glutamate 
receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205–37. 
doi:10.1146/annurev.pharmtox.37.1.205 
Cooper, R., Hildebrandt, S., Gerlach, A.L., 2014. Drinking motives in alcohol use disorder 
patients with and without social anxiety disorder. Anxiety. Stress. Coping 27, 113–22. 
doi:10.1080/10615806.2013.823482 
Cortese, B.M., Phan, K.L., 2005. The role of glutamate in anxiety and related disorders. 
CNS Spectr. 10, 820–30. 
Corti, C., Aldegheri, L., Somogyi, P., Ferraguti, F., 2002. Distribution and synaptic 
localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. 
Neuroscience 110, 403–20. 
Cosford, N.D.P., Roppe, J., Tehrani, L., Schweiger, E.J., Seiders, T.J., Chaudary, A., Rao, 
S., Varney, M.A., 2003. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent 
and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. 
Bioorg. Med. Chem. Lett. 13, 351–4. 
Cryan, J.F., Holmes, A., 2005. The ascent of mouse: advances in modelling human 
depression and anxiety. Nat. Rev. Drug Discov. 4, 775–90. doi:10.1038/nrd1825 
Cryan, J.F., Kelly, P.H., Neijt, H.C., Sansig, G., Flor, P.J., van Der Putten, H., 2003. 
Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic 
glutamate receptor mGluR7. Eur. J. Neurosci. 17, 2409–17. 
Cryan, J.F., Mombereau, C., 2004. In search of a depressed mouse: utility of models for 
studying depression-related behavior in genetically modified mice. Mol. Psychiatry 9, 
326–57. doi:10.1038/sj.mp.4001457 
Cryan, J.F., Mombereau, C., Vassout, A., 2005a. The tail suspension test as a model for 
assessing antidepressant activity: review of pharmacological and genetic studies in 
mice. Neurosci. Biobehav. Rev. 29, 571–625. doi:10.1016/j.neubiorev.2005.03.009 
Cryan, J.F., Slattery, D.A., 2007. Animal models of mood disorders: Recent developments. 
Curr. Opin. Psychiatry 20, 1–7. doi:10.1097/YCO.0b013e3280117733 
Cryan, J.F., Valentino, R.J., Lucki, I., 2005b. Assessing substrates underlying the 
behavioral effects of antidepressants using the modified rat forced swimming test. 
Neurosci. Biobehav. Rev. 29, 547–69. doi:10.1016/j.neubiorev.2005.03.008 
D’Antoni, S., Berretta, A., Seminara, G., Longone, P., Giuffrida-Stella, A.M., Battaglia, 
G., Sortino, M.A., Nicoletti, F., Catania, M. V, 2011. A prolonged pharmacological 
blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord 
motor neurons against excitotoxic death. Neurobiol. Dis. 42, 252–64. 
doi:10.1016/j.nbd.2011.01.013 
D’Onofrio, M., Cuomo, L., Battaglia, G., Ngomba, R.T., Storto, M., Kingston, A.E., Orzi, 
F., De Blasi, A., Di Iorio, P., Nicoletti, F., Bruno, V., 2001. Neuroprotection mediated 
References 
136 
 
by glial group-II metabotropic glutamate receptors requires the activation of the MAP 
kinase and the phosphatidylinositol-3-kinase pathways. J. Neurochem. 78, 435–45. 
Davis, M.J., Haley, T., Duvoisin, R.M., Raber, J., 2012. Measures of anxiety, sensorimotor 
function, and memory in male and female mGluR4−/− mice. Behav. Brain Res. 229, 
21–8. doi:10.1016/j.bbr.2011.12.037 
Davis, M.J., Iancu, O.D., Acher, F.C., Stewart, B.M., Eiwaz, M.A., Duvoisin, R.M., Raber, 
J., 2013. Role of mGluR4 in acquisition of fear learning and memory. 
Neuropharmacology 66, 365–72. doi:10.1016/j.neuropharm.2012.07.038 
De Kloet, E.R., Joëls, M., Holsboer, F., 2005. Stress and the brain: from adaptation to 
disease. Nat. Rev. Neurosci. 6, 463–75. doi:10.1038/nrn1683 
De Rover, M., Meye, F.J., Ramakers, G.M.J., 2008. Presynaptic metabotropic glutamate 
receptors regulate glutamatergic input to dopamine neurons in the ventral tegmental 
area. Neuroscience 154, 1318–23. doi:10.1016/j.neuroscience.2008.04.055 
Der-Avakian, A., Mazei-Robison, M.S., Kesby, J.P., Nestler, E.J., Markou, A., 2014. 
Enduring deficits in brain reward function after chronic social defeat in rats: 
susceptibility, resilience, and antidepressant response. Biol. Psychiatry 76, 542–9. 
doi:10.1016/j.biopsych.2014.01.013 
DeRijk, R., de Kloet, E.R., 2005. Corticosteroid receptor genetic polymorphisms and stress 
responsivity. Endocrine 28, 263–70. doi:10.1385/ENDO:28:3:263 
Deschwanden, A., Karolewicz, B., Feyissa, A.M., Treyer, V., Ametamey, S.M., Johayem, 
A., Burger, C., Auberson, Y.P., Sovago, J., Stockmeier, C.A., Buck, A., Hasler, G., 
2011. Reduced metabotropic glutamate receptor 5 density in major depression 
determined by [(11)C]ABP688 PET and postmortem study. Am. J. Psychiatry 168, 
727–34. doi:10.1176/appi.ajp.2011.09111607 
DeVries, A.C., Craft, T.K.S., Glasper, E.R., Neigh, G.N., Alexander, J.K., 2007. 2006 Curt 
P. Richter award winner: Social influences on stress responses and health. 
Psychoneuroendocrinology 32, 587–603. doi:10.1016/j.psyneuen.2007.04.007 
Dhabhar, F.S., 2000. Acute stress enhances while chronic stress suppresses skin immunity. 
The role of stress hormones and leukocyte trafficking. Ann. N. Y. Acad. Sci. 917, 
876–93. 
Dhabhar, F.S., 2002. A hassle a day may keep the doctor away: stress and the 
augmentation of immune function. Integr. Comp. Biol. 42, 556–64. 
doi:10.1093/icb/42.3.556 
Djordjevic, J., Djordjevic, A., Adzic, M., Radojcic, M.B., 2012. Effects of chronic social 
isolation on Wistar rat behavior and brain plasticity markers. Neuropsychobiology 66, 
112–9. doi:10.1159/000338605 
Dobi, A., Sartori, S.B., Busti, D., Van der Putten, H., Singewald, N., Shigemoto, R., 
Ferraguti, F., 2013. Neural substrates for the distinct effects of presynaptic group III 
References 
137 
 
metabotropic glutamate receptors on extinction of contextual fear conditioning in 
mice. Neuropharmacology 66, 274–89. doi:10.1016/j.neuropharm.2012.05.025 
Drew, G.M., Mitchell, V.A., Vaughan, C.W., 2008. Glutamate spillover modulates 
GABAergic synaptic transmission in the rat midbrain periaqueductal grey via 
metabotropic glutamate receptors and endocannabinoid signaling. J. Neurosci. 28, 
808–15. doi:10.1523/JNEUROSCI.4876-07.2008 
Duclot, F., Kabbaj, M., 2013. Individual Differences in Novelty Seeking Predict 
Subsequent Vulnerability to Social Defeat through a Differential Epigenetic 
Regulation of Brain-Derived Neurotrophic Factor Expression. J. Neurosci. 33, 11048–
11060. doi:10.1523/JNEUROSCI.0199-13.2013 
Duffy, L.C., Zielezny, M.A., Marshall, J.R., Byers, T.E., Weiser, M.M., Phillips, J.F., 
Calkins, B.M., Ogra, P.L., Graham, S., 1991. Relevance of major stress events as an 
indicator of disease activity prevalence in inflammatory bowel disease. Behav. Med. 
17, 101–10. doi:10.1080/08964289.1991.9937553 
Durand, D., Carniglia, L., Beauquis, J., Caruso, C., Saravia, F., Lasaga, M., 2014. 
Astroglial mGlu3 receptors promote alpha-secretase-mediated amyloid precursor 
protein cleavage. Neuropharmacology 79, 180–9. 
doi:10.1016/j.neuropharm.2013.11.015 
Durand, D., Carniglia, L., Caruso, C., Lasaga, M., 2013. mGlu3 receptor and astrocytes: 
partners in neuroprotection. Neuropharmacology 66, 1–11. 
doi:10.1016/j.neuropharm.2012.04.009 
Duvoisin, R.M., Pfankuch, T., Wilson, J.M., Grabell, J., Chhajlani, V., Brown, D.G., 
Johnson, E., Raber, J., 2010. Acute pharmacological modulation of mGluR8 reduces 
measures of anxiety. Behav. Brain Res. 212, 168–73. doi:10.1016/j.bbr.2010.04.006 
Duvoisin, R.M., Villasana, L., Davis, M.J., Winder, D.G., Raber, J., 2011. Opposing roles 
of mGluR8 in measures of anxiety involving non-social and social challenges. Behav. 
Brain Res. 221, 50–4. doi:10.1016/j.bbr.2011.02.049 
Duvoisin, R.M., Zhang, C., Pfankuch, T.F., O’Connor, H., Gayet-Primo, J., Quraishi, S., 
Raber, J., 2005. Increased measures of anxiety and weight gain in mice lacking the 
group III metabotropic glutamate receptor mGluR8. Eur. J. Neurosci. 22, 425–36. 
doi:10.1111/j.1460-9568.2005.04210.x 
Eaden, J., 2003. Review article: the data supporting a role for aminosalicylates in the 
chemoprevention of colorectal cancer in patients with inflammatory bowel disease. 
Aliment. Pharmacol. Ther. 18 Suppl 2, 15–21. 
Eaden, J., 2004. Review article: colorectal carcinoma and inflammatory bowel disease. 
Aliment. Pharmacol. Ther. 20 Suppl 4, 24–30. doi:10.1111/j.1365-2036.2004.02046.x 
Eaden, J., Abrams, K., Ekbom, A., Jackson, E., Mayberry, J., 2000. Colorectal cancer 
prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther. 14, 
145–53. 
References 
138 
 
Eiland, L., McEwen, B.S., 2012. Early life stress followed by subsequent adult chronic 
stress potentiates anxiety and blunts hippocampal structural remodeling. 
Hippocampus 22, 82–91. doi:10.1002/hipo.20862 
Enz, R., 2007. The trick of the tail: protein-protein interactions of metabotropic glutamate 
receptors. Bioessays 29, 60–73. doi:10.1002/bies.20518 
Fanselow, M.S., 1980. Conditioned and unconditional components of post-shock freezing. 
Pavlov. J. Biol. Sci. 15, 177–82. 
Farazifard, R., Wu, S.H., 2010. Metabotropic glutamate receptors modulate glutamatergic 
and GABAergic synaptic transmission in the central nucleus of the inferior colliculus. 
Brain Res. 1325, 28–40. doi:10.1016/j.brainres.2010.02.021 
Fatemi, S.H., Folsom, T.D., Kneeland, R.E., Yousefi, M.K., Liesch, S.B., Thuras, P.D., 
2013. Impairment of fragile X mental retardation protein-metabotropic glutamate 
receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin 
substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine 
phosphatase, and h. Mol. Autism 4, 21. doi:10.1186/2040-2392-4-21 
Fatemi, S.H., Folsom, T.D., Rooney, R.J., Thuras, P.D., 2013. mRNA and protein 
expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and 
mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl. Psychiatry 3, 
e271. doi:10.1038/tp.2013.46 
Fendt, M., Imobersteg, S., Peterlik, D., Chaperon, F., Mattes, C., Wittmann, C., Olpe, H.-
R., Mosbacher, J., Vranesic, I., van der Putten, H., McAllister, K.H., Flor, P.J., Gee, 
C.E., 2013. Differential roles of mGlu(7) and mGlu(8) in amygdala-dependent 
behavior and physiology. Neuropharmacology 72, 215–23. 
doi:10.1016/j.neuropharm.2013.04.052 
Fendt, M., Schmid, S., Thakker, D.R., Jacobson, L.H., Yamamoto, R., Mitsukawa, K., 
Maier, R., Natt, F., Hüsken, D., Kelly, P.H., McAllister, K.H., Hoyer, D., van der 
Putten, H., Cryan, J.F., Flor, P.J., 2008. mGluR7 facilitates extinction of aversive 
memories and controls amygdala plasticity. Mol. Psychiatry 13, 970–9. 
doi:10.1038/sj.mp.4002073 
Ferraguti, F., Shigemoto, R., 2006. Metabotropic glutamate receptors. Cell Tissue Res. 
326, 483–504. doi:10.1007/s00441-006-0266-5 
Fieblinger, T., Sebastianutto, I., Alcacer, C., Bimpisidis, Z., Maslava, N., Sandberg, S., 
Engblom, D., Cenci, M.A., 2014. Mechanisms of dopamine D1 receptor-mediated 
ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic 
glutamate receptor type 5. J. Neurosci. 34, 4728–40. doi:10.1523/JNEUROSCI.2702-
13.2014 
Flor, P.J., Acher, F.C., 2012. Orthosteric versus allosteric GPCR activation: the great 
challenge of group-III mGluRs. Biochem. Pharmacol. 84, 414–24. 
doi:10.1016/j.bcp.2012.04.013 
References 
139 
 
Follesa, P., Ticku, M.K., 1996. NMDA receptor upregulation: molecular studies in 
cultured mouse cortical neurons after chronic antagonist exposure. J. Neurosci. 16, 
2172–8. 
Franklin, T.B., Saab, B.J., Mansuy, I.M., 2012. Neural mechanisms of stress resilience and 
vulnerability. Neuron 75, 747–61. doi:10.1016/j.neuron.2012.08.016 
Füchsl, A.M., Langgartner, D., Reber, S.O., 2013. Mechanisms underlying the increased 
plasma ACTH levels in chronic psychosocially stressed male mice. PLoS One 8, 
e84161. doi:10.1371/journal.pone.0084161 
Füchsl, A.M., Neumann, I.D., Reber, S.O., 2014. Stress resilience: a low-anxiety genotype 
protects male mice from the consequences of chronic psychosocial stress. 
Endocrinology 155, 117–26. doi:10.1210/en.2013-1742 
Fukumoto, K., Chaki, S., 2015. Involvement of serotonergic system in the effect of a 
metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. J. 
Pharmacol. Sci. 127, 57–61. doi:10.1016/j.jphs.2014.09.003 
Fuxe, K., Borroto-Escuela, D.O., 2015. Basimglurant for treatment of major depressive 
disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. 
Expert Opin. Investig. Drugs 24, 1247–60. doi:10.1517/13543784.2015.1074175 
Gasparini, F., Bilbe, G., Gomez-Mancilla, B., Spooren, W., 2008. mGluR5 antagonists: 
discovery, characterization and drug development. Curr. Opin. Drug Discov. Devel. 
11, 655–65. 
Gasparotto, O.C., Lopes, D.M., Carobrez, S.G., 2005. Pair housing affects anxiety-like 
behaviors induced by a social but not by a physiological stressor in male Swiss mice. 
Physiol. Behav. 85, 603–12. doi:10.1016/j.physbeh.2005.06.014 
Geddes, A.E., Huang, X.-F., Newell, K.A., 2011. Reciprocal signalling between NR2 
subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Prog. 
Neuropsychopharmacol. Biol. Psychiatry 35, 896–904. 
doi:10.1016/j.pnpbp.2011.02.017 
Gee, C.E., Peterlik, D., Neuhäuser, C., Bouhelal, R., Kaupmann, K., Laue, G., Uschold-
Schmidt, N., Feuerbach, D., Zimmermann, K., Ofner, S., Cryan, J.F., van der Putten, 
H., Fendt, M., Vranesic, I., Glatthar, R., Flor, P.J., 2014. Blocking metabotropic 
glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits 
amygdala plasticity, stress, and anxiety-related behavior. J. Biol. Chem. 289, 10975–
87. doi:10.1074/jbc.M113.542654 
Gillespie, C.F., Phifer, J., Bradley, B., Ressler, K.J., 2009. Risk and resilience: Genetic and 
environmental influences on development of the stress response. Depress. Anxiety 26, 
984–992. doi:10.1002/da.20605 
Goddyn, H., Callaerts-Vegh, Z., Stroobants, S., Dirikx, T., Vansteenwegen, D., Hermans, 
D., Putten, H. van der, D’Hooge, R., 2008. Deficits in acquisition and extinction of 
References 
140 
 
conditioned responses in mGluR7 knockout mice. Neurobiol. Learn. Mem. 90, 103–
111. doi:10.1016/j.nlm.2008.01.001 
Gola, H., Engler, H., Schauer, M., Adenauer, H., Riether, C., Kolassa, S., Elbert, T., 
Kolassa, I.-T., 2012. Victims of rape show increased cortisol responses to trauma 
reminders: A study in individuals with war- and torture-related PTSD. 
Psychoneuroendocrinology 37, 213–220. doi:10.1016/j.psyneuen.2011.06.005 
Gomez-Mancilla, B., Berry-Kravis, E., Hagerman, R., von Raison, F., Apostol, G., Ufer, 
M., Gasparini, F., Jacquemont, S., 2014. Development of mavoglurant and its 
potential for the treatment of fragile X syndrome. Expert Opin. Investig. Drugs 23, 
125–34. doi:10.1517/13543784.2014.857400 
Graybeal, C., Kiselycznyk, C., Holmes, A., 2012. Stress-induced deficits in cognition and 
emotionality: a role of glutamate. Curr. Top. Behav. Neurosci. 12, 189–207. 
doi:10.1007/7854_2011_193 
Gregory, K.J., Noetzel, M.J., Niswender, C.M., 2013. Pharmacology of metabotropic 
glutamate receptor allosteric modulators: structural basis and therapeutic potential for 
CNS disorders. Prog. Mol. Biol. Transl. Sci. 115, 61–121. doi:10.1016/B978-0-12-
394587-7.00002-6 
Grueter, B.A., Winder, D.G., 2005. Group II and III metabotropic glutamate receptors 
suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria 
terminalis. Neuropsychopharmacology 30, 1302–11. doi:10.1038/sj.npp.1300672 
Guidotti, G., Calabrese, F., Anacker, C., Racagni, G., Pariante, C.M., Riva, M.A., 2013. 
Glucocorticoid receptor and FKBP5 expression is altered following exposure to 
chronic stress: modulation by antidepressant treatment. Neuropsychopharmacology 
38, 616–27. doi:10.1038/npp.2012.225 
Guimarães-Souza, E.M., Calaza, K.C., 2012. Selective activation of group III metabotropic 
glutamate receptor subtypes produces different patterns of γ-aminobutyric acid 
immunoreactivity and glutamate release in the retina. J. Neurosci. Res. 90, 2349–61. 
doi:10.1002/jnr.23123 
Hamilton, S.P., 2011. A new lead from genetic studies in depressed siblings: assessing 
studies of chromosome 3. Am. J. Psychiatry 168, 783–9. 
doi:10.1176/appi.ajp.2011.11060835 
Hammen, C., 2005. Stress and depression. Annu. Rev. Clin. Psychol. 1, 293–319. 
doi:10.1146/annurev.clinpsy.1.102803.143938 
Harris, A.P., Holmes, M.C., de Kloet, E.R., Chapman, K.E., Seckl, J.R., 2013. 
Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and 
behaviour. Psychoneuroendocrinology 38, 648–58. 
doi:10.1016/j.psyneuen.2012.08.007 
Hashimoto, K., 2013. Therapeutic implications for NMDA receptors in mood disorders. 
Expert Rev. Neurother. 13, 735–7. doi:10.1586/14737175.2013.811894 
References 
141 
 
Hashimoto, K., Sawa, A., Iyo, M., 2007. Increased levels of glutamate in brains from 
patients with mood disorders. Biol. Psychiatry 62, 1310–6. 
doi:10.1016/j.biopsych.2007.03.017 
Hayashi, Y., Momiyama, A., Takahashi, T., Ohishi, H., Ogawa-Meguro, R., Shigemoto, 
R., Mizuno, N., Nakanishi, S., 1993. Role of a metabotropic glutamate receptor in 
synaptic modulation in the accessory olfactory bulb. Nature 366, 687–90. 
doi:10.1038/366687a0 
Heilig, M., 2004. The NPY system in stress, anxiety and depression. Neuropeptides 38, 
213–24. doi:10.1016/j.npep.2004.05.002 
Heim, C., Ehlert, U., Hellhammer, D.H., 2000. The potential role of hypocortisolism in the 
pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 25, 1–
35. 
Heim, C., Nemeroff, C.B., 2001. The role of childhood trauma in the neurobiology of 
mood and anxiety disorders: preclinical and clinical studies. Biol. Psychiatry 49, 
1023–39. 
Henn, F.A., Vollmayr, B., 2005. Stress models of depression: forming genetically 
vulnerable strains. Neurosci. Biobehav. Rev. 29, 799–804. 
doi:10.1016/j.neubiorev.2005.03.019 
Herman, E.J., Bubser, M., Conn, P.J., Jones, C.K., 2012. Metabotropic glutamate receptors 
for new treatments in schizophrenia. Handb. Exp. Pharmacol. 297–365. 
doi:10.1007/978-3-642-25758-2_11 
Hikichi, H., Murai, T., Okuda, S., Maehara, S., Satow, A., Ise, S., Nishino, M., Suzuki, G., 
Takehana, H., Hata, M., Ohta, H., 2010. Effects of a novel metabotropic glutamate 
receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-
ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in 
rodents. Eur. J. Pharmacol. 639, 106–14. doi:10.1016/j.ejphar.2009.08.047 
Hintermann, S., Vranesic, I., Allgeier, H., Brülisauer, A., Hoyer, D., Lemaire, M., 
Moenius, T., Urwyler, S., Whitebread, S., Gasparini, F., Auberson, Y.P., 2007. 
ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 
receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution 
studies. Bioorg. Med. Chem. 15, 903–14. doi:10.1016/j.bmc.2006.10.038 
Hollis, F., Kabbaj, M., 2014. Social defeat as an animal model for depression. ILAR J. 55, 
221–32. doi:10.1093/ilar/ilu002 
Hollis, F., Wang, H., Dietz, D., Gunjan, A., Kabbaj, M., 2010. The effects of repeated 
social defeat on long-term depressive-like behavior and short-term histone 
modifications in the hippocampus in male Sprague-Dawley rats. Psychopharmacology 
(Berl). 211, 69–77. doi:10.1007/s00213-010-1869-9 
Holmes, P. V, 2003. Rodent models of depression: reexamining validity without 
anthropomorphic inference. Crit. Rev. Neurobiol. 15, 143–74. 
References 
142 
 
Holsboer, F., Barden, N., 1996. Antidepressants and hypothalamic-pituitary-adrenocortical 
regulation. Endocr. Rev. 17, 187–205. doi:10.1210/edrv-17-2-187 
Homayoun, H., Stefani, M.R., Adams, B.W., Tamagan, G.D., Moghaddam, B., 2004. 
Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working 
Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. 
Neuropsychopharmacology 29, 1259–69. doi:10.1038/sj.npp.1300417 
Hughes, Z.A., Neal, S.J., Smith, D.L., Sukoff Rizzo, S.J., Pulicicchio, C.M., Lotarski, S., 
Lu, S., Dwyer, J.M., Brennan, J., Olsen, M., Bender, C.N., Kouranova, E., Andree, 
T.H., Harrison, J.E., Whiteside, G.T., Springer, D., O’Neil, S. V, Leonard, S.K., 
Schechter, L.E., Dunlop, J., Rosenzweig-Lipson, S., Ring, R.H., 2013. Negative 
allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum 
activity relevant to treatment resistant depression. Neuropharmacology 66, 202–14. 
doi:10.1016/j.neuropharm.2012.04.007 
Iacovelli, L., Bruno, V., Salvatore, L., Melchiorri, D., Gradini, R., Caricasole, A., Barletta, 
E., De Blasi, A., Nicoletti, F., 2002. Native group-III metabotropic glutamate 
receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-
kinase pathways. J. Neurochem. 82, 216–23. 
Iacovelli, L., Capobianco, L., Iula, M., Di Giorgi Gerevini, V., Picascia, A., Blahos, J., 
Melchiorri, D., Nicoletti, F., De Blasi, A., 2004. Regulation of mGlu4 metabotropic 
glutamate receptor signaling by type-2 G-protein coupled receptor kinase (GRK2). 
Mol. Pharmacol. 65, 1103–10. doi:10.1124/mol.65.5.1103 
Iacovelli, L., Felicioni, M., Nisticò, R., Nicoletti, F., De Blasi, A., 2014. Selective 
regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G 
protein-coupled receptor kinases and arrestins. Neuropharmacology 77, 303–12. 
doi:10.1016/j.neuropharm.2013.10.013 
Inta, D., Filipovic, D., Lima-Ojeda, J.M., Dormann, C., Pfeiffer, N., Gasparini, F., Gass, 
P., 2012. The mGlu5 receptor antagonist MPEP activates specific stress-related brain 
regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: 
significance for the use as anxiolytic/antidepressant drug. Neuropharmacology 62, 
2034–9. doi:10.1016/j.neuropharm.2011.12.035 
Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, 
E., Büttelmann, B., Ceccarelli, S., Clemann, N., David, B., Funk, C., Guba, W., 
Harrison, A., Hartung, T., Honer, M., Huwyler, J., Kuratli, M., Niederhauser, U., 
Pähler, A., Peters, J.-U., Petersen, A., Prinssen, E., Ricci, A., Rueher, D., Rueher, M., 
Schneider, M., Spurr, P., Stoll, T., Tännler, D., Wichmann, J., Porter, R.H., Wettstein, 
J.G., Lindemann, L., 2015. Metabotropic Glutamate Receptor 5 Negative Allosteric 
Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-
4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for 
Psychiatric Diseases. J. Med. Chem. 58, 1358–71. doi:10.1021/jm501642c 
Jang, I.-S., 2014. Metabotropic glutamate receptors inhibit GABA release in rat histamine 
neurons. Neurosci. Lett. 579, 106–9. doi:10.1016/j.neulet.2014.07.022 
References 
143 
 
Julio-Pieper, M., Flor, P.J., Dinan, T.G., Cryan, J.F., 2011. Exciting times beyond the 
brain: metabotropic glutamate receptors in peripheral and non-neural tissues. 
Pharmacol. Rev. 63, 35–58. doi:10.1124/pr.110.004036 
Julio-Pieper, M., Hyland, N.P., Bravo, J.A., Dinan, T.G., Cryan, J.F., 2010. A novel role 
for the metabotropic glutamate receptor-7: modulation of faecal water content and 
colonic electrolyte transport in the mouse. Br. J. Pharmacol. 160, 367–75. 
doi:10.1111/j.1476-5381.2010.00713.x 
Kalinichev, M., Le Poul, E., Boléa, C., Girard, F., Campo, B., Fonsi, M., Royer-Urios, I., 
Browne, S.E., Uslaner, J.M., Davis, M.J., Raber, J., Duvoisin, R., Bate, S.T., 
Reynolds, I.J., Poli, S., Celanire, S., 2014. Characterization of the novel positive 
allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent 
models of neuropsychiatric disorders. J. Pharmacol. Exp. Ther. 350, 495–505. 
doi:10.1124/jpet.114.214437 
Kalinichev, M., Rouillier, M., Girard, F., Royer-Urios, I., Bournique, B., Finn, T., Charvin, 
D., Campo, B., Le Poul, E., Mutel, V., Poli, S., Neale, S.A., Salt, T.E., Lütjens, R., 
2013. ADX71743, a potent and selective negative allosteric modulator of 
metabotropic glutamate receptor 7: in vitro and in vivo characterization. J. Pharmacol. 
Exp. Ther. 344, 624–36. doi:10.1124/jpet.112.200915 
Karatsoreos, I.N., Bhagat, S.M., Bowles, N.P., Weil, Z.M., Pfaff, D.W., McEwen, B.S., 
2010. Endocrine and physiological changes in response to chronic corticosterone: a 
potential model of the metabolic syndrome in mouse. Endocrinology 151, 2117–27. 
doi:10.1210/en.2009-1436 
Keeney, A., Jessop, D.S., Harbuz, M.S., Marsden, C.A., Hogg, S., Blackburn-Munro, R.E., 
2006. Differential effects of acute and chronic social defeat stress on hypothalamic-
pituitary-adrenal axis function and hippocampal serotonin release in mice. J. 
Neuroendocrinol. 18, 330–8. doi:10.1111/j.1365-2826.2006.01422.x 
Keller-Wood, M., 2015. Hypothalamic-Pituitary--Adrenal Axis-Feedback Control. Compr. 
Physiol. 5, 1161–82. doi:10.1002/cphy.c140065 
Kennedy, S.H., 2008. Core symptoms of major depressive disorder: relevance to diagnosis 
and treatment. Dialogues Clin. Neurosci. 10, 271–7. 
Kew, J.N.C., Kemp, J.A., 2005. Ionotropic and metabotropic glutamate receptor structure 
and pharmacology. Psychopharmacology (Berl). 179, 4–29. doi:10.1007/s00213-005-
2200-z 
Kim, C.H., Lee, J., Lee, J.-Y., Roche, K.W., 2008. Metabotropic glutamate receptors: 
phosphorylation and receptor signaling. J. Neurosci. Res. 86, 1–10. 
doi:10.1002/jnr.21437 
Kim, J.J., Foy, M.R., Thompson, R.F., 1996. Behavioral stress modifies hippocampal 
plasticity through N-methyl-D-aspartate receptor activation. Proc. Natl. Acad. Sci. U. 
S. A. 93, 4750–3. 
References 
144 
 
Kim, S.J., Jin, Y., Kim, J., Shin, J.H., Worley, P.F., Linden, D.J., 2008. Transient 
upregulation of postsynaptic IP3-gated Ca release underlies short-term potentiation of 
metabotropic glutamate receptor 1 signaling in cerebellar Purkinje cells. J. Neurosci. 
28, 4350–5. doi:10.1523/JNEUROSCI.0284-08.2008 
Kinoshita, A., Ohishi, H., Nomura, S., Shigemoto, R., Nakanishi, S., Mizuno, N., 1996. 
Presynaptic localization of a metabotropic glutamate receptor, mGluR4a, in the 
cerebellar cortex: a light and electron microscope study in the rat. Neurosci. Lett. 207, 
199–202. 
Kinoshita, A., Shigemoto, R., Ohishi, H., van der Putten, H., Mizuno, N., 1998. 
Immunohistochemical localization of metabotropic glutamate receptors, mGluR7a 
and mGluR7b, in the central nervous system of the adult rat and mouse: a light and 
electron microscopic study. J. Comp. Neurol. 393, 332–52. 
Kintscher, M., Breustedt, J., Miceli, S., Schmitz, D., Wozny, C., 2012. Group II 
metabotropic glutamate receptors depress synaptic transmission onto subicular burst 
firing neurons. PLoS One 7, e45039. doi:10.1371/journal.pone.0045039 
Kłak, K., Pałucha, A., Brański, P., Sowa, M., Pilc, A., 2007. Combined administration of 
PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III 
receptor agonist evokes antidepressant-like effects in rats. Amino Acids 32, 169–72. 
doi:10.1007/s00726-006-0316-z 
Klar, R., Walker, A.G., Ghose, D., Grueter, B.A., Engers, D.W., Hopkins, C.R., Lindsley, 
C.W., Xiang, Z., Conn, P.J., Niswender, C.M., 2015. Activation of Metabotropic 
Glutamate Receptor 7 Is Required for Induction of Long-Term Potentiation at SC-
CA1 Synapses in the Hippocampus. J. Neurosci. 35, 7600–15. 
doi:10.1523/JNEUROSCI.4543-14.2015 
Klodzinska, A., Tatarczyńska, E., Chojnacka-Wójcik, E., Nowak, G., Cosford, N.D.P., 
Pilc, A., 2004. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 
receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47, 342–
50. doi:10.1016/j.neuropharm.2004.04.013 
Kłodzińska, A., Tatarczyńska, E., Chojnacka-Wójcik, E., Pilc, A., 2000. Anxiolytic-like 
effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-
pyridine (MPEP) in rats. Pol. J. Pharmacol. 52, 463–6. 
Koolhaas, J.M., De Boer, S.F., De Rutter, A.J., Meerlo, P., Sgoifo, A., 1997. Social stress 
in rats and mice. Acta Physiol. Scand. Suppl. 640, 69–72. 
Kosinski, C.M., Risso Bradley, S., Conn, P.J., Levey, A.I., Landwehrmeyer, G.B., Penney, 
J.B., Young, A.B., Standaert, D.G., 1999. Localization of metabotropic glutamate 
receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J. Comp. Neurol. 
415, 266–84. 
Kotov, R., Gamez, W., Schmidt, F., Watson, D., 2010. Linking “big” personality traits to 
anxiety, depressive, and substance use disorders: a meta-analysis. Psychol. Bull. 136, 
768–821. doi:10.1037/a0020327 
References 
145 
 
Kouzis, A.C., Eaton, W.W., 1998. Absence of social networks, social support and health 
services utilization. Psychol. Med. 28, 1301–10. 
Krishnan, V., Berton, O., Nestler, E., 2008. The use of animal models in psychiatric 
research and treatment. Am. J. Psychiatry 165, 1109. 
doi:10.1176/appi.ajp.2008.08071076 
Krishnan, V., Han, M.-H., Graham, D.L., Berton, O., Renthal, W., Russo, S.J., Laplant, Q., 
Graham, A., Lutter, M., Lagace, D.C., Ghose, S., Reister, R., Tannous, P., Green, 
T.A., Neve, R.L., Chakravarty, S., Kumar, A., Eisch, A.J., Self, D.W., Lee, F.S., 
Tamminga, C.A., Cooper, D.C., Gershenfeld, H.K., Nestler, E.J., 2007. Molecular 
adaptations underlying susceptibility and resistance to social defeat in brain reward 
regions. Cell 131, 391–404. doi:10.1016/j.cell.2007.09.018 
Krishnan, V., Nestler, E.J., 2008. The molecular neurobiology of depression. Nature 455, 
894–902. doi:10.1038/nature07455 
Krishnan, V., Nestler, E.J., 2010. Linking molecules to mood: new insight into the biology 
of depression. Am. J. Psychiatry 167, 1305–20. doi:10.1176/appi.ajp.2009.10030434 
Krishnan, V., Nestler, E.J., 2011. Animal models of depression: molecular perspectives. 
Curr. Top. Behav. Neurosci. 7, 121–47. doi:10.1007/7854_2010_108 
Lan, M.J., McLoughlin, G.A., Griffin, J.L., Tsang, T.M., Huang, J.T.J., Yuan, P., Manji, 
H., Holmes, E., Bahn, S., 2009. Metabonomic analysis identifies molecular changes 
associated with the pathophysiology and drug treatment of bipolar disorder. Mol. 
Psychiatry 14, 269–79. doi:10.1038/sj.mp.4002130 
Langgartner, D., Füchsl, A.M., Uschold-Schmidt, N., Slattery, D.A., Reber, S.O., 2015. 
Chronic subordinate colony housing paradigm: a mouse model to characterize the 
consequences of insufficient glucocorticoid signaling. Front. psychiatry 6, 18. 
doi:10.3389/fpsyt.2015.00018 
Lapierre, Y.D., Tremblay, A., Gagnon, A., Monpremier, P., Berliss, H., Oyewumi, L.K., 
1982. A therapeutic and discontinuation study of clobazam and diazepam in anxiety 
neurosis. J. Clin. Psychiatry 43, 372–4. 
Lapin, I.P., 1995. Only controls: effect of handling, sham injection, and intraperitoneal 
injection of saline on behavior of mice in an elevated plus-maze. J. Pharmacol. 
Toxicol. Methods 34, 73–7. 
Lavreysen, H., Dautzenberg, F.M., 2008. Therapeutic potential of group III metabotropic 
glutamate receptors. Curr. Med. Chem. 15, 671–84. 
Levenstein, S., Prantera, C., Varvo, V., Scribano, M.L., Andreoli, A., Luzi, C., Arcà, M., 
Berto, E., Milite, G., Marcheggiano, A., 2000. Stress and exacerbation in ulcerative 
colitis: a prospective study of patients enrolled in remission. Am. J. Gastroenterol. 95, 
1213–20. doi:10.1111/j.1572-0241.2000.02012.x 
References 
146 
 
Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R.J., Pettegrew, J.W., 
2000. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. 
Psychiatry 47, 586–93. 
Li, G., Jørgensen, M., Campbell, B.M., 2013. Metabotropic glutamate receptor 5-negative 
allosteric modulators for the treatment of psychiatric and neurological disorders 
(2009-July 2013). Pharm. Pat. Anal. 2, 767–802. doi:10.4155/ppa.13.58 
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.-Y., Aghajanian, G., 
Duman, R.S., 2010. mTOR-dependent synapse formation underlies the rapid 
antidepressant effects of NMDA antagonists. Science 329, 959–64. 
doi:10.1126/science.1190287 
Li, X., Need, A.B., Baez, M., Witkin, J.M., 2006. Metabotropic glutamate 5 receptor 
antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. 
Ther. 319, 254–9. doi:10.1124/jpet.106.103143 
Lin, C.-H., You, J.-R., Wei, K.-C., Gean, P.-W., 2014. Stimulating ERK/PI3K/NFκB 
signaling pathways upon activation of mGluR2/3 restores OGD-induced impairment 
in glutamate clearance in astrocytes. Eur. J. Neurosci. 39, 83–96. 
doi:10.1111/ejn.12383 
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., 
Hartung, T., Kolczewski, S., Büttelmann, B., Flament, C., Diener, C., Fischer, C., 
Gatti, S., Prinssen, E.P., Parrott, N., Hoffmann, G., Wettstein, J.G., 2011. CTEP: a 
novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 
inhibitor. J. Pharmacol. Exp. Ther. 339, 474–86. doi:10.1124/jpet.111.185660 
Lindemann, L., Porter, R.H., Scharf, S.H., Kuennecke, B., Bruns, A., von Kienlin, M., 
Harrison, A.C., Paehler, A., Funk, C., Gloge, A., Schneider, M., Parrott, N.J., 
Polonchuk, L., Niederhauser, U., Morairty, S.R., Kilduff, T.S., Vieira, E., 
Kolczewski, S., Wichmann, J., Hartung, T., Honer, M., Borroni, E., Moreau, J.-L., 
Prinssen, E., Spooren, W., Wettstein, J.G., Jaeschke, G., 2015. Pharmacology of 
basimglurant (RO4917523, RG7090), a unique mGlu5 negative allosteric modulator 
in clinical development for depression. J. Pharmacol. Exp. Ther. 353, 213–33. 
doi:10.1124/jpet.114.222463 
Linden, A.-M., Baez, M., Bergeron, M., Schoepp, D.D., 2003. Increased c-Fos expression 
in the centromedial nucleus of the thalamus in metabotropic glutamate 8 receptor 
knockout mice following the elevated plus maze test. Neuroscience 121, 167–78. 
Linden, A.-M., Johnson, B.G., Peters, S.C., Shannon, H.E., Tian, M., Wang, Y., Yu, J.L., 
Köster, A., Baez, M., Schoepp, D.D., 2002. Increased anxiety-related behavior in 
mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 
43, 251–9. 
Lindsley, C.W., Emmitte, K.A., 2009. Recent progress in the discovery and development 
of negative allosteric modulators of mGluR5. Curr. Opin. Drug Discov. Devel. 12, 
446–57. 
References 
147 
 
Lister, R.G., 1987. The use of a plus-maze to measure anxiety in the mouse. 
Psychopharmacology (Berl). 92, 180–5. 
Liu, C.Y., Jiang, X.X., Zhu, Y.H., Wei, D.N., 2012. Metabotropic glutamate receptor 5 
antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: 
role of brain-derived neurotrophic factor. Neuroscience 223, 219–24. 
doi:10.1016/j.neuroscience.2012.08.010 
Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–8. 
doi:10.1006/meth.2001.1262 
Lorenzetti, V., Allen, N.B., Fornito, A., Yücel, M., 2009. Structural brain abnormalities in 
major depressive disorder: a selective review of recent MRI studies. J. Affect. Disord. 
117, 1–17. doi:10.1016/j.jad.2008.11.021 
Lu, Y.M., Jia, Z., Janus, C., Henderson, J.T., Gerlai, R., Wojtowicz, J.M., Roder, J.C., 
1997. Mice lacking metabotropic glutamate receptor 5 show impaired learning and 
reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17, 
5196–205. 
Lucki, I., 1998. The spectrum of behaviors influenced by serotonin. Biol. Psychiatry 44, 
151–62. 
Lucki, I., 2001. A prescription to resist proscriptions for murine models of depression. 
Psychopharmacology (Berl). 153, 395–8. 
Lupien, S.J., McEwen, B.S., Gunnar, M.R., Heim, C., 2009. Effects of stress throughout 
the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 10, 434–45. 
doi:10.1038/nrn2639 
Macinnes, N., Duty, S., 2008. Group III metabotropic glutamate receptors act as hetero-
receptors modulating evoked GABA release in the globus pallidus in vivo. Eur. J. 
Pharmacol. 580, 95–9. doi:10.1016/j.ejphar.2007.10.030 
Maeng, S., Zarate, C.A., 2007. The role of glutamate in mood disorders: results from the 
ketamine in major depression study and the presumed cellular mechanism underlying 
its antidepressant effects. Curr. Psychiatry Rep. 9, 467–74. 
Magariños, A.M., McEwen, B.S., 1995. Stress-induced atrophy of apical dendrites of 
hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory 
amino acid receptors. Neuroscience 69, 89–98. 
Mason, J.W., 1968. A review of psychoendocrine research on the sympathetic-adrenal 
medullary system. Psychosom. Med. 30, Suppl:631–53. 
Masugi, M., Yokoi, M., Shigemoto, R., Muguruma, K., Watanabe, Y., Sansig, G., van der 
Putten, H., Nakanishi, S., 1999. Metabotropic glutamate receptor subtype 7 ablation 
causes deficit in fear response and conditioned taste aversion. J. Neurosci. 19, 955–
63. 
References 
148 
 
Mauri, M.C., Ferrara, A., Boscati, L., Bravin, S., Zamberlan, F., Alecci, M., Invernizzi, G., 
1998. Plasma and platelet amino acid concentrations in patients affected by major 
depression and under fluvoxamine treatment. Neuropsychobiology 37, 124–9. 
McEwen, B.S., 1998. Stress, adaptation, and disease. Allostasis and allostatic load. Ann. 
N. Y. Acad. Sci. 840, 33–44. 
McEwen, B.S., 2004. Protection and damage from acute and chronic stress: allostasis and 
allostatic overload and relevance to the pathophysiology of psychiatric disorders. 
Ann. N. Y. Acad. Sci. 1032, 1–7. doi:10.1196/annals.1314.001 
McEwen, B.S., 2007. Physiology and neurobiology of stress and adaptation: central role of 
the brain. Physiol. Rev. 87, 873–904. doi:10.1152/physrev.00041.2006 
McEwen, B.S., Stellar, E., 1993. Stress and the individual. Mechanisms leading to disease. 
Arch. Intern. Med. 153, 2093–101. 
McEwen, B.S., Wingfield, J.C., 2003. The concept of allostasis in biology and 
biomedicine. Horm. Behav. 43, 2–15. 
McMullan, S.M., Phanavanh, B., Li, G.G., Barger, S.W., 2012. Metabotropic glutamate 
receptors inhibit microglial glutamate release. ASN Neuro 4. 
doi:10.1042/AN20120044 
Mercier, M.S., Lodge, D., 2014. Group III metabotropic glutamate receptors: 
pharmacology, physiology and therapeutic potential. Neurochem. Res. 39, 1876–94. 
doi:10.1007/s11064-014-1415-y 
Michalon, A., Bruns, A., Risterucci, C., Honer, M., Ballard, T.M., Ozmen, L., Jaeschke, 
G., Wettstein, J.G., von Kienlin, M., Künnecke, B., Lindemann, L., 2014. Chronic 
metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity 
and improves cognitive performance in fragile X mice. Biol. Psychiatry 75, 189–97. 
doi:10.1016/j.biopsych.2013.05.038 
Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., 
Jaeschke, G., Bear, M.F., Lindemann, L., 2012. Chronic pharmacological mGlu5 
inhibition corrects fragile X in adult mice. Neuron 74, 49–56. 
doi:10.1016/j.neuron.2012.03.009 
Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C.R., Kawahara, R., 2006. 
Correlation between plasma levels of glutamate, alanine and serine with severity of 
depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1155–8. 
doi:10.1016/j.pnpbp.2006.03.036 
Mitsukawa, K., Mombereau, C., Lötscher, E., Uzunov, D.P., van der Putten, H., Flor, P.J., 
Cryan, J.F., 2006. Metabotropic glutamate receptor subtype 7 ablation causes 
dysregulation of the HPA axis and increases hippocampal BDNF protein levels: 
implications for stress-related psychiatric disorders. Neuropsychopharmacology 31, 
1112–22. doi:10.1038/sj.npp.1300926 
References 
149 
 
Mitsukawa, K., Yamamoto, R., Ofner, S., Nozulak, J., Pescott, O., Lukic, S., Stoehr, N., 
Mombereau, C., Kuhn, R., McAllister, K.H., van der Putten, H., Cryan, J.F., Flor, 
P.J., 2005. A selective metabotropic glutamate receptor 7 agonist: activation of 
receptor signaling via an allosteric site modulates stress parameters in vivo. Proc. 
Natl. Acad. Sci. U. S. A. 102, 18712–7. doi:10.1073/pnas.0508063102 
Molina-Hernández, M., Tellez-Alcántara, N.P., Pérez-García, J., Olivera-Lopez, J.I., 
Jaramillo, M.T., 2006. Antidepressant-like and anxiolytic-like actions of the mGlu5 
receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. 
Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1129–35. 
doi:10.1016/j.pnpbp.2006.04.022 
Morley, K.C., Baillie, A., Leung, S., Addolorato, G., Leggio, L., Haber, P.S., 2014. 
Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid 
Anxiety. Alcohol Alcohol 654–660. doi:10.1093/alcalc/agu062 
Morton, R.A., Baptista-Hon, D.T., Hales, T.G., Lovinger, D.M., 2015. Agonist- and 
antagonist-induced up-regulation of surface 5-HT3 A receptors. Br. J. Pharmacol. 
172, 4066–77. doi:10.1111/bph.13197 
Müller, N., Schwarz, M.J., 2007. The immune-mediated alteration of serotonin and 
glutamate: towards an integrated view of depression. Mol. Psychiatry 12, 988–1000. 
doi:10.1038/sj.mp.4002006 
Muscat, R., Willner, P., 1992. Suppression of sucrose drinking by chronic mild 
unpredictable stress: a methodological analysis. Neurosci. Biobehav. Rev. 16, 507–
17. 
Nakamura, M., Kurihara, H., Suzuki, G., Mitsuya, M., Ohkubo, M., Ohta, H., 2010. 
Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 
antagonists. Bioorg. Med. Chem. Lett. 20, 726–9. doi:10.1016/j.bmcl.2009.11.070 
Nakanishi, S., 1992. Molecular diversity of glutamate receptors and implications for brain 
function. Science 258, 597–603. 
Nasser, Y., Keenan, C.M., Ma, A.C., McCafferty, D.-M., Sharkey, K.A., 2007. Expression 
of a functional metabotropic glutamate receptor 5 on enteric glia is altered in states of 
inflammation. Glia 55, 859–72. doi:10.1002/glia.20507 
Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., Monteggia, L.M., 2002a. 
Neurobiology of depression. Neuron 34, 13–25. 
Nestler, E.J., Gould, E., Manji, H., Buncan, M., Duman, R.S., Greshenfeld, H.K., Hen, R., 
Koester, S., Lederhendler, I., Meaney, M., Robbins, T., Winsky, L., Zalcman, S., 
2002b. Preclinical models: status of basic research in depression. Biol. Psychiatry 52, 
503–28. 
Nestler, E.J., Hyman, S.E., 2010. Animal models of neuropsychiatric disorders. Nat. 
Neurosci. 13, 1161–9. doi:10.1038/nn.2647 
References 
150 
 
Newell, K.A., Matosin, N., 2014. Rethinking metabotropic glutamate receptor 5 
pathological findings in psychiatric disorders: implications for the future of novel 
therapeutics. BMC Psychiatry 14, 23. doi:10.1186/1471-244X-14-23 
Ngomba, R.T., Santolini, I., Salt, T.E., Ferraguti, F., Battaglia, G., Nicoletti, F., van 
Luijtelaar, G., 2011. Metabotropic glutamate receptors in the thalamocortical 
network: strategic targets for the treatment of absence epilepsy. Epilepsia 52, 1211–
22. doi:10.1111/j.1528-1167.2011.03082.x 
Nickols, H.H., Conn, P.J., 2014. Development of allosteric modulators of GPCRs for 
treatment of CNS disorders. Neurobiol. Dis. 61, 55–71. 
doi:10.1016/j.nbd.2013.09.013 
Nicoletti, F., Bockaert, J., Collingridge, G.L., Conn, P.J., Ferraguti, F., Schoepp, D.D., 
Wroblewski, J.T., Pin, J.P., 2011. Metabotropic glutamate receptors: from the 
workbench to the bedside. Neuropharmacology 60, 1017–41. 
doi:10.1016/j.neuropharm.2010.10.022 
Nicoletti, F., Bruno, V., Catania, M. V, Battaglia, G., Copani, A., Barbagallo, G., Ceña, V., 
Sanchez-Prieto, J., Spano, P.F., Pizzi, M., 1999. Group-I metabotropic glutamate 
receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. 
Neuropharmacology 38, 1477–84. 
Nicoletti, F., Bruno, V., Ngomba, R.T., Gradini, R., Battaglia, G., 2015. Metabotropic 
glutamate receptors as drug targets: what’s new? Curr. Opin. Pharmacol. 20, 89–94. 
doi:10.1016/j.coph.2014.12.002 
Niswender, C.M., Conn, P.J., 2010. Metabotropic glutamate receptors: physiology, 
pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322. 
doi:10.1146/annurev.pharmtox.011008.145533 
Niswender, C.M., Johnson, K.A., Miller, N.R., Ayala, J.E., Luo, Q., Williams, R., Saleh, 
S., Orton, D., Weaver, C.D., Conn, P.J., 2010. Context-dependent pharmacology 
exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. 
Mol. Pharmacol. 77, 459–68. doi:10.1124/mol.109.058768 
Niswender, C.M., Johnson, K.A., Weaver, C.D., Jones, C.K., Xiang, Z., Luo, Q., 
Rodriguez, A.L., Marlo, J.E., de Paulis, T., Thompson, A.D., Days, E.L., Nalywajko, 
T., Austin, C.A., Williams, M.B., Ayala, J.E., Williams, R., Lindsley, C.W., Conn, 
P.J., 2008. Discovery, characterization, and antiparkinsonian effect of novel positive 
allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol. 74, 
1345–58. doi:10.1124/mol.108.049551 
Nordquist, R.E., Durkin, S., Jaeschke, G., Spooren, W., 2007. Stress-induced 
hyperthermia: effects of acute and repeated dosing of MPEP. Eur. J. Pharmacol. 568, 
199–202. doi:10.1016/j.ejphar.2007.04.034 
Nyuyki, K.D., Beiderbeck, D.I., Lukas, M., Neumann, I.D., Reber, S.O., 2012. Chronic 
subordinate colony housing (CSC) as a model of chronic psychosocial stress in male 
rats. PLoS One 7, e52371. doi:10.1371/journal.pone.0052371 
References 
151 
 
O’Connor, R.M., Pusceddu, M.M., Dinan, T.G., Cryan, J.F., 2013. Impact of early-life 
stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, 
electroconvulsive shock therapy and fluoxetine treatment. Neuropharmacology 66, 
236–41. doi:10.1016/j.neuropharm.2012.05.006 
O’Connor, R.M., Cryan, J.F., 2013. The effects of mGlu₇ receptor modulation in 
behavioural models sensitive to antidepressant action in two mouse strains. Behav. 
Pharmacol. 24, 105–13. doi:10.1097/FBP.0b013e32835efc78 
O’Connor, R.M., Pusceddu, M.M., O’Leary, O.F., Savignac, H.M., Bravo, J.A., El 
Yacoubi, M., Vaugeois, J.-M., Dinan, T.G., Cryan, J.F., 2013a. Hippocampal group 
III mGlu receptor mRNA levels are not altered in specific mouse models of stress, 
depression and antidepressant action. Pharmacol. Biochem. Behav. 103, 561–7. 
doi:10.1016/j.pbb.2012.09.017 
O’Connor, R.M., Thakker, D.R., Schmutz, M., van der Putten, H., Hoyer, D., Flor, P.J., 
Cryan, J.F., 2013b. Adult siRNA-induced knockdown of mGlu7 receptors reduces 
anxiety in the mouse. Neuropharmacology 72, 66–73. 
doi:10.1016/j.neuropharm.2013.03.028 
O’Leary, D.M., Movsesyan, V., Vicini, S., Faden, A.I., 2000. Selective mGluR5 
antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal 
toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 
131, 1429–1437. doi:10.1038/sj.bjp.0703715 
Obermeier, F., Schwarz, H., Dunger, N., Strauch, U.G., Grunwald, N., Schölmerich, J., 
Falk, W., 2003. OX40/OX40L interaction induces the expression of CXCR5 and 
contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur. J. 
Immunol. 33, 3265–74. doi:10.1002/eji.200324124 
Ohishi, H., Shigemoto, R., Nakanishi, S., Mizuno, N., 1993a. Distribution of the 
messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central 
nervous system of the rat. Neuroscience 53, 1009–18. 
Ohishi, H., Shigemoto, R., Nakanishi, S., Mizuno, N., 1993b. Distribution of the mRNA 
for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ 
hybridization study. J. Comp. Neurol. 335, 252–66. doi:10.1002/cne.903350209 
Olivier, B., Zethof, T., Pattij, T., van Boogaert, M., van Oorschot, R., Leahy, C., Oosting, 
R., Bouwknecht, A., Veening, J., van der Gugten, J., Groenink, L., 2003. Stress-
induced hyperthermia and anxiety: pharmacological validation. Eur. J. Pharmacol. 
463, 117–32. 
Pałucha, A., Brański, P., Szewczyk, B., Wierońska, J.M., Kłak, K., Pilc, A., 2005. 
Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 
antagonist. Pharmacol. Biochem. Behav. 81, 901–6. doi:10.1016/j.pbb.2005.06.015 
Palucha, A., Klak, K., Branski, P., van der Putten, H., Flor, P.J., Pilc, A., 2007. Activation 
of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology 
(Berl). 194, 555–62. doi:10.1007/s00213-007-0856-2 
References 
152 
 
Palucha, A., Pilc, A., 2007. Metabotropic glutamate receptor ligands as possible anxiolytic 
and antidepressant drugs. Pharmacol. Ther. 115, 116–47. 
doi:10.1016/j.pharmthera.2007.04.007 
Pałucha, A., Tatarczyńska, E., Brański, P., Szewczyk, B., Wierońska, J.M., Kłak, K., 
Chojnacka-Wójcik, E., Nowak, G., Pilc, A., 2004. Group III mGlu receptor agonists 
produce anxiolytic- and antidepressant-like effects after central administration in rats. 
Neuropharmacology 46, 151–9. 
Pałucha-Poniewiera, A., Brański, P., Wierońska, J.M., Stachowicz, K., Sławińska, A., Pilc, 
A., 2014a. The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the 
tail suspension test in mice is serotonin dependent. Psychopharmacology (Berl). 231, 
97–107. doi:10.1007/s00213-013-3206-6 
Pałucha-Poniewiera, A., Pilc, A., 2013. A selective mGlu7 receptor antagonist MMPIP 
reversed antidepressant-like effects of AMN082 in rats. Behav. Brain Res. 238, 109–
12. doi:10.1016/j.bbr.2012.10.004 
Pałucha-Poniewiera, A., Szewczyk, B., Pilc, A., 2014b. Activation of the mTOR signaling 
pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the 
mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology 82, 59–68. 
doi:10.1016/j.neuropharm.2014.03.001 
Panatier, A., Poulain, D.A., Oliet, S.H.R., 2004. Regulation of transmitter release by high-
affinity group III mGluRs in the supraoptic nucleus of the rat hypothalamus. 
Neuropharmacology 47, 333–41. doi:10.1016/j.neuropharm.2004.05.003 
Pecknold, J.C., McClure, D.J., Appeltauer, L., Wrzesinski, L., Allan, T., 1982. Treatment 
of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard 
(diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 2, 129–33. 
Pelkey, K.A., Yuan, X., Lavezzari, G., Roche, K.W., McBain, C.J., 2007. mGluR7 
undergoes rapid internalization in response to activation by the allosteric agonist 
AMN082. Neuropharmacology 52, 108–17. doi:10.1016/j.neuropharm.2006.07.020 
Peterlik, D., Flor, P.J., Uschold-Schmidt, N., 2016a. The Emerging Role of Metabotropic 
Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders. 
Curr. Neuropharmacol. 14(5), 514–39 
Peterlik, D., Stangl, C., Bauer, A., Bludau, A., Keller, J., Grabski, D., Killian, T., Schmidt, 
D., Zajicek, F., Jaeschke, G., Lindemann, L., Reber, S.O., Flor, P.J., Uschold-
Schmidt, N., 2016b. Blocking Metabotropic Glutamate Receptor Subtype 5 Relieves 
Maladaptive Stress Consequences Induced by Chronic Male Subordination. Brain. 
Behav. Immun., doi:10.1016/j.bbi.2016.08.007, in press 
Peterlik, D., Stangl, C., Bludau, A., Grabski, D., Strasser, R., Schmidt, D., Flor, P.J., 
Uschold-Schmidt, N., 2016c. Relief from detrimental consequences of chronic 
psychosocial stress in mice deficient for the metabotropic glutamate receptor subtype 
7. Neuropharmacology, doi:10.1016/j.neuropharm.2016.04.036, in press 
References 
153 
 
Peters, S., Grunwald, N., Rümmele, P., Endlicher, E., Lechner, A., Neumann, I.D., 
Obermeier, F., Reber, S.O., 2012. Chronic psychosocial stress increases the risk for 
inflammation-related colon carcinogenesis in male mice. Stress 15, 403–15. 
doi:10.3109/10253890.2011.631232 
Peters, S., Slattery, D.A., Flor, P.J., Neumann, I.D., Reber, S.O., 2013. Differential effects 
of baclofen and oxytocin on the increased ethanol consumption following chronic 
psychosocial stress in mice. Addict. Biol. 18, 66–77. doi:10.1111/adb.12001 
Peters, S., Slattery, D.A., Uschold-Schmidt, N., Reber, S.O., Neumann, I.D., 2014. Dose-
dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin 
receptor binding and stress-related parameters in mice. Psychoneuroendocrinology 42, 
225–36. doi:10.1016/j.psyneuen.2014.01.021 
Petrov, D., Pedros, I., de Lemos, M.L., Pallàs, M., Canudas, A.M., Lazarowski, A., Beas-
Zarate, C., Auladell, C., Folch, J., Camins, A., 2014. Mavoglurant as a treatment for 
Parkinson’s disease. Expert Opin. Investig. Drugs 23, 1165–79. 
doi:10.1517/13543784.2014.931370 
Picconi, B., Calabresi, P., 2014. Targeting metabotropic glutamate receptors as a new 
strategy against levodopa-induced dyskinesia in Parkinson’s disease? Mov. Disord. 
29, 715–9. doi:10.1002/mds.25851 
Pignatelli, M., Piccinin, S., Molinaro, G., Di Menna, L., Riozzi, B., Cannella, M., 
Motolese, M., Vetere, G., Catania, M.V., Battaglia, G., Nicoletti, F., Nisticò, R., 
Bruno, V., 2014. Changes in mGlu5 receptor-dependent synaptic plasticity and 
coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling 
angelman syndrome. J. Neurosci. 34, 4558–66. doi:10.1523/JNEUROSCI.1846-
13.2014 
Pilc, A., Chaki, S., Nowak, G., Witkin, J.M., 2008. Mood disorders: regulation by 
metabotropic glutamate receptors. Biochem. Pharmacol. 75, 997–1006. 
doi:10.1016/j.bcp.2007.09.021 
Pilc, A., Kłodzińska, A., Brański, P., Nowak, G., Pałucha, A., Szewczyk, B., Tatarczyńska, 
E., Chojnacka-Wójcik, E., Wierońska, J.M., 2002. Multiple MPEP administrations 
evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43, 181–
7. 
Pin, J.P., Duvoisin, R., 1995. The metabotropic glutamate receptors: structure and 
functions. Neuropharmacology 34, 1–26. 
Pinheiro, P.S., Mulle, C., 2008. Presynaptic glutamate receptors: physiological functions 
and mechanisms of action. Nat. Rev. Neurosci. 9, 423–36. doi:10.1038/nrn2379 
Planells-Cases, R., Lerma, J., Ferrer-Montiel, A., 2006. Pharmacological intervention at 
ionotropic glutamate receptor complexes. Curr. Pharm. Des. 12, 3583–96. 
References 
154 
 
Pokusa, M., Prokopova, B., Hlavacova, N., Makatsori, A., Jezova, D., 2014. Effect of 
blockade of mGluR5 on stress hormone release and its gene expression in the adrenal 
gland. Can. J. Physiol. Pharmacol. 92, 686–92. doi:10.1139/cjpp-2014-0030 
Pomierny-Chamioło, L., Poleszak, E., Pilc, A., Nowak, G., 2010. NMDA but not AMPA 
glutamatergic receptors are involved in the antidepressant-like activity of MTEP 
during the forced swim test in mice. Pharmacol. Rep. 62, 1186–90. 
Pomierny-Chamioło, L., Rup, K., Pomierny, B., Niedzielska, E., Kalivas, P.W., Filip, M., 
2014. Metabotropic glutamatergic receptors and their ligands in drug addiction. 
Pharmacol. Ther. 142, 281–305. doi:10.1016/j.pharmthera.2013.12.012 
Porsolt, R.D., Bertin, A., Jalfre, M., 1977a. Behavioral despair in mice: a primary 
screening test for antidepressants. Arch. Int. Pharmacodyn. thérapie 229, 327–36. 
Porsolt, R.D., Le Pichon, M., Jalfre, M., 1977b. Depression: a new animal model sensitive 
to antidepressant treatments. Nature 266, 730–2. 
Porter, R.H.P., Jaeschke, G., Spooren, W., Ballard, T.M., Büttelmann, B., Kolczewski, S., 
Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., Mühlemann, A., Gatti, S., Mutel, 
V., Malherbe, P., 2005. Fenobam: a clinically validated nonbenzodiazepine anxiolytic 
is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse 
agonist activity. J. Pharmacol. Exp. Ther. 315, 711–21. doi:10.1124/jpet.105.089839 
Quiroz, J.A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Fontoura, P., Santarelli, L., 
2015. P.2.f.027 The efficacy and safety of basimglurant as adjunctive therapy in 
major depression; a randomised, double-blind, placebo-controlled study. Eur. 
Neuropsychopharmacol. 24, S468. doi:10.1016/S0924-977X(14)70748-5 
Raber, J., Duvoisin, R.M., 2014. Novel metabotropic glutamate receptor 4 and glutamate 
receptor 8 therapeutics for the treatment of anxiety. Expert Opin. Investig. Drugs 24, 
519–28. doi:10.1517/13543784.2014.986264 
Rascol, O., Fox, S., Gasparini, F., Kenney, C., Di Paolo, T., Gomez-Mancilla, B., 2014. 
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-
induced dyskinesias. Parkinsonism Relat. Disord. 20, 947–56. 
doi:10.1016/j.parkreldis.2014.05.003 
Razzoli, M., Carboni, L., Andreoli, M., Michielin, F., Ballottari, A., Arban, R., 2011. 
Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in 
the mouse. Pharmacol. Biochem. Behav. 97, 566–76. doi:10.1016/j.pbb.2010.09.010 
Razzoli, M., Carboni, L., Arban, R., 2009. Alterations of behavioral and endocrinological 
reactivity induced by 3 brief social defeats in rats: relevance to human 
psychopathology. Psychoneuroendocrinology 34, 1405–16. 
doi:10.1016/j.psyneuen.2009.04.018 
Razzoli, M., Carboni, L., Guidi, A., Gerrard, P., Arban, R., 2007. Social defeat-induced 
contextual conditioning differentially imprints behavioral and adrenal reactivity: a 
References 
155 
 
time-course study in the rat. Physiol. Behav. 92, 734–40. 
doi:10.1016/j.physbeh.2007.05.063 
Razzoli, M., Roncari, E., Guidi, A., Carboni, L., Arban, R., Gerrard, P., Bacchi, F., 2006. 
Conditioning properties of social subordination in rats: behavioral and biochemical 
correlates of anxiety. Horm. Behav. 50, 245–51. doi:10.1016/j.yhbeh.2006.03.007 
Reber, S.O., Birkeneder, L., Veenema, A.H., Obermeier, F., Falk, W., Straub, R.H., 
Neumann, I.D., 2007. Adrenal insufficiency and colonic inflammation after a novel 
chronic psycho-social stress paradigm in mice: implications and mechanisms. 
Endocrinology 148, 670–82. doi:10.1210/en.2006-0983 
Reber, S.O., Neumann, I.D., 2008. Defensive behavioral strategies and enhanced state 
anxiety during chronic subordinate colony housing are accompanied by reduced 
hypothalamic vasopressin, but not oxytocin, expression. Ann. N. Y. Acad. Sci. 1148, 
184–95. doi:10.1196/annals.1410.003 
Reber, S.O., Peters, S., Slattery, D.A., Hofmann, C., Schölmerich, J., Neumann, I.D., 
Obermeier, F., 2011. Mucosal immunosuppression and epithelial barrier defects are 
key events in murine psychosocial stress-induced colitis. Brain. Behav. Immun. 25, 
1153–61. doi:10.1016/j.bbi.2011.03.004 
Rodgers, R.J., Haller, J., Holmes, A., Halasz, J., Walton, T.J., Brain, P.F., 1999. 
Corticosterone response to the plus-maze: high correlation with risk assessment in rats 
and mice. Physiol. Behav. 68, 47–53. 
Rondard, P., Pin, J.-P., 2015. Dynamics and modulation of metabotropic glutamate 
receptors. Curr. Opin. Pharmacol. 20C, 95–101. doi:10.1016/j.coph.2014.12.001 
Salminen, O., Lahtinen, S., Ahtee, L., 1996. Expression of Fos protein in various rat brain 
areas following acute nicotine and diazepam. Pharmacol. Biochem. Behav. 54, 241–8. 
Salomé, N., Landgraf, R., Viltart, O., 2006. Confinement to the open arm of the elevated-
plus maze as anxiety paradigm: behavioral validation. Behav. Neurosci. 120, 719–23. 
doi:10.1037/0735-7044.120.3.719 
Sansig, G., Bushell, T.J., Clarke, V.R., Rozov, A., Burnashev, N., Portet, C., Gasparini, F., 
Schmutz, M., Klebs, K., Shigemoto, R., Flor, P.J., Kuhn, R., Knoepfel, T., Schroeder, 
M., Hampson, D.R., Collett, V.J., Zhang, C., Duvoisin, R.M., Collingridge, G.L., van 
Der Putten, H., 2001. Increased seizure susceptibility in mice lacking metabotropic 
glutamate receptor 7. J. Neurosci. 21, 8734–45. 
Sarría, R., Díez, J., Losada, J., Doñate-Oliver, F., Kuhn, R., Grandes, P., 2006. 
Immunocytochemical localization of metabotropic (mGluR2/3 and mGluR4a) and 
ionotropic (GluR2/3) glutamate receptors in adrenal medullary ganglion cells. Histol. 
Histopathol. 21, 141–7. 
Scaccianoce, S., Matrisciano, F., Del Bianco, P., Caricasole, A., Di Giorgi Gerevini, V., 
Cappuccio, I., Melchiorri, D., Battaglia, G., Nicoletti, F., 2003. Endogenous 
References 
156 
 
activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-
pituitary-adrenocortical axis. Neuropharmacology 44, 555–61. 
Scharf, S.H., Jaeschke, G., Wettstein, J.G., Lindemann, L., 2014. Metabotropic glutamate 
receptor 5 as drug target for Fragile X syndrome. Curr. Opin. Pharmacol. 20C, 124–
134. doi:10.1016/j.coph.2014.11.004 
Schmidt, D., Reber, S.O., Botteron, C., Barth, T., Peterlik, D., Uschold, N., Männel, D.N., 
Lechner, A., 2010. Chronic psychosocial stress promotes systemic immune activation 
and the development of inflammatory Th cell responses. Brain. Behav. Immun. 24, 
1097–104. doi:10.1016/j.bbi.2010.04.014 
Schmidt, M. V, Sterlemann, V., Ganea, K., Liebl, C., Alam, S., Harbich, D., Greetfeld, M., 
Uhr, M., Holsboer, F., Müller, M.B., 2007. Persistent neuroendocrine and behavioral 
effects of a novel, etiologically relevant mouse paradigm for chronic social stress 
during adolescence. Psychoneuroendocrinology 32, 417–29. 
doi:10.1016/j.psyneuen.2007.02.011 
Schmittgen, T.D., Livak, K.J., 2008. Analyzing real-time PCR data by the comparative 
C(T) method. Nat. Protoc. 3, 1101–8. 
Schneiderman, N., Ironson, G., Siegel, S.D., 2005. Stress and health: psychological, 
behavioral, and biological determinants. Annu. Rev. Clin. Psychol. 1, 607–628. 
doi:10.1146/annurev.clinpsy.1.102803.144141 
Schoepp, D.D., 2001. Unveiling the functions of presynaptic metabotropic glutamate 
receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299, 12–20. 
Schoepp, D.D., Jane, D.E., Monn, J.A., 1999. Pharmacological agents acting at subtypes of 
metabotropic glutamate receptors. Neuropharmacology 38, 1431–76. 
Schrader, L.A., Tasker, J.G., 1997. Presynaptic modulation by metabotropic glutamate 
receptors of excitatory and inhibitory synaptic inputs to hypothalamic magnocellular 
neurons. J. Neurophysiol. 77, 527–36. 
Seligman, M.E., Beagley, G., 1975. Learned helplessness in the rat. J. Comp. Physiol. 
Psychol. 88, 534–41. 
Seligman, M.E., Rosellini, R.A., Kozak, M.J., 1975. Learned helplessness in the rat: time 
course, immunization, and reversibility. J. Comp. Physiol. Psychol. 88, 542–7. 
Selye, H., 1973. The evolution of the stress concept. Am. Sci. 61, 692–9. 
Selye, H., 1998. A syndrome produced by diverse nocuous agents. 1936. J. 
Neuropsychiatry Clin. Neurosci. 10, 230–1. doi:10.1176/jnp.10.2.230a 
Semyanov, A., Kullmann, D.M., 2000. Modulation of GABAergic signaling among 
interneurons by metabotropic glutamate receptors. Neuron 25, 663–72. 
References 
157 
 
Sgoifo, A., Meerlo, P., 2002. Animal models of social stress: implications for the study of 
stress related pathologies in humans. Stress 5, 1–2. 
doi:10.1080/102538902900012314 
Sheldon, A.L., Robinson, M.B., 2007. The role of glutamate transporters in 
neurodegenerative diseases and potential opportunities for intervention. Neurochem. 
Int. 51, 333–55. doi:10.1016/j.neuint.2007.03.012 
Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P.J., 
Neki, A., Abe, T., Nakanishi, S., Mizuno, N., 1997. Differential presynaptic 
localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. 
Neurosci. 17, 7503–22. 
Shyn, S.I., Shi, J., Kraft, J.B., Potash, J.B., Knowles, J.A., Weissman, M.M., Garriock, 
H.A., Yokoyama, J.S., McGrath, P.J., Peters, E.J., Scheftner, W.A., Coryell, W., 
Lawson, W.B., Jancic, D., Gejman, P. V, Sanders, A.R., Holmans, P., Slager, S.L., 
Levinson, D.F., Hamilton, S.P., 2011. Novel loci for major depression identified by 
genome-wide association study of Sequenced Treatment Alternatives to Relieve 
Depression and meta-analysis of three studies. Mol. Psychiatry 16, 202–15. 
doi:10.1038/mp.2009.125 
Singewald, G.M., Nguyen, N.K., Neumann, I.D., Singewald, N., Reber, S.O., 2009. Effect 
of chronic psychosocial stress-induced by subordinate colony (CSC) housing on brain 
neuronal activity patterns in mice. Stress 12, 58–69. doi:10.1080/10253890802042082 
Singewald, N., Salchner, P., Sharp, T., 2003. Induction of c-Fos expression in specific 
areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry 53, 
275–83. 
Slattery, D.A., Uschold, N., Magoni, M., Bär, J., Popoli, M., Neumann, I.D., Reber, S.O., 
2012. Behavioural consequences of two chronic psychosocial stress paradigms: 
anxiety without depression. Psychoneuroendocrinology 37, 702–14. 
doi:10.1016/j.psyneuen.2011.09.002 
Sławińska, A., Wierońska, J.M., Stachowicz, K., Pałucha-Poniewiera, A., Uberti, M.A., 
Bacolod, M.A., Doller, D., Pilc, A., 2013. Anxiolytic- but not antidepressant-like 
activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ 
receptor. Neuropharmacology 66, 225–35. doi:10.1016/j.neuropharm.2012.05.001 
Somogyi, P., Dalezios, Y., Luján, R., Roberts, J.D.B., Watanabe, M., Shigemoto, R., 2003. 
High level of mGluR7 in the presynaptic active zones of select populations of 
GABAergic terminals innervating interneurons in the rat hippocampus. Eur. J. 
Neurosci. 17, 2503–20. 
Spooren, W.P., Vassout, A., Neijt, H.C., Kuhn, R., Gasparini, F., Roux, S., Porsolt, R.D., 
Gentsch, C., 2000. Anxiolytic-like effects of the prototypical metabotropic glutamate 
receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. 
Exp. Ther. 295, 1267–75. 
References 
158 
 
Stachowicz, K., Brañski, P., Kłak, K., van der Putten, H., Cryan, J.F., Flor, P.J., Andrzej, 
P., 2008. Selective activation of metabotropic G-protein-coupled glutamate 7 receptor 
elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. 
Behav. Pharmacol. 19, 597–603. doi:10.1097/FBP.0b013e32830cd839 
Stachowicz, K., Gołembiowska, K., Sowa, M., Nowak, G., Chojnacka-Wójcik, E., Pilc, A., 
2007. Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in 
rats is serotonin dependent. Neuropharmacology 53, 741–8. 
doi:10.1016/j.neuropharm.2007.08.002 
Stachowicz, K., Kłak, K., Kłodzińska, A., Chojnacka-Wojcik, E., Pilc, A., 2004. 
Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. 
Eur. J. Pharmacol. 498, 153–6. doi:10.1016/j.ejphar.2004.07.001 
Stachowicz, K., Kłodzińska, A., Palucha-Poniewiera, A., Schann, S., Neuville, P., Pilc, A., 
2009. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not 
antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. 
Neuropharmacology 57, 227–34. doi:10.1016/j.neuropharm.2009.06.005 
Stoop, R., Conquet, F., Zuber, B., Voronin, L.L., Pralong, E., 2003. Activation of 
metabotropic glutamate 5 and NMDA receptors underlies the induction of persistent 
bursting and associated long-lasting changes in CA3 recurrent connections. J. 
Neurosci. 23, 5634–44. 
Storto, M., de Grazia, U., Battaglia, G., Felli, M.P., Maroder, M., Gulino, A., Ragona, G., 
Nicoletti, F., Screpanti, I., Frati, L., Calogero, A., 2000. Expression of metabotropic 
glutamate receptors in murine thymocytes and thymic stromal cells. J. 
Neuroimmunol. 109, 112–20. 
Strekalova, T., Gorenkova, N., Schunk, E., Dolgov, O., Bartsch, D., 2006. Selective effects 
of citalopram in a mouse model of stress-induced anhedonia with a control for chronic 
stress. Behav. Pharmacol. 17, 271–87. 
Sukoff Rizzo, S.J., Leonard, S.K., Gilbert, A., Dollings, P., Smith, D.L., Zhang, M.-Y., Di, 
L., Platt, B.J., Neal, S., Dwyer, J.M., Bender, C.N., Zhang, J., Lock, T., Kowal, D., 
Kramer, A., Randall, A., Huselton, C., Vishwanathan, K., Tse, S.Y., Butera, J., Ring, 
R.H., Rosenzweig-Lipson, S., Hughes, Z.A., Dunlop, J., 2011. The metabotropic 
glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in 
disguise? J. Pharmacol. Exp. Ther. 338, 345–52. doi:10.1124/jpet.110.177378 
Summa, M., Di Prisco, S., Grilli, M., Usai, C., Marchi, M., Pittaluga, A., 2013. Presynaptic 
mGlu7 receptors control GABA release in mouse hippocampus. Neuropharmacology 
66, 215–24. doi:10.1016/j.neuropharm.2012.04.020 
Sumner, B.E.H., Cruise, L.A., Slattery, D.A., Hill, D.R., Shahid, M., Henry, B., 2004. 
Testing the validity of c-fos expression profiling to aid the therapeutic classification 
of psychoactive drugs. Psychopharmacology (Berl). 171, 306–21. 
doi:10.1007/s00213-003-1579-7 
References 
159 
 
Swanson, C.J., Bures, M., Johnson, M.P., Linden, A.-M., Monn, J.A., Schoepp, D.D., 
2005. Metabotropic glutamate receptors as novel targets for anxiety and stress 
disorders. Nat. Rev. Drug Discov. 4, 131–44. doi:10.1038/nrd1630 
Tamaru, Y., Nomura, S., Mizuno, N., Shigemoto, R., 2001. Distribution of metabotropic 
glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- 
and postsynaptic sites. Neuroscience 106, 481–503. 
Tamashiro, K.L.K., Nguyen, M.M.N., Sakai, R.R., 2005. Social stress: from rodents to 
primates. Front. Neuroendocrinol. 26, 27–40. doi:10.1016/j.yfrne.2005.03.001 
Tanabe, Y., Nomura, A., Masu, M., Shigemoto, R., Mizuno, N., Nakanishi, S., 1993. 
Signal transduction, pharmacological properties, and expression patterns of two rat 
metabotropic glutamate receptors, mGluR3 and mGluR4. J. Neurosci. 13, 1372–8. 
Tang, J., Xue, W., Xia, B., Ren, L., Tao, W., Chen, C., Zhang, H., Wu, R., Wang, Q., Wu, 
H., Duan, J., Chen, G., 2015. Involvement of normalized NMDA receptor and 
mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on 
chronically stressed mice. Sci. Rep. 5, 13573. doi:10.1038/srep13573 
Tang, Z.-Q., Liu, Y.-W., Shi, W., Dinh, E.H., Hamlet, W.R., Curry, R.J., Lu, Y., 2013. 
Activation of synaptic group II metabotropic glutamate receptors induces long-term 
depression at GABAergic synapses in CNS neurons. J. Neurosci. 33, 15964–77. 
doi:10.1523/JNEUROSCI.0202-13.2013 
Tatarczyńska, E., Klodzińska, A., Chojnacka-Wójcik, E., Palucha, A., Gasparini, F., Kuhn, 
R., Pilc, A., 2001. Potential anxiolytic- and antidepressant-like effects of MPEP, a 
potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 
132, 1423–30. doi:10.1038/sj.bjp.0703923 
Tatarczyńska, E., Pałucha, A., Szewczyk, B., Chojnacka-Wójcik, E., Wierońska, J., Pilc, 
A., 2002. Anxiolytic- and antidepressant-like effects of group III metabotropic 
glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) 
in rats. Pol. J. Pharmacol. 54, 707–10. 
Thomas, L.S., Jane, D.E., Harris, J.R., Croucher, M.J., 2000. Metabotropic glutamate 
autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release 
in the rat forebrain in vitro. Neuropharmacology 39, 1554–66. 
Tian, D., Stoppel, L.J., Heynen, A.J., Lindemann, L., Jaeschke, G., Mills, A.A., Bear, 
M.F., 2015. Contribution of mGluR5 to pathophysiology in a mouse model of human 
chromosome 16p11.2 microdeletion. Nat. Neurosci. 18, 182–4. doi:10.1038/nn.3911 
Tichá, K., Mikulecká, A., Mareš, P., 2011. Behavioral consequences of the mGlu5 receptor 
antagonist MTEP in immature rats. Pharmacol. Biochem. Behav. 99, 619–25. 
doi:10.1016/j.pbb.2011.06.007 
Tokita, K., Yamaji, T., Hashimoto, K., 2012. Roles of glutamate signaling in preclinical 
and/or mechanistic models of depression. Pharmacol. Biochem. Behav. 100, 688–704. 
doi:10.1016/j.pbb.2011.04.016 
References 
160 
 
Toth, I., Dietz, M., Peterlik, D., Huber, S.E., Fendt, M., Neumann, I.D., Flor, P.J., Slattery, 
D.A., 2012. Pharmacological interference with metabotropic glutamate receptor 
subtype 7 but not subtype 5 differentially affects within- and between-session 
extinction of Pavlovian conditioned fear. Neuropharmacology 62, 1619–1626. 
doi:10.1016/j.neuropharm.2011.10.021 
Tsankova, N.M., Berton, O., Renthal, W., Kumar, A., Neve, R.L., Nestler, E.J., 2006. 
Sustained hippocampal chromatin regulation in a mouse model of depression and 
antidepressant action. Nat. Neurosci. 9, 519–25. doi:10.1038/nn1659 
Tu, J.C., Xiao, B., Naisbitt, S., Yuan, J.P., Petralia, R.S., Brakeman, P., Doan, A., Aakalu, 
V.K., Lanahan, A.A., Sheng, M., Worley, P.F., 1999. Coupling of mGluR/Homer and 
PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23, 
583–92. 
Turle-Lorenzo, N., Breysse, N., Baunez, C., Amalric, M., 2005. Functional interaction 
between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease. 
Psychopharmacology (Berl). 179, 117–27. doi:10.1007/s00213-005-2202-x 
Ulrich-Lai, Y.M., Herman, J.P., 2009. Neural regulation of endocrine and autonomic stress 
responses. Nat. Rev. Neurosci. 10, 397–409. doi:10.1038/nrn2647 
Uschold-Schmidt, N., Nyuyki, K.D., Füchsl, A.M., Neumann, I.D., Reber, S.O., 2012. 
Chronic psychosocial stress results in sensitization of the HPA axis to acute 
heterotypic stressors despite a reduction of adrenal in vitro ACTH responsiveness. 
Psychoneuroendocrinology 37, 1676–87. doi:10.1016/j.psyneuen.2012.02.015 
Uschold-Schmidt, N., Peterlik, D., Füchsl, A.M., Reber, S.O., 2013. HPA axis changes 
during the initial phase of psychosocial stressor exposure in male mice. J. Endocrinol. 
218, 193–203. doi:10.1530/JOE-13-0027 
Van Hogezand, R.A., Eichhorn, R.F., Choudry, A., Veenendaal, R.A., Lamers, C.B.H.W., 
2002. Malignancies in inflammatory bowel disease: fact or fiction? Scand. J. 
Gastroenterol. Suppl. 48–53. 
Veenema, A.H., Reber, S.O., Selch, S., Obermeier, F., Neumann, I.D., 2008. Early life 
stress enhances the vulnerability to chronic psychosocial stress and experimental 
colitis in adult mice. Endocrinology 149, 2727–36. doi:10.1210/en.2007-1469 
Vega, W.A., Sribney, W.M., Aguilar-Gaxiola, S., Kolody, B., 2004. 12-month prevalence 
of DSM-III-R psychiatric disorders among Mexican Americans: nativity, social 
assimilation, and age determinants. J. Nerv. Ment. Dis. 192, 532–41. 
Venzala, E., García-García, A.L., Elizalde, N., Delagrange, P., Tordera, R.M., 2012. 
Chronic social defeat stress model: behavioral features, antidepressant action, and 
interaction with biological risk factors. Psychopharmacology (Berl). 224, 313–25. 
doi:10.1007/s00213-012-2754-5 
Verkhratsky, A., Kirchhoff, F., 2007. Glutamate-mediated neuronal-glial transmission. J. 
Anat. 210, 651–60. doi:10.1111/j.1469-7580.2007.00734.x 
References 
161 
 
Vinkers, C.H., Penning, R., Hellhammer, J., Verster, J.C., Klaessens, J.H.G.M., Olivier, B., 
Kalkman, C.J., 2013. The effect of stress on core and peripheral body temperature in 
humans. Stress 16, 520–30. doi:10.3109/10253890.2013.807243 
Virtanen, M., Kivimäki, M., 2012. Saved by the bell: does working too much increase the 
likelihood of depression? Expert Rev. Neurother. 12, 497–9. doi:10.1586/ern.12.29 
Virtanen, M., Nyberg, S.T., Batty, G.D., Jokela, M., Heikkilä, K., Fransson, E.I., 
Alfredsson, L., Bjorner, J.B., Borritz, M., Burr, H., Casini, A., Clays, E., De Bacquer, 
D., Dragano, N., Elovainio, M., Erbel, R., Ferrie, J.E., Hamer, M., Jöckel, K.-H., 
Kittel, F., Knutsson, A., Koskenvuo, M., Koskinen, A., Lunau, T., Madsen, I.E.H., 
Nielsen, M.L., Nordin, M., Oksanen, T., Pahkin, K., Pejtersen, J.H., Pentti, J., 
Rugulies, R., Salo, P., Shipley, M.J., Siegrist, J., Steptoe, A., Suominen, S.B., 
Theorell, T., Toppinen-Tanner, S., Väänänen, A., Vahtera, J., Westerholm, P.J.M., 
Westerlund, H., Slopen, N., Kawachi, I., Singh-Manoux, A., Kivimäki, M., 2013. 
Perceived job insecurity as a risk factor for incident coronary heart disease: systematic 
review and meta-analysis. BMJ 347, f4746. 
Vranesic, I., Ofner, S., Flor, P.J., Bilbe, G., Bouhelal, R., Enz, A., Desrayaud, S., 
McAllister, K., Kuhn, R., Gasparini, F., 2014. AFQ056/mavoglurant, a novel 
clinically effective mGluR5 antagonist: identification, SAR and pharmacological 
characterization. Bioorg. Med. Chem. 22, 5790–803. doi:10.1016/j.bmc.2014.09.033 
Wagner, K. V, Hartmann, J., Labermaier, C., Häusl, A.S., Zhao, G., Harbich, D., Schmid, 
B., Wang, X.-D., Santarelli, S., Kohl, C., Gassen, N.C., Matosin, N., Schieven, M., 
Webhofer, C., Turck, C.W., Lindemann, L., Jaschke, G., Wettstein, J.G., Rein, T., 
Müller, M.B., Schmidt, M. V, 2014. Homer1/mGluR5 Activity Moderates 
Vulnerability to Chronic Social Stress. Neuropsychopharmacology 40, 1222–33. 
doi:10.1038/npp.2014.308 
Wagner, K. V, Wang, X.-D., Liebl, C., Scharf, S.H., Müller, M.B., Schmidt, M. V, 2011. 
Pituitary glucocorticoid receptor deletion reduces vulnerability to chronic stress. 
Psychoneuroendocrinology 36, 579–87. doi:10.1016/j.psyneuen.2010.09.007 
Webster, M.J., Knable, M.B., O’Grady, J., Orthmann, J., Weickert, C.S., 2002. Regional 
specificity of brain glucocorticoid receptor mRNA alterations in subjects with 
schizophrenia and mood disorders. Mol. Psychiatry 7, 985–94, 924. 
doi:10.1038/sj.mp.4001139 
Weickert, C.S., Fung, S.J., Catts, V.S., Schofield, P.R., Allen, K.M., Moore, L.T., Newell, 
K.A., Pellen, D., Huang, X.-F., Catts, S. V, Weickert, T.W., 2013. Molecular 
evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol. 
Psychiatry 18, 1185–92. doi:10.1038/mp.2012.137 
West, A.P., 1990. Neurobehavioral studies of forced swimming: the role of learning and 
memory in the forced swim test. Prog. Neuropsychopharmacol. Biol. Psychiatry 14, 
863–77. 
Wierońska, J.M., Brański, P., Szewczyk, B., Pałucha, A., Papp, M., Gruca, P., Moryl, E., 
Pilc, A., 2001. Changes in the expression of metabotropic glutamate receptor 5 
References 
162 
 
(mGluR5) in the rat hippocampus in an animal model of depression. Pol. J. 
Pharmacol. 53, 659–62. 
Wierońska, J.M., Pilc, A., 2009. Metabotropic glutamate receptors in the tripartite synapse 
as a target for new psychotropic drugs. Neurochem. Int. 55, 85–97. 
doi:10.1016/j.neuint.2009.02.019 
Wierońska, J.M., Smiałowska, M., Brański, P., Gasparini, F., Kłodzińska, A., Szewczyk, 
B., Pałucha, A., Chojnacka-Wójcik, E., Pilc, A., 2004. In the amygdala anxiolytic 
action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not 
GABAA signaling. Neuropsychopharmacology 29, 514–21. 
doi:10.1038/sj.npp.1300322 
Willard, S.S., Koochekpour, S., 2013. Glutamate, glutamate receptors, and downstream 
signaling pathways. Int. J. Biol. Sci. 9, 948–59. doi:10.7150/ijbs.6426 
Willner, P., 1984. The validity of animal models of depression. Psychopharmacology 
(Berl). 83, 1–16. 
Willner, P., 1997. Validity, reliability and utility of the chronic mild stress model of 
depression: a 10-year review and evaluation. Psychopharmacology (Berl). 134, 319–
29. 
Willner, P., Muscat, R., Papp, M., 1992. Chronic mild stress-induced anhedonia: a realistic 
animal model of depression. Neurosci. Biobehav. Rev. 16, 525–34. 
Witkin, J.M., Marek, G.J., Johnson, B.G., Schoepp, D.D., 2007. Metabotropic glutamate 
receptors in the control of mood disorders. CNS Neurol. Disord. Drug Targets 6, 87–
100. 
Wood, M.R., Hopkins, C.R., Brogan, J.T., Conn, P.J., Lindsley, C.W., 2011. “Molecular 
switches” on mGluR allosteric ligands that modulate modes of pharmacology. 
Biochemistry 50, 2403–10. doi:10.1021/bi200129s 
Wood, S.K., Walker, H.E., Valentino, R.J., Bhatnagar, S., 2010. Individual differences in 
reactivity to social stress predict susceptibility and resilience to a depressive 
phenotype: role of corticotropin-releasing factor. Endocrinology 151, 1795–805. 
doi:10.1210/en.2009-1026 
Woodhall, G.L., Ayman, G., Jones, R.S.G., 2007. Differential control of two forms of 
glutamate release by group III metabotropic glutamate receptors at rat entorhinal 
synapses. Neuroscience 148, 7–21. doi:10.1016/j.neuroscience.2007.06.002 
Wu, H., Wang, C., Gregory, K.J., Han, G.W., Cho, H.P., Xia, Y., Niswender, C.M., 
Katritch, V., Meiler, J., Cherezov, V., Conn, P.J., Stevens, R.C., 2014. Structure of a 
class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. 
Science 344, 58–64. doi:10.1126/science.1249489 
References 
163 
 
Xiao, A.Y., Homma, M., Wang, X.Q., Wang, X., Yu, S.P., 2001. Role of K(+) efflux in 
apoptosis induced by AMPA and kainate in mouse cortical neurons. Neuroscience 
108, 61–7. 
Xu, J., Zhu, Y., Contractor, A., Heinemann, S.F., 2009. mGluR5 has a critical role in 
inhibitory learning. J. Neurosci. 29, 3676–84. doi:10.1523/JNEUROSCI.5716-
08.2009 
Yehuda, R., 1997a. Stress and glucocorticoid. Science 275, 1662–3. 
Yehuda, R., 1997b. Sensitization of the hypothalamic-pituitary-adrenal axis in 
posttraumatic stress disorder. Ann. N. Y. Acad. Sci. 821, 57–75. 
Yim, Y.S., Lee, J., Kim, G.-T., Song, T., Kim, C.H., Kim, D.G., 2012. Hippocampal 
mGluR5 predicts an occurrence of helplessness behavior after repetitive exposure to 
uncontrollable stress. Neurosci. Lett. 519, 62–6. doi:10.1016/j.neulet.2012.05.022 
Yin, S., Niswender, C.M., 2014. Progress toward advanced understanding of metabotropic 
glutamate receptors: structure, signaling and therapeutic indications. Cell. Signal. 26, 
2284–97. doi:10.1016/j.cellsig.2014.04.022 
Yoburn, B.C., 1988. Opioid antagonist-induced upregulation and functional 
supersensitivity. Rev. Clin. Basic Pharm. 7, 109–28. 
Yoburn, B.C., Duttaroy, A., Shah, S., Davis, T., 1994. Opioid antagonist-induced receptor 
upregulation: effects of concurrent agonist administration. Brain Res. Bull. 33, 237–
40. 
Youn, D., 2014. Differential roles of signal transduction mechanisms in long-term 
potentiation of excitatory synaptic transmission induced by activation of group I 
mGluRs in the spinal trigeminal subnucleus oralis. Brain Res. Bull. 108, 37–43. 
doi:10.1016/j.brainresbull.2014.08.003 
Youn, D.-H., 2014. Long-term potentiation by activation of group I metabotropic 
glutamate receptors at excitatory synapses in the spinal trigeminal subnucleus oralis. 
Neurosci. Lett. 560, 36–40. doi:10.1016/j.neulet.2013.11.056 
Zarate, C.A., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., 
Charney, D.S., Manji, H.K., 2006. A randomized trial of an N-methyl-D-aspartate 
antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–64. 
doi:10.1001/archpsyc.63.8.856 
Zelena, D., Haller, J., Halász, J., Makara, G.B., 1999. Social stress of variable intensity: 
physiological and behavioral consequences. Brain Res. Bull. 48, 297–302. 
Zethof, T.J., Van der Heyden, J.A., Tolboom, J.T., Olivier, B., 1994. Stress-induced 
hyperthermia in mice: a methodological study. Physiol. Behav. 55, 109–15. 
Zhang, C., Yuan, X.-R., Li, H.-Y., Zhao, Z.-J., Liao, Y.-W., Wang, X.-Y., Su, J., Sang, S.-
S., Liu, Q., 2015. Anti-Cancer Effect of Metabotropic Glutamate Receptor 1 
References 
164 
 
Inhibition in Human Glioma U87 Cells: Involvement of PI3K/Akt/mTOR Pathway. 
Cell. Physiol. Biochem. 35, 419–32. doi:10.1159/000369707 
Abbreviations 
Abbreviations 
168 
 
 
5-HT 5-hydroxytryptamine, serotonin 
ACPT-I (1S,3R,4S)-1-aminocyclopentane-1,3,4-
tricarboxylic acid 
ACTH adrenocorticotropic hormone 
ADX71743 6-(2,4-dimethylphenyl)-2-ethyl-4,5,6,7-
tetrahydro-1,3-benzoxazol-4-one 
ADX88178 4-methyl-N-[5-methyl-4-(1H-pyrazol-4-yl)-
1,3-thiazol-2-yl]pyrimidin-2-amine 
AFQ056, mavoglurant methyl(3aR,4S,7aR)-4-hydroxy-4-[2-
(3methylphenyl)ethynyl]-3,3a,5,6,7,7a-
hexahydro-2H-indole-1-carboxylate 
AMN082 N,N'-dibenzhydrylethane-1,2-diamine 
dihydrochloride 
AMPA 2-amino-3-(5-methyl-3-oxo-2,3-dihydro-1,2-
oxazol-4-yl)propanoic acid 
ANOVA analysis of variance 
ANS autonomic nervous system 
AVP arginine vasopressin 
AZ12216052 2-{[(4-bromophenyl)methyl]sulfanyl}-N-[4-
(butan-2-yl)phenyl]acetamide 
basimglurant 2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-
1H-imidazol-4-yl]ethynyl}pyridine 
BDNF brain-derived neurotrophic factor 
BSA bovine serum albumin 
Ca calcium 
CA closed arm 
cAMP cyclic adenosine monophosphate 
cDNA complementary deoxyribonucleic acid 
CMS chronic mild stress 
CNS central nervous system 
CO2 carbon dioxide 
CORT  corticosterone 
CPPG 2-amino-2-cyclopropyl-2-(4-
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phosphonophenyl)acetic acid 
CRC colorectal cancer 
CRH  corticotropin releasing hormone 
CS conditioned stimulus 
CSC  chronic subordinate colony housing 
CSDS chronic social defeat stress 
CSF cerebrospinal fluid 
CTEP 4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy) 
phenyl]imidazol-4-yl]ethynyl]pyridine 
CUS chronic unpredictable stress 
DAG  diacylglycerol 
DAG diacylglycerol 
db decibel 
DCPG 4-[(1S)-1-amino-2 hydroxy-2-
oxoethyl]phthalic acid 
DMEM  Dulbecco`s Modified Eagle Medium 
DOPA dehydroxyphenylalanine 
DZP diazepam 
EDTA  ethylendiamintetraacetic Acid 
ELISA  enzyme linked immunosorbent assay 
EPF  elevated platform 
EPM  elevated plus-maze 
ERK extracellular receptor kinase 
EtOH ethanol 
fenobam 3-(3-chlorophenyl)-1-(1-methyl-4-oxo-5H-
imidazol-2-yl)urea 
FST  forced swim test 
FXS Fragile X syndrome 
GABA  gamma-aminobutyric acid 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GC glucocorticoid 
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Glu glutamate 
GPCR G-protein-coupled receptor 
GR glucocorticoid receptor 
GRM7 gene coding for mGlu7 receptors 
GRN-529 2-{2-[2-(difluoromethoxy)-5-({5H,6H,7H-
pyrrolo[3,4-b]pyridin-6-
yl}carbonyl)phenyl]ethynyl}pyridine 
h hour 
HC hippocampus 
HDRS Hamilton depression rating scale 
HPA  hypothalamic-pituitary-adrenocortical 
HPLC/MS high-performance liquid chromatography/mass 
spectrometry 
HT hypothalamus 
i.c.v. intracerebroventricular 
i.p.  intraperitoneal 
IBD inflammatory bowel disease 
IFN-γ interferon-γ 
iGlu ionotropic glutamate receptor 
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IP3  inositol 1,4,5-trisphosphate 
IP3 {[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-
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acid 
kainate, KA (2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-
en-2-yl)pyrrolidine-2-carboxylate 
kg kilogram 
kHz kilohertz 
KO knockout 
LDB light-dark box 
LH learned helplessness 
LPS  lipopolysaccharide 
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LTP long-term potentiation 
Lu AF21934 (1S,2R)-2-[(aminooxy)methyl]-N-(3,4-
dichlorophenyl)cyclohexane-1-carboxamide 
lx lux 
mA milliampere 
MADRS Montgomery-Asberg depression rating scale 
MAPK  mitogen-activated protein kinase 
MDD major depressive disorder 
mesLNC  mesenteric lymph node cells 
Met-1 N-benzhydrylethane-1,2-diamine 
mg milligram 
mGlu metabotropic glutamate receptor 
min  Minute 
mM  millimolar 
MMPIP 6-(4-methoxyphenyl)-5-methyl-3-(pyridin-4-
yl)-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one 
MPEP 2-methyl-6-(2-phenylethynyl)pyridine 
MR  mineralocorticoid receptor 
mRNA  messenger ribonucleic acid 
MTEP 3-[2-(2-methyl-1,3-thiazol-4 yl)ethynyl] 
pyridine 
mTOR mammalian target of rapamycin 
NAM negative allosteric modulator 
nM  nanomolar 
NMDA (2R)-2-(methylamino)butanedioic acid 
NPY neuropeptide Y 
OA  open arm 
OB olfactory bulbectomy 
OF open field 
PAM positive allosteric modulator 
PBS  phosphate-buffered Saline 
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PD Parkinson’s disease 
PEG Polyethyleneglycol 
PFC  prefrontal cortex 
PFC prefrontal cortex 
PHCCC 7-hydroxyimino-N-phenyl-1,7a 
dihydrocyclopropa[b]chromene-1a-
carboxamide 
PI3-kinase phosphatidyl inositol 3-kinase 
PICK1 protein interacting with PKC alpha 
PKA  proteinkinase A 
PKC proteinkinase C 
PLC phospholipase C 
PSD-95 postsynaptic density-95 
PVN  paraventricular nucleus 
qPCR quantitative polymerase chain reaction 
RPMI Roswell Park Memorial Institute 
RS-PPG 2-amino-2-(4-phosphonophenyl)acetic acid 
s seconds 
s.c. sub-cutaneous 
S.E.M standard error of mean 
SHC  single-housed control 
SIH stress-induced hyperthermia 
siRNA small interfering RNA 
SNS  sympathetic nervous system 
SPAT social preference/avoidance test 
T1, T2 temperature 1, temperature 2 
TCA tricyclic antidepressant 
Th2  T helper 2 
TRD treatment-resistant depression 
US unconditioned stimulus 
VEH vehicle 
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VFTD Venus flytrap domain 
vs. versus 
VU0155041 (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl] 
cyclohexane-1-carboxylic acid 
WT Wildtype 
XAP044 7-hydroxy-3-(4-iodophenoxy)-4Hchromen-4-
one 
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Abstract 
 
Etiology and pharmacotherapy of stress-related psychiatric conditions and somatoform 
disorders are areas of high unmet medical need. Stressors holding chronic plus 
psychosocial components thereby bear the highest health risk. Although the metabotropic 
glutamate receptor subtype 5 (mGlu5) is well studied in the context of acute stress-induced 
behaviors and physiology, virtually nothing is known about its potential involvement in 
chronic psychosocial stress. Using the mGlu5 negative allosteric modulator CTEP (2-
chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4yl]ethynyl]pyridine), 
a close analogue of the clinically active drug basimglurant - but optimized for rodent 
studies, as well as mGlu5-deficient mice in combination with a mouse model of male 
subordination (termed CSC, chronic subordinate colony housing), we demonstrate that 
mGlu5 mediates multiple physiological, immunological, and behavioral consequences of 
chronic psychosocial stressor exposure. For instance, CTEP dose-dependently relieved 
hypothalamo-pituitary-adrenal axis dysfunctions, colonic inflammation as well as the 
CSC-induced increase in innate anxiety; genetic ablation of mGlu5 in mice largely 
reproduced the stress-protective effects of CTEP and additionally ameliorated CSC-
induced physiological anxiety. Interestingly, CSC also induced an upregulation of mGlu5 
in the hippocampus, a stress-regulating brain area. Taken together, our findings provide 
evidence that mGlu5 is an important mediator for a wide range of chronic psychosocial 
stress-induced alterations and a potentially valuable drug target for the treatment of chronic 
stress-related pathologies in man. 
 
Copyright © 2016 Elsevier Inc. All rights reserved. 
 
KEYWORDS: CTEP; Chronic psychosocial stress; Chronic subordinate colony housing; Knockout; Stress-
protective phenotype; mGlu5 
 
PMID: 27524668     DOI: 10.1016/j.bbi.2016.08.007     [PubMed - as supplied by publisher]  
First pages of first/joint-first author publications 
177 
 
 
Neuropharmacology. 2016 May 14. pii: S0028-3908(16)30176-9. doi: 10.1016/j.neuropharm.2016.04.036. 
[Epub ahead of print] 
 
Relief from detrimental consequences of chronic psychosocial stress in 
mice deficient for the metabotropic glutamate receptor subtype 7. 
 
Peterlik D1, Stangl C1, Bludau A1, Grabski D1, Strasser R1, Schmidt D2, Flor PJ3, Uschold-
Schmidt N4. 
 
1Faculty of Biology and Preclinical Medicine, Laboratory of Molecular and Cellular Neurobiology, 
University of Regensburg, Regensburg, Germany. 
2Institute of Immunology, University of Regensburg, Regensburg, Germany. 
3Faculty of Biology and Preclinical Medicine, Laboratory of Molecular and Cellular Neurobiology, 
University of Regensburg, Regensburg, Germany. Electronic address: peter.flor@ur.de. 
4Faculty of Biology and Preclinical Medicine, Laboratory of Molecular and Cellular Neurobiology, 
University of Regensburg, Regensburg, Germany. Electronic address: nicole.uschold@ur.de. 
 
Abstract 
 
Chronic stress-related psychiatric conditions and comorbid somatic pathologies are an 
enormous public health concern in modern society. The etiology of these disorders is 
complex, with stressors holding a chronic and psychosocial component representing the 
most acknowledged risk factor. During the last decades, research on the metabotropic 
glutamate receptor (mGlu) system advanced dramatically and much attention was given to 
the role of the metabotropic glutamate receptor subtype 7 (mGlu7) in acute stress-related 
behavior and physiology. However, virtually nothing is known about the potential 
involvement of mGlu7 in chronic psychosocial stress-related conditions. Using the chronic 
subordinate colony housing (CSC, 19 days) in male mice, we addressed whether central 
mGlu7 is altered upon chronic psychosocial stressor exposure and whether genetic ablation 
of mGlu7 interferes with the multitude of chronic stress-induced alterations. CSC exposure 
resulted in a downregulation of mGlu7 mRNA transcript levels in the prefrontal cortex, a 
brain region relevant for stress-related behaviors and physiology. Interestingly, mGlu7 
deficiency relieved multiple chronic stress-induced alterations including the CSC-induced 
anxiety-prone phenotype; mGlu7 ablation also ameliorated CSC-induced physiological and 
immunological consequences such as hypothalamo-pituitary-adrenal (HPA) axis 
dysfunctions and colonic inflammation, respectively. Together, our findings provide first 
evidence for the involvement of mGlu7 in a wide range of behavioral and physiological 
alterations in response to chronic psychosocial stressor exposure. Moreover, the stress-
protective phenotype of genetic mGlu7 ablation suggests mGlu7 pharmacological blockade 
to be a relevant option for the treatment of chronic stress-related emotional and somatic 
dysfunctions. 
 
Copyright © 2016 Elsevier Ltd. All rights reserved. 
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Abstract 
 
The metabotropic glutamate receptor subtype 7 (mGlu7) is an important presynaptic 
regulator of neurotransmission in the mammalian CNS. mGlu7 function has been linked 
to autism, drug abuse, anxiety, and depression. Despite this, it has been difficult to 
develop specific blockers of native mGlu7 signaling in relevant brain areas such as 
amygdala and limbic cortex. Here, we present the mGlu7-selective antagonist 7-hydroxy-
3-(4-iodophenoxy)-4H-chromen-4-one (XAP044), which inhibits lateral amygdala long 
term potentiation (LTP) in brain slices from wild type mice with a half-maximal blockade 
at 88 nm. There was no effect of XAP044 on LTP of mGlu7-deficient mice, indicating 
that this pharmacological effect is mGlu7-dependent. Unexpectedly and in contrast to all 
previous mGlu7-selective drugs, XAP044 does not act via the seven-transmembrane 
region but rather via a binding pocket localized in mGlu7's extracellular Venus flytrap 
domain, a region generally known for orthosteric agonist binding. This was shown by 
chimeric receptor studies in recombinant cell line assays. XAP044 demonstrates good 
brain exposure and wide spectrum anti-stress and antidepressant- and anxiolytic-like 
efficacy in rodent behavioral paradigms. XAP044 reduces freezing during acquisition of 
Pavlovian fear and reduces innate anxiety, which is consistent with the phenotypes of 
mGlu7-deficient mice, the results of mGlu7 siRNA knockdown studies, and the inhibition 
of amygdala LTP by XAP044. Thus, we present an mGlu7 antagonist with a novel 
molecular mode of pharmacological action, providing significant application potential in 
psychiatry. Modeling the selective interaction between XAP044 and mGlu7's Venus 
flytrap domain, whose three-dimensional structure is already known, will facilitate future 
drug development supported by computer-assisted drug design.  
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Abstract 
 
Chronic stress-related psychiatric conditions such as anxiety, depression, and alcohol 
abuse are an enormous public health concern. The etiology of these pathologies is 
complex, with psychosocial stressors being among the most frequently discussed risk 
factors. The brain glutamatergic neurotransmitter system has often been found involved in 
behaviors and pathophysiologies resulting from acute stress and fear. Despite this, 
relatively little is known about the role of glutamatergic system components in chronic 
psychosocial stress, neither in rodents nor in humans. Recently, drug discovery efforts at 
the metabotropic receptor subtypes of the glutamatergic system (mGlu1-8 receptors) led to 
the identification of pharmacological tools with emerging potential in psychiatric 
conditions. But again, the contribution of individual mGlu subtypes to the manifestation 
of physiological, molecular, and behavioral consequences of chronic psychosocial stress 
remains still largely unaddressed. The current review will describe animal models 
typically used to analyze acute and particularly chronic stress conditions, including 
models of psychosocial stress, and there we will discuss the emerging roles for mGlu 
receptor subtypes. Indeed, accumulating evidence indicates relevance and potential 
therapeutic usefulness of mGlu2/3 ligands and mGlu5 receptor antagonists in chronic 
stress-related disorders. In addition, a role for further mechanisms, e.g. mGlu7-selective 
compounds, is beginning to emerge. These mechanisms are important to be analyzed in 
chronic psychosocial stress paradigms, e.g. in the chronic subordinate colony housing 
(CSC) model. We summarize the early results and discuss necessary future investigations, 
especially for mGlu5 and mGlu7 receptor blockers, which might serve to suggest 
improved therapeutic strategies to treat stress-related disorders.  
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